Serum Concentration of Continuously administered Vancomycin influences Efficacy and Safety in Critically Ill Adults: A Systematic Review

Author names

- **Katrin Viertel** (corresponding author) [a,b,c]
  viertelk@kliniken-koeln.de
  Telephone: 0049 0221 8907 13439
  - [a] Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - [b] Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - [c] Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Alfred-Herrhausen-Straße 50, 58455 Witten, Germany.
- **Elisabeth Feles** [a, b, c]
- felese@kliniken-koeln.de
  - [a] Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - [b] Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - [c] Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Alfred-Herrhausen-Straße 50, 58455 Witten, Germany.
- **Melanie Schulte** [a]
- schulteme@kliniken-koeln.de
  - [a] Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
- **Thorsten Annecke** [d]
  annecket@kliniken-koeln.de
  - [d] Department of Anaesthesiology and Intensive Care Medicine, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
- **Frauke Mattner** [b,c]
  mattnerf@kliniken-koeln.de
  - [b] Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - [c] Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Alfred-Herrhausen-Straße 50, 58455 Witten, Germany.

Serum Concentration of Continuously administered Vancomycin influences Efficacy and Safety in Critically Ill Adults: A Systematic Review

Abstract

Vancomycin is an antibiotic to treat gram-positive infections in critically ill adults. For continuously administered vancomycin (CI), various target ranges have been used in the past, ranging from 15-20 mg/L to 30-40 mg/L. This systematic literature review was conducted to investigate the impact of steady-state serum concentration (Css) of CI on the safety and efficacy of therapy in critically ill adults**.** According to the PRISMA statement, relevant literature was identified by searching two electronic databases (PubMed, Cochrane Library) and Google Scholar from inception until July 2023, focussing on studies reporting measured Css and treatment outcomes (e.g. mortality, nephrotoxicity) with CI. Due to the heterogeneity of the studies, a narrative synthesis of the evidence was performed. Twenty-one publications were included with a total of 2,949 patients with CI (pts). Mortality was higher (two studies, n=388 pts) and clinical cure lower (one study, n=40 pts) with a Css <15 mg/L measured 24 hours after initiation of CI (C24). An adequate loading dose appeared most important for maintaining higher C24. Generally, higher Css were associated with higher rates of acute kidney injury (AKI) (fifteen studies, n=2,331 pts). We calculated that a Css <25 mg/L (vs. ≥25 mg/L) was preferable for reducing nephrotoxicity (three studies, n=515 pts). Despite sparse data availability, the target range of 15-25 mg/L in CI may increase clinical cure and reduce mortality and AKI. In future research, vancomycin Css cohorts should be formed to allow evaluation of the impact of Css of CI on treatment outcomes.

Keywords:

Acute kidney injury, intensive care unit (ICU), mortality, continuous infusion, sepsis, vancomycin, drug level

1 Introduction

Infections in intensive care units (ICU) are highly prevalent. More than half of ICU patients may become infected during their ICU stay [1], and between 8-22% of infections are acquired nosocomially [1, 2]. Infections with gram-positive pathogens regularly occur in critically ill patients [3-5] causing one third (21-67%) of all infections [6]. Available since the 1950s, the glycopeptide vancomycin remains an important antibiotic for the treatment of infections with gram-positive bacteria, particularly methicillin-resistant *Staphylococcus aureus* (MRSA), coagulase-negative staphylococci (CoNS) and *Enterococcus faecium* [7-11]. It is also frequently used in sepsis therapy as empirical treatment in combination with beta-lactam antibiotics in areas with high prevalence of MRSA [12]. Physiological changes caused by critical illness may often alter drug excretion and lead to inappropriate drug levels; renal insufficiency particularly affects drug elimination [13-15]. Additionally, vancomycin itself can impair renal function by inducing acute tubulointerstitial nephritis [16, 17] or acute tubular necrosis [18] leading to acute kidney injury (AKI). AKI worsens the outcome of the ICU stay [19, 20]. The appropriate dosage of vancomycin has therefore been under discussion for some time. Vancomycin is administered via intermittent infusion (II) or continuous infusion (CI). CI appears to hold several advantages over II. These include a lower potential risk of AKI [21-25], earlier or higher target attainment [24-35], less variability in serum concentrations [26, 32, 34, 36] and easier and less expensive monitoring of drug levels [26, 29, 31, 34]. Several studies have been published in the past with CI using multiple target ranges of vancomycin steady-state serum concentration (Css). These were (indication-

independent) 15-20 mg/L [17, 31, 37-40], 15-25 mg/L [29, 30, 32, 41-47], 20-25 mg/L [33, 34, 48-50], 20-30 mg/L [26, 51-61], 25-30 mg/L [62], 20-40 mg/L [61] and 30-40 mg/L [63], respectively. As far as we are aware, there is a lack of a comprehensive comparative evaluation of the influence of vancomycin serum concentration during continuous infusion of vancomycin on therapeutic outcomes of efficacy (e.g. clinical and microbiological outcomes such as mortality or cure) and safety (e.g. nephrotoxicity such as AKI) in critically ill adult patients. Therefore, this review examines the current knowledge on the impact of Css on the efficacy and safety of CI in critically ill adults in the ICU.

2 Materials and Methods

A systematic review was carried out in accordance with the PRISMA guidelines (preferred reporting items for systematic review and meta-analysis) [64].

2.1 Selection Criteria

According to the PICOS questions (population, intervention, comparison, outcomes and study design), enrollment of papers was performed as follows:

- **Population**: Adults (age ≥18 years) having been treated with vancomycin in an ICU.
- **Intervention**: Continuous infusion of vancomycin.
- **Comparison**: Vancomycin with or without: intermittent infusion, chronic kidney injury (CKD), renal replacement therapy (RRT), obesity or different dosing regimens.
- **Outcomes**: Vancomycin steady-state serum level (about 24 hours after the start of therapy (C24), average serum level during the entire duration of therapy or at least three days of therapy (Cmean), area under the serum

concentration-time curve for 24 hours (AUC24)) and efficacy or safety. Efficacy was defined as clinical or microbiological success or failure (e.g. survival or mortality, cure or relapse). Safety was defined as occurrence of nephrotoxicity (e.g. AKI).

- **Study design**: Clinical trials and observational studies.

Studies with the following criteria were excluded: Nonhuman data, paediatric patients (age <18 years), records without intravenous vancomycin application, records without CI, non-ICU setting, lacking efficacy or safety data, omitted vancomycin serum levels, case reports, comments, editorials, reviews and meta-analyses. In addition, investigations with less than 30 patients with CI, studies with a duration of less than one year and studies assessing fewer patient records than patients were included in the study were excluded from our analysis. Exclusion based on the language of publication was not performed.

2.2 Data Sources

A literature search from inception until 15 July 2023 in two electronic databases (MEDLINE through the PubMed interface, Cochrane Library) and Google Scholar was performed using the combined search terms *"vancomycin "* and "*continuous*" (PubMed: (vancomycin[Title]) AND (continuous), Cochrane Library: Title Abstract Keyword: vancomycin; AND All Text: continuous, Google Scholar: allintitle: vancomycin continuous).

2.3 Study Selection

Initially, the exclusion of doubles was carried out. Thereupon, articles were selected based on the information obtained from the title and abstract according to the inclusion criteria. Pertinent articles or those not providing sufficient information via

title or abstract were evaluated in full text. Finally, the selected articles were critically read in total (Figure 1).

2.4 Quality Assessment

The quality of the studies selected for inclusion was rated using two tools: The Newcastle-Ottawa Scale (NOS) for non-randomized studies [65, 66] and the Cochrane risk of bias tool for randomized trials (RoB 2) [67]. Using the NOS a “star system” described the suitability of the selection of the study groups (one star maximum each), the comparability of the groups (two stars maximum) and the ascertainment of the exposure or outcome of interest (one star maximum each). The total number of stars of each study was interpreted as "good quality" at 8-9 stars, "fair quality" at 6-7 stars, "questionable quality" at 4-5 stars, "poor quality" at 2-3 stars and "serious risk of bias" at 0-1 stars. With the RoB 2 scale, risk of bias was categorized by “low risk”, “high risk” or “some concerns”, with "low risk" of overall bias interpreted as "good quality," "high risk" as "serious risk," and "some concern" as "questionable quality”. Due to the heterogeneity of the study designs (e.g. inclusion or exclusion of patients with chronic kidney disease) and outcome measures (e.g. use of different definitions for AKI or mortality), it was not possible to summarize the results in a meta-analysis. In accordance with the Cochrane Consumers and Communication Review Group guideline [68], we therefore performed a narrative synthesis of the evidence. To minimize the influence of seasonal variations in infection type and frequency on study results (selection bias) [69-71], investigations with a duration of less than one year or a population number of less than 30 patients with CI were excluded from our analysis. Attrition bias from publications that analyzed fewer patient records than were included in the study was prevented by excluding them from our evaluation. Because of the inhomogeneous coverage of potential factors

affecting outcome, such as disease severity or concomitant nephrotoxin use, some degree of performance and reporting bias was to be expected. Language bias was avoided by including all languages of publication. The free internet translation programme www.Deepl.com/Translator was used for translation where necessary.

2.5 Data Extraction

The main characteristics of the included studies were outlined in five tables, which are accessible online via the supplementary material: design, type of study and main objective (Table S1), characteristics of the study population (Table S2), information regarding the treatment with vancomycin (Table S3), main findings in terms of efficacy (Table S4) and safety (Table S5). "*Efficacy*" connotes clinical or microbiological cure, improvement, persistence, progression, relapse or reinfection (further definitions displayed in Table S11), mortality/survival and target attainment, while "*safety*" stands for extrarenal but mainly nephrotoxic adverse events (Table 1). Some of the values given have been calculated by us in the presence of sufficient numerical data.

2.6 Analysis

The reported average Css were primarily divided into three categories: Vancomycin serum level on the second day, i.e. approximately 24 hours after initiation of CI (C24), mean vancomycin serum level during the entire duration of CI or at least three days of CI (Cmean) and area under the serum concentration-time curve for a period of 24 hours during CI (AUC24). The mortality rate was differentiated into "in-hospital", "ICU", "infection-related," "x-days" (e.g. 28-days), "end of therapy" or "not reported". Likewise, nephrotoxicity in the form of AKI was classified according to Table 1 in "AKIN", "KDIGO", "RIFLE", "Rybak2009", "Rybak2020", "RRT" or "other". To compare

the reported Css, in cases where no mean but only the median was stated, the mean and standard deviation were calculated according to the method described by Wan et al.: *mean=(median+lower quartile+upper quartile)/3* [72]. In order to use only one value per study for the comparison, weighted means of serum concentration, mortality, nephrotoxicity or target attainment rates were calculated if values were given only for subgroups but not the entire CI population of a study. Because individual values of the study population were not available, no relationship between the variables could be tested by regression analysis. But to give an impression of interdependence, average Css, i.e. C24, Cmean, AUC24, were plotted against the corresponding percentage rates of clinical failure (mortality, persistence or progression of infection symptoms), clinical success (cure, improvement of infection symptoms), microbiological failure (persistence, escalation, relapse), microbiological success (cure), AKI or target attainment, respectively. Additionally, scatterplots were created comparing rates of target attainment to mortality or AKI, mortality to AKI and target attainment to target range. For comparison of the different cohorts and based on the parameters identified as significant predictors for outcomes in the included studies (Table 3), the dosing (planned loading dose (pLD) and planned maintenance dose (pMD), actually applied loading dose (aLD) and actually applied maintenance dose (aMD)), length of therapy with vancomycin (LOT), age, gender distribution, body weight (BW), kidney status at baseline (serum creatinine (SCr), creatinine clearance (CrCl)), amount of patients with sepsis, severity of illness at start of CI (APACHE II score (Acute Physiology and Chronic Health Evaluation score), SAPS II (Simplified Acute Physiology Score), SOFA score (Sepsis-related Organ Failure Assessment score)), amount of patients with mechanical ventilation and concomitant reported nephrotoxins were added to the scatterplots. The relative risk, its confidence interval, z-value and p-value for AKI at Css above or below 25 mg/L were calculated by the

formulas described by Altman et al. [73] and displayed in a forest plot. The collected data were summarized and graphically plotted using Microsoft Excel (2016) and the *ggplot2* and *epitools* packages of the R Statistical Software (v4.2.0; R Core Team 2021).

3 Results

3.1 Bibliographic Search

Across the various databases, 1,770 articles were identified (915 from PubMed, 284 from Cochrane databases, 456 from Google Scholar and 115 from a manual search in the reference lists of related publications). 465 duplicate studies were excluded, leaving 1,305 records for further investigation. A total of 1,177 publications were classified as inappropriate according to the PICOS criteria after inspection of the title and abstract, mainly because of the absence of intravenous or continuous use of vancomycin. Of the remaining 128 full-text articles, twenty-one were evaluated for data extraction and inclusion in this systematic review. Eighteen reported efficacy data and sixteen presented safety data. Figure 1 shows the selection process.

3.2 Quality of Included Studies

The methodological quality of the studies included in this review varied, but did not influence inclusion in the analysis. The detailed results of the risk of bias assessment are shown in Supplementary Table S8 and Table S9.

3.3 Characteristics of Included Studies

Only two randomized controlled trials met the inclusion criteria [34, 47]. Two of the included studies were multicenter investigations [34, 46]. One-third had a prospective design [34, 41, 47, 52, 53, 55, 74, 75]. The studies were conducted between 2001

and 2020 and the majority (16/21) was performed in Europe [33, 34, 43, 44, 46-48, 52, 53, 55, 56, 58, 59, 61, 74, 76]. In two-thirds of the studies different patient groups were compared [33, 34, 42-44, 46, 47, 49, 53, 56, 61, 74, 76]. Equally, in thirteen studies only patients on CI were included [41-43, 46, 48, 52, 53, 55-59, 75]. In total 2,949 patients treated with CI were enrolled in the trials. In two-fifths of the studies only patients with sepsis were included [43, 52, 53, 55-59, 74], where different definitions were used [77-80]. Positive cultures were described in almost half of the studies [46, 48, 52, 55, 56, 58, 59, 61, 74, 75], which ranged from 6% to 100%. In two studies it was specialized in infections caused by beta-lactam-resistant pathogens (i.e. MRSA, methicillin-resistant CoNS) [34, 47]. Additional use of nephrotoxins was described in about two fifth of the publications [33, 34, 43, 46, 48, 56, 61, 76]. Aminoglycosides were listed most frequently (7/8) [33, 34, 43, 46, 48, 56, 61]. The heterogeneous characteristics of the included studies can be seen in Table 2 or in more detail in Supplementary Table S1 and Table S2.

3.4 Characteristics of Vancomycin Treatment

In general, the vancomycin therapy consisted of a loading dose (LD) and a maintenance dose (MD). The dosing regimen was differentiated according to a fixed or body weight-dependent protocol, if necessary with adaptation according to renal function. Mean LD ranged from 500 mg [74] to 2,894 mg [42] and from 8 mg/kg BW [74] to 35 mg/kg BW [52]. The average daily MD ranged from 396 mg/d or 5 mg/kg BW/d [43] to 3,039 mg/d or 42 mg/kg BW/d [42]. A total dose throughout the course of therapy was reported in five studies and ranged from 3.6 g to 14 g [43, 47, 56, 61, 76]. In seventeen studies the average duration of vancomycin therapy was reported [33, 34, 41-44, 46-49, 55, 56, 58, 59, 61, 75, 76]. It ranged from 3 days [55] to 15 days [46] (mean 6 days, IQR 5-9 days). Different Css ranges were aimed for,

but no indication dependence was evident: 20-30 mg/L (n=7 [52, 53, 55-59]), 15-25 mg/L (n=6 [41-44, 46, 47]), 20-25 mg/L (n=4 [33, 34, 48, 49]), 20-40 mg/L (n=1 [61]), 20 mg/L (n=1 [74]). In half of the studies, average C24 were reported. They were distributed as follows: 15-<20 mg/L (n=2 [56, 74]), 20-<25 mg/L (n=9 [41, 42, 48, 52, 53, 55, 57-59]). No study had an average C24 <15 mg/L or ≥25 mg/L (Supplementary Figure S6a). In two thirds of the studies, Cmean were stated or could be calculated. They were distributed as follows: 15-<20 mg/L (n=3 [44, 47, 76]), 20-<25 mg/L (n=6 [34, 41, 49, 56, 59, 61]), 25-<30 mg/L (n=2 [33, 58]), ≥30 mg/L (n=1 [75]) (Supplementary Figure S6b). Different kinds of immunoassays were used for measurement, which measured the total vancomycin amount in the serum. In seven studies an average AUC24 (total) value was presented [33, 34, 42, 43, 52, 55, 75], which was most often calculated by a (log-) trapezoidal rule (n=4). Mean AUC24(/MIC) data ranged from 477 mg*h/L [43] to 788 mg*h/L [75] (Supplementary Figure S6c). The parameters for treatment with vancomycin are depicted in Table 2 and in Supplementary Table S3.

3.4.1 Target Attainment

In half of the studies a target attainment (TA) rate was reported (n=1,391 pts; Table 2: 24-92%) [41-43, 48, 49, 52, 53, 55, 57-59]. Additionally, in one third each the rate of subtherapeutic and supratherapeutic levels was described [41, 44, 49, 55, 57-59]. In no study a dependence of TA on Css per se was detected, but a higher vancomycin dose increased TA (Table 3) [58, 59]. We noticed that a lower and wider target range was achieved more often (Figure 2). In no study the *time within* the target range was reported, but in three studies a *time required to reach* the target Css was stated, a link to efficacy would be questionable. It took 16 hours (target range

20-25 mg/L, ICU mortality 21%) [33], 36 hours (target range 20-25 mg/L, ICU mortality 37%) [34] and 48 hours (target range 20-30 mg/L, ICU mortality 30%) [59].

3.5 Characteristics of Outcome Parameters

Css-dependent efficacy and safety of CI were analyzed. However, there was not a single study whose primary objective was the target concentration range-dependent comparison of outcome parameters. Results are displayed in Table 2 and in Supplementary Table S4 and Table S5.

3.5.1 Efficacy

Efficacy was mentioned in eighteen studies and could be divided into clinical or microbiological treatment failure or success (n=2,648 patients with CI (pts)) (Table 2 or Supplementary Table S4, Table S10 or Table S11) [33, 34, 41-43, 46-49, 52, 55-59, 61, 74, 76]. Only for C24 <15 mg/L could a significant association with in-hospital mortality or clinical cure be shown (n=388 pts) [43, 74]. No other statistically significant associations were found between Css and clinical or microbiological success or failure. Five studies compared cohorts with different Css and treatment effectiveness. Mohammedi et al. (n=40 pts) used a constant loading dose (500 mg = 7.5±1.5 mg/kg) and a weight-based approach (15 mg/kg = 1,147±317 mg) [74]. This resulted in different Css of 14.9±5 mg/L and 18.5±6 mg/L. Differences in ICU mortality (50% vs. 35%, p=not significant) and clinical cure (56% vs. 93%, p<0.02) were noticed, arguing for the higher dose and resulting higher C24 (Figure 3a). Spadaro et al. (n=348 pts) studied patients with CrCl above (A) and below (B) 50 mL/min [43]. They reported a significant correlation between subtherapeutic levels at first measurement (C24 target: 15-25 mg/L) and in-hospital mortality (OR 2.1,

p=0.003) (Table 3). Additionally, they found lower AUC24/MIC with also numerically lower ICU mortality (M) in group A (A: 468±79, M: 21.4%; B: 490±84, M: 23.9%). Lin et al. (n=52 pts) distinguished between obese (o; BMI > 35 kg/m²) and non-obese (no; BMI < 30 kg/m²) patients [42]. No statistically significant differences were noticed between groups in respect to mean Css and mortality (C24: o/no: 20±4 mg/L; AUC24: o: 488±92 mg*h/L, no: 481±91 mg*h/L; M: o: 19.2%, no: 15.4%). In a subset analysis, Akers et al. (n=90 pts) distinguished between patients with gram-positive bacteremia (1), patients with sepsis without proven gram-positive bacteremia (2) and patients with pneumonia (3) (Cmean: 1: 19±3 mg/L, 2: 21±4 mg/L , 3: 22±4 mg/L) [49]. A slight numerical difference in serum levels was observed, which was not associated with in-hospital mortality (1: 16%, 2: 70%, 3: 35%) and was not studied in relation to the impact on microbiological failure (Cmean overall: 20±4 mg/L; failure overall: 18%). Wysocki et al. (n=61 pts) associated a Cmean of 23±4 mg/L or AUC24 of 596±159 mg*h/L with treatment success and a Cmean of 25±5 mg/L or AUC24 of 685±260 mg*h/L with treatment failure [34]. Higher SCr values were measured in therapy failure, so that an increase in SCr and subsequent increase in Css could be a marker for therapy failure.

3.5.2 Safety

Safety was discussed in sixteen studies (n=2,383 pts) (Table 2 or Supplementary Table S5), with “nephrotoxicity” in the form of AKI being dealt with most often (15/16, n=2,331 pts) [33, 34, 42-44, 46-49, 53, 56, 61, 74-76]. Different definitions were used to describe AKI (Table 1); the frequency varied from 0% [42, 47, 74] to 60% [48]. Higher Css (especially >30 mg/L) were identified as a significant predictor of AKI occurrence by multivariate regression analysis (Table 3) [46, 56, 76]. In contrast, Spadaro et al. found no relationship between AKI and Css [43]. In four studies

(n=863 pts) vancomycin serum concentration-dependent nephrotoxicity was described, the incidences of which varied widely: Spadaro et al. (n=348 pts) saw no nephrotoxicity at Css of 25-30 mg/L and an incidence <8% (<28/348) when the Css exceeded 30 mg/L [43]. Cianferoni et al. (n=207 pts) described an increasing incidence the higher the Css, with a maximum of 38% (25/66) above a level of 25 mg/L [56]. They also established a link between Css, the onset of AKI and ICU mortality, with rising mortality and AKI rate at higher Css (no AKI: C24 18.7 mg/L, Cmean 21.2 mg/L, M 18%; early AKI: C24 24.5 mg/L, Cmean 27.2 mg/L, M 46%). However, it could not be ruled out that the escalated serum concentrations were only a marker for a declining glomerular filtration and did not cause AKI per se. Perin et al. (n=179 pts) noted an AKI rate of 55% (72/131) with Css <25 mg/L versus 77% (34/44) with Css >25 mg/L [48]. Spapen et al. (n=129 pts) demonstrated an increase in AKI the higher the Css: <25 mg/L: 4.5% (3/68), 25-30 mg/L: 31% (9/29), >30 mg/L: 81% (26/32) [46]. Additionally, mortality was higher in patients with AKI (no AKI: 20%, AKI: 53%, p=0.01). Comparing the information from the latter three studies (the only ones that provided patient numbers with concentration-dependent AKI rates), there appeared to be an advantage in terms of AKI occurrence when the target concentration was <25 mg/L (Figure 5, Supplementary Table S6 and Table S7).

4 **Discussion**

Although vancomycin has been used for decades to treat infections with gram-positive pathogens and in numerous studies data on vancomycin concentration and therapeutic outcome was published, this systematic review shows that there is few data on the target serum concentration range to achieve effective yet tolerable therapy during CI in critically ill adult patients.

4.1 Target attainment

The literature did not provide associations between TA and Css; achievement of target ranges was used to evaluate new dosing protocols [42, 53, 55] or different dosing modalities [24, 25]. Based on differences in tissue penetration of vancomycin [81] or pathogen susceptibility [82], an indication-dependent target range selection would be likely. For example, Tsutsuura et al. showed that in MRSA bacteraemia, but not MRSA infections per se, higher trough concentrations resulted in significantly less treatment failures [83]. However, no correlation between the selected target range and the investigated indication was apparent to us in the synopsis. When plotting the TA rate and Css of each trial, higher TA was observed with higher LD without influence of MD (Figure 2a/b). In studies with sepsis or burn patients, lower TA rates were found. Physiological changes during sepsis or burns may have played a role (e.g. capillary leakage or oedema) [13-15]. However, it should be noted that different definitions of sepsis were used in the studies, making it difficult to compare patients and sepsis rates. Temporal differences (16-48 h) to reach target Css could be due to another dosing regimen (higher vancomycin doses equal faster TA) [33, 34, 59].

4.2 Efficacy

An assessment of the reported mortality data was difficult. Mortality seemed to depend on numerous factors and was not only influenced by Css. Furthermore, there was very little comparative concentration and mortality data. Higher C24 resulted in lower mortality rates, with a concentration above 15 mg/L found to be favorable [43, 74]. A target concentration for Cmean or AUC24 leading to lower mortality was not evaluated. Looking at the available datasets of each study's average Css and mortality rate, we also noticed an association of ICU mortality with C24 (R^2=0.7435), but not with Cmean (R^2=0.0057) or AUC24 (R^2=0.0009) (Figure 3a-c). In a

consensus review published in 2020 by several societies on the dosing and monitoring of vancomycin, for CI a lower limit of the target Css range of 20 mg/L (=AUC24/MIC ≥480 if MIC≤1 mg/L; PK/PD target not validated) was recommended [84]. This threshold was pharmacokinetically, microbiologically and clinically justified [34], was used in most studies considered [84], but was not derived from concentration comparative effectiveness studies. For II, the same practice guideline and meta-analyses recommended AUC_{total}/MIC-guided monitoring with a value ≥400 (if MIC≤1 mg/L, determined by broth microdilution (BMD)) as the PK/PD target for efficacy [83-85]. For CI, this target would correspond to a concentration of 17 mg/L (if MIC=1 mg/L) and is thus close to the lower limit of the target concentration range found in our research. Cristallini et al. calculated AUC24/MIC ratios ≥400 (if MIC≤1 mg/L) for C24 ≥15 mg/L [52]. The PK/PD threshold resulted from studies with infections with MRSA whose ECOFF of ≤2 mg/L is half that of MRCoNS or E faecalis [82, 84]. Studies on the optimal vancomycin PK/PD target for infections with these germs are lacking. However, Ampe et al. calculated AUC_{total}/MIC_{BMD}=667, AUC_{free}/MIC_{BMD}=452, AUC_{total}/MIC_{Etest}=457 and AUC_{free}/MIC_{Etest}=301 as the thresholds between clinical success or failure in ward patients with mono-infections of various gram-positive pathogens and CI as the only effective agent [86]. A transfer of dose recommendations from II to CI is uncertain, though. When comparing mortality during CI and II, meta-analyses have found no difference [22-25]. Nevertheless, the average measured Css in the included studies were always higher for CI and additionally differed within the comparison groups. A meta-analysis on mortality of the same Css of CI vs. II is missing so far. Additionally, for II Dalton et al. demonstrated that the use of AUC/MIC to predict patient outcome was modest [87], and Tsutsuura et al. found no significant difference in mortality rates with trough- versus AUC-guided treatment monitoring [83]. For CI, the benefit of PK/PD-guided therapy remains

completely unclear. Mohammedi et al. emphasized the need for sufficient LD to maintain high C24 and reduce mortality [74]. We observed the importance of sufficient LD as well (Supplementary Table S3). Additionally, higher MD seemed to result in lower mortality in the C24 cohort (Supplementary Table S3). Reaching high therapeutic levels as early as possible at the beginning of anti-infective therapy is in accordance with general recommendations [15, 88-93]. CI has advantages over II in this respect [26-29, 32-34]. However, sufficient dosing in critically ill patients is challenging [15], partly due to the increased volume of distribution with impaired capillary barrier function and the probable losses through renal function and replacement procedures [14]. The difficulty of appropriate dosing could account for the heterogeneity of doses applied in the studies included in this review. From our diagrams (Figure 3a-c), it could be deducted that dialysis was a predictor of mortality, supported by the known higher mortality of dialysis patients [94]. The initial severity of illness, as measured by APACHE II, SAPS II or SOFA score, may also have influenced mortality (Supplementary Table S2). Css and clinical cure in two CI cohorts were only compared by Mohammedi et al. (higher C24 equals higher cure) [74], whereas Css and microbiological efficacy were not analysed comparatively in any study. For Cmean and clinical success, the comparison of results by Stepan et al. and Wysocki et al. coincided with the analysis of Mohammedi et al. (higher Cmean equals higher cure), but not for microbiological success (higher Cmean equals lower cure) (Supplementary Table S10) [34, 47, 74]. This may be related to different observation periods (five days vs. end of treatment). With II, higher trough levels or AUC24/MIC values resulted in better clinical *and* microbiological cure [95-97].

4.3 Safety

The nephrotoxicity of vancomycin is known [98], with CI being significantly associated with a lower risk compared to II [22-25]. However, definitions of reported AKI varied. As Hutschala et al. and Koeze et al. showed, this had implications for the reported incidence, timing and outcome of AKI [33, 99]. Newer definitions such as AKIN (Acute Kidney Injury Network) [100] or KDIGO (Kidney Disease Improving Global Outcomes) [101] are more sensitive, resulting in higher reported rates of AKI. In our comparison, we related only similar AKI definitions. Due to poor tissue penetration, [81] the therapy with vancomycin is limited as the dose cannot be increased arbitrarily. The upper limit of Css that keeps the impairment of renal function within acceptable limits, weighing the benefits and harms, is much debated. In dataset plots of Css against AKI rate, we found that higher Css and longer duration of therapy increased the rate of AKI (Figure 4), as also calculated by Cianferoni et al. and Hanrahan et al. with multiple regression (Table 3) [56, 76]. For II, an upper trough level limit of 20 mg/L was established and AUC24/MIC ≤600 (if MIC≤1 mg/L, determined by BMD) was set as PK/PD target for safety [83, 84]. For CI, this target corresponds to a Css of 25 mg/L [84] and coincides with the preferred concentration we calculated. However, due to a lack of data, we could not compare 25 mg/L with other thresholds such as the previously described upper limits of 28 mg/L or 30 mg/L [46, 102]. Elevated AUC24 levels have also been reported to increase the risk of AKI in CI [37, 83]. AKI per se (vancomycin-independent) has been associated with worse treatment outcome (e.g. mortality, long-term impaired renal function) [20] and longer ICU and hospital stays, as well as higher costs for the healthcare system [103-105]. Cianferoni et al. and Spapen et al. also noted prolonged deterioration in renal function after AKI, and they and Omuro et al. described increased mortality in

patients who developed AKI with CI [46, 56, 61]. AKI with CI has negative consequences and should consequently be avoided.

4.4 Limitations

Several limitation should be considered when interpreting the results. First, of the twenty-one included studies, only two were randomized controlled trials; most were retrospective or observational studies. Because of their observational design, allocation bias, selection bias and various types of other confounding factors may influence the results of our report. Publication bias is to be expected, since publications that demonstrate an effect are more likely to be published. Second, no raw data was available. Instead, our plotting of datasets was performed with means and medians. Thus, the compilation of a meta-analysis or the calculation of cut-off values for efficacy was not possible. Third, our forest plot included data only from the studies that provided the number of patients with concentration-dependent AKI. Fourth, to distinguish vancomycin-induced nephrotoxicity from the naturally high rate of AKI in ICU patients, a comparison group would have been necessary in all studies. Albeit, only Omuro et al. used a control group, but the included patients were randomly selected and no matching was done [61]. Fifth, in accordance with clinical TDM routine, only the total amount of vancomycin in serum (bound + free) was measured in the studies, although it is rather the drug not bound to plasma proteins that is active [106, 107]. Variations in protein binding of vancomycin (<10-82%) [107-110] and albumin concentration of critically ill patients [15] have been described. Thus, the active vancomycin concentration varies greatly. Berthoin et al. reported poor correlation between total and free vancomycin concentration (R^2=0.55) [111] and concluded that to reduce the treatment failure rate in infection by less susceptible organisms, the free concentration should rather be determined. The

procedure for sensitive germs remains unclear. Since the free concentration cannot be determined in most laboratories, it should be investigated whether the individual protein concentration is a useful surrogate parameter for free vancomycin. Finally, only few AUC24 and only one AUC24/MIC value were available. Rybak et al. argue for sufficiency of AUC24 determination because the MIC distribution is narrow at ≤1 mg/L, measurement is not very accurate or values are not readily available, and test methods vary widely [84]. Nevertheless, knowledge of MIC values and inclusion of these in therapy assessment is important, since higher therapy failure has been described for MIC >1 mg/L and higher necessary dosage would increase nephrotoxicity [86, 112].

5 Conclusions

Despite currently sparse data availability, it appeared that for continuous infusion of vancomycin (CI) mortality was reduced and clinical cure increased with C24 above 15 mg/L and AKI may be reduced with Css below 25 mg/L. The range of 15-25 mg/L to aim for in CI needs to be validated by direct comparison with other concentration ranges, just as the definition of specific AUC(/MIC) or indication-dependent target Css need to be further investigated to achieve a safe (i.e. least damaging to the kidneys) and simultaneously most effective (i.e. therapeutically successful) therapy. To this end, future research should always sort patients by vancomycin serum concentration groups. Large prospective controlled studies are needed for this purpose.

6 Declarations

Acknowledgments

We acknowledge Viola Fuchs for her support in supervising the research project and we thank Daniel Mai for providing the R Statistical Software, Alexander and Renate Viertel for assistance with data analysis and Andreas Ismair for basic help in the writing process of the manuscript.

Funding

This research received no external funding.

Competing Interests

None of the other authors has any conflict of interest to declare.

Ethical Approval

Not required.

Author contributions

K.V. and F.M. conceived of the presented idea. K.V. conducted the study selection and data extraction. M.S. extracted data from a sample of eligible studies, good agreement was achieved with the data extracted by K.V.. K.V. and F.M. analysed the data. K.V. wrote the manuscript with support and critical revision from F.M., T.A., E.F. and M.S.. F.M. supervised the project. All authors reviewed and contributed to the final manuscript. All authors have read and agreed to the published version of the manuscript.

Declaration of Generative AI and AI-assisted technologies in the writing process

During the preparation of this work the author(s) used the free internet translational programme Deepl (www.Deepl.com/Translator) in order to improve the linguistic quality of the manuscript. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

7 References

References

[1] Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. Jama. 2020;323:1478-87.

[2] European Centre for Disease Prevention and Control (ECDC). Healthcare-associated infections in intensive care units - Annual Epidemiological Report for 2017. Stockholm: ECDC. 2019.

[3] Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017;36:1999-2006.

[4] Rello J, Molano D, Villabon M, Reina R, Rita-Quispe R, Previgliano I, et al. Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts. Medicina intensiva. 2013;37:241-7.

[5] Geffers C, Zuschneid I, Sohr D, Rüden H, Gastmeier P. Erreger nosokomialer Infektionen auf Intensivstationen: Daten des Krankenhaus-Infektions-Surveillance-Systems (KISS) aus 274 Intensivstationen. Anästhesiol Intensivmed Notfallmed Schmerzther. 2004;40:15-9.

[6] Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen (NRZ). Infektionssurveillance im Modul ITS-KISS, Referenzdaten - Berechnungszeitraum: Januar 2017 bis Dezember 2020. KISS Krankenhaus-Infektions-Surveillance-System. 2021.

[7] Anderson RC, Worth HM, Harris PN, Chen KK. Vancomycin, a new antibiotic. IV. Pharmacologic and toxicologic studies. Antibiotics annual. 1956:75-81.

[8] Rybak MJ, Rotschafer JC, Rodvold KA. Vancomycin: over 50 years later and still a work in progress. Pharmacotherapy. 2013;33:1253-5.

[9] Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52:e18-55.

[10] Moellering RC, Jr. Vancomycin: a 50-year reassessment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;42 Suppl 1:S3-4.

[11] Levine DP. Vancomycin: a history. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;42 Suppl 1:S5-12.

[12] Buckman SA, Turnbull IR, Mazuski JE. Empiric Antibiotics for Sepsis. Surgical infections. 2018;19:147-54.

[13] Jamal JA, Roger C, Roberts JA. Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics. Anaesthesia, critical care & pain medicine. 2018;37:515-7.

[14] Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive care medicine. 2013;39:2070-82.

[15] Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. The Lancet Infectious diseases. 2014;14:498-509.

[16] Hsu SI. Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy. 2001;21:1233-9.

[17] Matthews Z. Vancomycin continuous infusion: a cohort of 23 intensive care unit patients. The Australian Journal of Hospital Pharmacy. 2001;31:108-10.

[18] Belen C, Budhiraja P, Bracamonte E, Popovtzer M. Biopsy-proven acute tubular necrosis associated with vancomycin in an adult patient. Renal failure. 2012;34:502-5.

[19] Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney international. 2002;62:986-96.

[20] Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive care medicine. 2015;41:1411-23.
[21] Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents. 2015;46:249-53.
[22] Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47:28-35.
[23] Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. The Journal of antimicrobial chemotherapy. 2012;67:17-24.
[24] Chu Y, Luo Y, Quan X, Jiang M, Zhou B. Intermittent vs. continuous vancomycin infusion for gram-positive infections: A systematic review and meta-analysis. Journal of infection and public health. 2020;13:591-7.
[25] Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis. Critical care medicine. 2020;48:912-8.
[26] Hong LT, Goolsby TA, Sherman DS, Mueller SW, Reynolds P, Cava L, et al. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. Journal of critical care. 2015;30:1153.e1-6.
[27] Tafelski S, Nachtigall I, Troeger U, Deja M, Krannich A, Günzel K, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application. Journal of infection and public health. 2015;8:355-63.
[28] Schlobohm CJ, Zhu E, Duby JJ. Continuous infusion versus intermittent infusion vancomycin in a burn center intensive care unit. Burns : journal of the International Society for Burn Injuries. 2021;47:1495-501.
[29] Yamada CH, Telles JP, Oliveira DDS, Cieslinski J, Ribeiro VST, Gasparetto J, et al. Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020;24:356-9.
[30] Bissell BD, Riggi G, Morrison C. Evaluation of Continuous Infusion Vancomycin Administration in a Critically Ill Trauma Population. Journal of intensive care medicine. 2020;35:570-5.
[31] Duszynska W, Taccone FS, Hurkacz M, Wiela-Hojenska A, Kübler A. Continuous vs. intermittent vancomycin therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus aureus. Minerva anestesiologica. 2016;82:284-93.
[32] Lin H, Bukovskaya Y, De Moya M, Lee J, Schmidt U. Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the race. Annals of intensive care. 2015;5:10.
[33] Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology. 2009;111:356-65.
[34] Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45:2460-7.
[35] Lin H, Levine A, Newman K, Eikermann M, Houle T, Yeh D, et al. 681: Evaluation of a vancomycin nomogram with a continuous infusion of vancomycin for ICU patients. Critical care medicine. 2018;46:327-.
[36] James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother. 1996;40:696-700.
[37] Ma NH, Walker SAN, Elligsen M, Kiss A, Palmay L, Ho G, et al. Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-

infusion versus continuous-infusion vancomycin. The Journal of antimicrobial chemotherapy. 2020;75:1038-46.
[38] Eldemiry EM, Sabry NA, Abbassi MM, Abdel Shafy SS, Mokhtar MS, Abdel Bary A. A specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients. SAGE open medicine. 2013;1:2050312113507921.
[39] van de Vijsel LM, Walker SA, Walker SE, Yamashita S, Simor A, Hladunewich M. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. The Canadian journal of hospital pharmacy. 2010;63:196-206.
[40] van den Heever T. Therapeutic drug monitoring for continuous infusion of vancomycin in critically ill patients. Dissertation, Department Critical Care University of the Free State, Universitas and Pelonomi Hospital, Bloemfontein, Free State. 2011.
[41] Sin JH, Newman K, Elshaboury RH, Yeh DD, de Moya MA, Lin H. Prospective evaluation of a continuous infusion vancomycin dosing nomogram in critically ill patients undergoing continuous venovenous haemofiltration. The Journal of antimicrobial chemotherapy. 2018;73:199-203.
[42] Lin H, Yeh DD, Levine AR. Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients. Critical care (London, England). 2016;20:205.
[43] Spadaro S, Berselli A, Fogagnolo A, Capuzzo M, Ragazzi R, Marangoni E, et al. Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction. BMC anesthesiology. 2015;15:95.
[44] Saugel B, Nowack MC, Hapfelmeier A, Umgelter A, Schultheiss C, Thies P, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. Journal of critical care. 2013;28:9-13.
[45] Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. The American surgeon. 2013;79:1185-90.
[46] Spapen HD, Janssen van Doorn K, Diltoer M, Verbrugghe W, Jacobs R, Dobbeleir N, et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Annals of intensive care. 2011;1:26.
[47] Stepan M, Chytra I, Pelnar P, Bergerova T, Kasal E. Continuous infusion versus intermittent administration of vancomycin in critically ill patients with Gram-positive infections resistant to beta-lactam antibiotics. Anesteziologie a intenzivni medicina. 2009;20:309-16.
[48] Perin N, Roger C, Marin G, Molinari N, Evrard A, Lavigne JP, et al. Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics (Basel, Switzerland). 2020;9.
[49] Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. Journal of burn care & research : official publication of the American Burn Association. 2012;33:e254-62.
[50] Vázquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. International journal of clinical pharmacology and therapeutics. 2008;46:140-5.
[51] Lacave G, Caille V, Bruneel F, Palette C, Legriel S, Grimaldi D, et al. Incidence and risk factors of acute kidney injury associated with continuous intravenous high-dose vancomycin in critically ill patients: A retrospective cohort study. Medicine. 2017;96:e6023.
[52] Cristallini S, Hites M, Kabtouri H, Roberts JA, Beumier M, Cotton F, et al. New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. Antimicrob Agents Chemother. 2016;60:4750-6.
[53] Baptista JP, Roberts JA, Sousa E, Freitas R, Deveza N, Pimentel J. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. Critical care (London, England). 2014;18:654.
[54] Saugel B, Gramm C, Wagner JY, Messer M, Lahmer T, Meidert AS, et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. Journal of critical care. 2014;29:351-5.

[55] Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolff F, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. The Journal of antimicrobial chemotherapy. 2013;68:2859-65.
[56] Cianferoni S, Devigili A, Ocampos-Martinez E, Penaccini L, Scolletta S, Abdelhadii A, et al. Development of acute kidney injury during continuous infusion of vancomycin in septic patients. Infection. 2013;41:811-20.
[57] Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents. 2013;41:564-8.
[58] Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013;41:261-6.
[59] Ocampos-Martinez E, Penaccini L, Scolletta S, Abdelhadii A, Devigili A, Cianferoni S, et al. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. Int J Antimicrob Agents. 2012;39:332-7.
[60] Albanèse J, Léone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44:1356-8.
[61] Omuro PK, Chackupurakal R, Fetz K, Wappler F, Sakka SG. Impact of continuous vs. intermittent vancomycin treatment on kidney function of critically ill patients. Anästhesiologie und Intensivmedizin. 2021;62:375-84.
[62] Carricajo A, Forgeot A, Morel J, Auboyer C, Zeni F, Aubert G. [Dosage adjustment of vancomycin in continuous infusion in critically ill-patients]. Annales francaises d'anesthesie et de reanimation. 2010;29:55-7.
[63] Di Filippo A, De Gaudio AR, Novelli A, Paternostro E, Pelagatti C, Livi P, et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy. 1998;44:63-8.
[64] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology. 2009;62:1006-12.
[65] Wells GA, Wells G, Shea B, Shea B, O'Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014.
[66] Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. Journal of evidence-based medicine. 2015;8:2-10.
[67] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
[68] Ryan R, Hill S, Prictor M, J. M. Cochrane Consumers and Communication group Study Quality Guide (CCCG). La Trobe University, Melbourne. ; 2013.
[69] Dowell SF. Seasonal variation in host susceptibility and cycles of certain infectious diseases. Emerging infectious diseases. 2001;7:369-74.
[70] Schwab F, Gastmeier P, Hoffmann P, Meyer E. Summer, sun and sepsis-The influence of outside temperature on nosocomial bloodstream infections: A cohort study and review of the literature. PloS one. 2020;15:e0234656.
[71] Schwab F, Geffers C, Behnke M, Gastmeier P. ICU mortality following ICU-acquired primary bloodstream infections according to the type of pathogen: A prospective cohort study in 937 Germany ICUs (2006-2015). PloS one. 2018;13:e0194210.
[72] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology. 2014;14:135.
[73] Altman DG, Bland JM. How to obtain the P value from a confidence interval. Bmj. 2011;343:d2304.

[74] Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents. 2006;27:259-62.
[75] Tuon FF, Yamada CH, Cieslinski J, Dos Santos Oliveira D, Ribeiro VST, Gasparetto J, et al. Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis. Therapeutic drug monitoring. 2021;43:807-11.
[76] Hanrahan TP, Harlow G, Hutchinson J, Dulhunty JM, Lipman J, Whitehouse T, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Critical care medicine. 2014;42:2527-36.
[77] ACCP/SCCM. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical care medicine. 1992;20:864-74.
[78] Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical care medicine. 2003;31:1250-6.
[79] Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-55.
[80] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315:801-10.
[81] Jager NGL, van Hest RM, Lipman J, Roberts JA, Cotta MO. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert review of clinical pharmacology. 2019;12:623-34.
[82] EUCAST (The European Committee on Antimicrobial Susceptibility Testing). Antimicrobial wild type distributions of microorganisms. 2023.
[83] Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC infectious diseases. 2021;21:153.
[84] Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020;77:835-64.
[85] Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. PloS one. 2016;11:e0146224.
[86] Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents. 2013;41:439-46.
[87] Dalton BR, Rajakumar I, Langevin A, Ondro C, Sabuda D, Griener TP, et al. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26:436-46.
[88] Sandiumenge A, Diaz E, Bodí M, Rello J. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive care medicine. 2003;29:876-83.
[89] Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004;38:521-8.

[90] Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. The Journal of antimicrobial chemotherapy. 2006;57:699-704.
[91] Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Critical care medicine. 2009;37:840-51; quiz 59.
[92] Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical pharmacokinetics. 2004;43:925-42.
[93] Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;36:1418-23.
[94] Saran R, Robinson B, Abbott K, al. e. US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75:suppl 1.
[95] Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther. 2013;35:772-9.
[96] Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52:975-81.
[97] Wang Y, Dai N, Wei W, Jiang C. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older. Clinical interventions in aging. 2021;16:1023-35.
[98] Kan WC, Chen YC, Wu VC, Shiao CC. Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application. International journal of molecular sciences. 2022;23.
[99] Koeze J, Keus F, Dieperink W, van der Horst IC, Zijlstra JG, van Meurs M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. BMC nephrology. 2017;18:70.
[100] Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical care (London, England). 2007;11:R31.
[101] Eknoyan G, Lameire N, Eckardt K, BI K. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Official Journal of the International Society of Nephrology. 2012;2.
[102] Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. The Journal of antimicrobial chemotherapy. 2008;62:168-71.
[103] Jeffres MN. The Whole Price of Vancomycin: Toxicities, Troughs, and Time. Drugs. 2017;77:1143-54.
[104] Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55:3278-83.
[105] Carreno J, Smiraglia T, Hunter C, Tobin E, Lomaestro B. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. Int J Antimicrob Agents. 2018;52:643-50.
[106] Summerfield SG, Yates JWT, Fairman DA. Free Drug Theory - No Longer Just a Hypothesis? Pharmaceutical research. 2022;39:213-22.
[107] Tsuji BT, Leonard SN, Rhomberg PR, Jones RN, Rybak MJ. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagnostic microbiology and infectious disease. 2008;60:441-4.
[108] Ackerman BH, Taylor EH, Olsen KM, Abdel-Malak W, Pappas AA. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988;22:300-3.

[109] De Cock PA, Desmet S, De Jaeger A, Biarent D, Dhont E, Herck I, et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? The Journal of antimicrobial chemotherapy. 2017;72:801-4.
[110] Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. Journal of clinical pharmacology. 2014;54:318-23.
[111] Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int J Antimicrob Agents. 2009;34:555-60.
[112] Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2013;17:e93-e100.
[113] Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Jr., Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-9.
[114] Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical care (London, England). 2004;8:R204-12.
[115] Ricard JD, Wolff M, Lacherade JC, Mourvillier B, Hidri N, Barnaud G, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007;44:250-5.
[116] Tiede C, Chiriac U, Dubinski D, Raimann FJ, Frey OR, Röhr AC, et al. Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion. Antibiotics (Basel, Switzerland). 2021;10.
[117] Wysocki M, Thomas F, Wolff MA, Pean Y, Ravaud Y, Herman B. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. The Journal of antimicrobial chemotherapy. 1995;35:352-4.
[118] Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55:2704-9.
[119] Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848-52.
[120] Pea F, Viale P, Cojutti P, Furlanut M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012;56:6343-8.
[121] Minichmayr IK, Roberts JA, Frey OR, Roehr AC, Kloft C, Brinkmann A. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. The Journal of antimicrobial chemotherapy. 2018;73:1330-9.
[122] Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. The New England journal of medicine. 1980;302:1106-9.

8 Tables and Figures

8.1 Definition of nephrotoxicity

***Table 1**: Compilation of all definitions of acute renal insufficiency (AKI) used in the included publications.*

	Serum creatinine (SCr)		**CrCl/eGFR$_{MDRD}$**	**Urine output (UO)**		**AKI range**	**Reference**
Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (Rybak2009) [113]:						5%	[43]
	SCr ↑ ≥1.5x baseline SCr	*or* SCr ↑ ≥0.5 mg/dL					
	for ≥2 consecutive measurements after several days of vancomycin therapy and in absence of alternative explanation						
KDIGO (2012) [101]						60%	[48]
1	SCr ↑ 1.5-1.9x baseline SCr (7 d)	*or* SCr ↑ ≥0.3 mg/dL (48 h)		<0.5 mL/kg/h for 6-12 h			
2	SCr ↑ 2.0-2.9x baseline SCr			<0.5 mL/kg/h for ≥12 h			
3	SCr ↑ ≥3.0x baseline SCr	*or* SCr ↑ ≥4.0 mg/dL	*or* initiation of RRT	<0.3 mL/kg/h for ≥24 h	*or* anuria for ≥12 h		
AKIN criteria (2007) [100]						20-50%	[33, 46, 61, 75]
1	SCr ↑ 1.5-2.0x baseline SCr (7 d)	*or* SCr ↑ ≥0.3 mg/dL (48 h)		<0.5 mL/kg/h for >6 h			
2	SCr ↑ 2.0-3.0x baseline SCr	*or* SCr ↑ ≥0.5 mg/dL		<0.5 mL/kg/h for >12 h			
3	SCr ↑ >3.0x baseline SCr	*or* acute SCr ↑ ≥0.5 mg/dL if SCr is ≥4 mg/dL	*or* initiation of RRT	<0.3 mL/kg/h for ≥24 h	*or* anuria for ≥12 h		
RIFLE category (ADQI) (2004) [114]						25-37%	[33, 76]
Risk	SCr ↑ ≥1.5x baseline SCr		*or* eGFR ↓ >25% from baseline	<0.5 mL/kg/h for 6-12 h			
Injury	SCr ↑ ≥2.0x baseline SCr		*or* eGFR ↓ >50% from baseline	<0.5 mL/kg/h for ≥12 h			
Failure	SCr ↑ ≥3.0x baseline SCr	*or* acute SCr ↑ ≥0.5 mg/dL if SCr is ≥4 mg/dL	*or* eGFR ↓ >75% from baseline	<0.3 mL/kg/h for ≥24 h	*or* anuria for ≥12 h		
Loss	Persistent acute renal failure (AFR): complete loss of kidney function for >4 weeks (requiring dialysis)						
ESRD	Complete loss of kidney function for >3 months (requiring dialysis)						
Other							
	Increase in SCr by >0.3 mg/dL on ≥2 consecutive days					6%	[53]
	Increase in SCr by 50% from baseline until the end of treatment					16%	[34]
	Increase in SCr by 0.5 mg/dL or ≥50% from baseline over 2 consecutive SCr values					0%	[42]
	Increase in SCr by 0.5 mg/dL or ≥50% from baseline to end of treatment; CVVH: daily urine output <0.3 mL/kg					20%	[49]
	Increase in SCr by 0.3 mg/dL or ≥50-100% from baseline over 2 consecutive days during and within 72 h after VCM discontinuation and/or daily urine output <0.5 mL/kg/h					24%	[56]
	Increase of SCr					0%	[47]
	Reduction of CrCl					0%	[47]
	Hemodialysis upon discharge from hospital					0%	[42]

	Start of RRT	7%	[44]
	Alterations in renal function	0%	[74]

ADQI: Acute Dialysis Quality Initiative, AHSP: American Society of Health-System Pharmacists, AKIN: Acute Kidney Injury Network, CrCl: creatinine clearance, eGFR: estimated glomerular filtration rate, ESRD: End Stage Renal Disease, IDSA: Infectious Diseases Society of America, KDIGO: Kidney Disease Improving Global Outcomes, MDRD: Modification of Diet in Renal Disease, ND: not described , PIDS: Pediatric Infectious Diseases Society, RRT: renal replacement therapy, SCr: serum creatinine, SIDP: Society of Infectious Diseases Pharmacists, ↑: increase, ↓: reduction

8.2 Flowchart

***Figure 1**: Flowchart of the study selection.*



8.3 Overview

***Table 2**: Overview of the main characteristics of the twenty-one included studies with continuous infusion of vancomycin.*

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome			
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results	
Akers 2012 [49]	USA	Retrospective single-center cohort study	2009/12-2006/01	Surgical (burn)	90		Burn patients (100%)	Css: 20-25 AUC24: ≥ 400	**Overall therapy:** 20.0±3.8 Gram-positive bacteremia: 19.3±3.2 Sepsis without proven gram-positive bacteremia: 21.2±4.2 Pneumonia: 22.0±3.9 Lack of postinfusion peak data prevented actual calculation of AUC	ECF	Mortality (in-hospital, 14-day, 28-day)	In-hospital mortality: All: 32.2% (29/90) Non-CVVH: 19.1% (13/68) Gram-positive bacteremia: 16 % (4/25) (4.4% (4/90)) Sepsis without gram-positive bacteremia: 70% (14/20) (15.6% (14/90)) Pneumonia: 35% (7/20) / 7.8% (7/90)	14-d mortality: All: 10% (9/90) 28-d mortality: All: 18.9% (17/90)
										EMF	Recurrence of gram-positive bacteremia after beginning of CI	MSSA: (2 of an unknown quantity) MRSA: (2 of an unknown quantity) Enterococci: (3 of an unknown quantity)	CI+II: 17.5% (10/57)
										SR	Non-CVVH: Increase in SCr by ≥ 0.5 mg/dL or at least 50% increase from start to end of vancomycin therapy CVVH: Urine output <0.3 mL/kg/d	All (CVVH + Non-CVVH): ≥ 50% SCr increase: 7.8% (7/90) ≥ 0.5 mg/dL SCr increase at end of therapy: 6.7% (6/90) ≥ 0.5 mg/dL SCr increase at any time during therapy: 20% (18/90) Non-CVVH: ≥ 50% SCr increase: 10.4% (7/68) ≥ 0.5 mg/dL SCr increase at end of therapy: 8.8% (6/68) ≥ 0.5 mg/dL SCr increase at any time during therapy: 22.1% (15/68)	
										SNR	Bone marrow toxicity: Difference in leukocytes, neutrophils and platelets at the beginning and end of CI	Leukocytes (x1000/µL): Start of CI 10.6 (8.4-17.5); End of CI: 12.2 (8.4-18.8) (p=0.22) Neutrophils (x1000/µL): Start of CI: 9.1 (6.7-14.8); End of CI: 9.9 (6.4-16.5) (p=0.33) Platelets (x1000/µL): Start of CI: 176 (101-271); End of CI: 236 (108-417) (p=0.001)	
Baptista 2014 [53]	Portugal	Retrospective/ Prospective single-center cohort study	A (MD 30 mg/kg/d): 13 months; B (MD nomogram): ND	Medical: A: 39.2% B: 20.0% Surgical: A: 60.8% B: 80.0%	104	A (MD 30 mg/kg/d): 79 B (MD nomogram): 25	Augmented renal clearance (77%) Mechanical ventilation (100%) Sepsis (100%)	Css: 20-30	**24 h:** A: 21.5±6.4 B: 24.5±5.2	SR	Increase in SCr by >0.3 mg/dL on ≥ 2 consecutive days	A (MD 30 mg/kg/d): 6.3% (5/79) B (MD nomogram): 4.0% (1/25)	
										SNR	Red-man-syndrome	ND	
Beumier	Belgium	Prospective	2012/05-	Medical: 69%	32		CRRT (100%)	Css: 20-30	**24 h:**	ECF	Mortality (ICU)	57% (18/32)	

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome				
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results		
2013 [55]		single-center cohort study	2011/01	Surgical: 31%			Mechanical ventilation (78%) Sepsis (100%)	AUC24: >400	24.3±9.3 679±150	ECS	Target attainment	*Target:* **12 h**: 69% **24 h**: 63%	*Subtherapeutic*: **12 h**: 3% **24 h**: 19%	*Supratherapeutic*: **12 h**: 28% **24 h**: 19%
Cianferoni 2013 [56]	Belgium	Retrospective single-center cohort study	2009/12-2008/01	Medical: All: 59% No AKI: 59% AKI: 62% (Early AKI: 60% Late AKI: 63%) Surgical: All: 41% No AKI: 41% AKI: 38% (Early AKI: 40% Late AKI: 37%)	207	No AKI: 157 AKI: 50 (Early AKI: 28 Late AKI: 22)	Mechanical ventilation (69%) Sepsis (100%)	Css: 20-30	**Overall therapy**: All: 22.3±7.0 No AKI: 21.2±6.8 AKI: 25.8±6.6 (Early AKI: 27.2±5.1 Late AKI: 24.1±7.8) **24 h**: All: 19.7±8.5 No AKI: 18.7±7.0 AKI: 22.5±9.6 (Early AKI: 24.5±7.8 Late AKI: 20.2±11.1)	ECF	Mortality (ICU)	All: 23% (48/207) No AKI: 18% (28/157) AKI: 40% (20/50)		Early AKI: 46% (13/28) Late AKI: 32% (7/22)
										SR	Daily urine output <0.5 ml/kg/h and/or increase of SCr ≥0.3 mg/dl or 50-100% increase from baseline (=VCM on first day of therapy) on at least two consecutive days during and within 72 h after VCM discontinuation Early AKI: Occurrence within first 2 days of therapy; Late AKI: Occurrence after 2 days of therapy; Severe AKI: Need for CRRT or HD within VCM therapy or up to 3 days after drug discontinuation	Total: 24% (50/207) VCM level <15 mg/L: 6% (2/34) 15-20 mg/L: 11% (5/47) 20-25 mg/L: 30% (18/60) 25-30 mg/L: 38% (15/39) >30 mg/L: 37% (10/27)	Early AKI: 56% (28/50) Late AKI 44% (22/50) CRRT/HD: No AKI: 2% (3/157 patients needing CRRT 9/11/13 d after VCM discontinuation) AKI: 18% (9/50) during VCM therapy	
Covajes 2013 [58]	Belgium	Retrospective single-center cohort study	2010/12-2008/01	Medical: 69% Surgical: 31%	85		CRRT (100%) Mechanical ventilation (84%) Sepsis (100%)	Css: 20-30	**24 h**: 24.7±9.0 **48 h**: 26.0±8.1 **72 h**: 27.7±9.3	ECF	Mortality (ICU)	59% (50/85)		
										ECS	Target attainment	*Target:* **24 h**: 51% **48 h**: 56% **72 h**: 67%	*Subtherapeutic*: **24 h**: 29% **48 h**: 22% **72 h**: 8%	*Supratherapeutic*: **24 h**: 20% **48 h**: 21% **72 h**: 26%
Cristallini 2016 [52]	Belgium	Prospective single-center cohort study	2013/05-2012/01	Medical: 36% Surgical: 64%	107		Mechanical ventilation (54%) Sepsis (100%)	Css: 20-30 AUC24: ND	**12 h**: 26.0±8.3 **24 h**: 23.0±6.8 **48 h**: 26.0±6.0 780±180	ECF	Mortality (ICU)	22% (24/107)		
										ECS	Target attainment	**12 h**: 56% **24 h**: 54% **48 h**: 73%		
Hanrahan 2014 [76]	UK	Retrospective single-center cohort study	2009/08-2004/12	Medical Surgical	653		ND	Css: ND	**Overall therapy**: 18.4±4.2	ECF	Mortality (ICU all-cause; within 72 h of last recorded VCM dose)	ICU: 26.3% (172/653) Mortality or nephrotoxicity within 72 h of cessation: 38.7% (253/653)	Within 72 h of last VCM: 19.9% (130/653)	
										SR	AKI (RIFLE [114])	24.7% (161/653) Nephrotoxicity or mortality within 72 h of cessation: 38.7% (253/653)		
Hutschala 2009 [33]	Austria	Retrospective single-center cohort study	2005/12-2001/01	Surgical (cardiosurgical)	119		Cardiosurgery (100%) CKD (0%; SCr >1.5 mg/dL))	Css: 20-25 AUC24: ND	**Overall therapy**: 25.0±4.0 Time to target: 16±8 h 529±98	ECF	Mortality (ICU, in-hospital)	ICU: 21% (25/119); In-hospital: 30.3% (36/119)	Timing of death in course of VCM administration: 9±3.3 d (1-20)	
										ECS	Improvement (= Reduction of CRP; leukocytes)	CRP: -66.4±41.6% ((before CS: 3,7±5,1 (0.5-25.1) at start of VCM: 22.64±10.1 (7.3-55); on 10th day of VCM: 7.6±5.69 (0.7-32.1))		
										SR	AKI (AKIN [100] and RIFLE [114])	**AKIN**: 49.6% (59/119)	RRT: 23.5% (28/119)	

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome				
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results		
												AKIN: 1: 29.4%; 2: 11,8 %; 3: 8.4 % **RIFLE**: 37% (44/119) RIFLE: R: 30.3%; I: 4.2 %; F: 2.5 %	Necessity to administer diuretics (furosemide): 12.6% (15/119)	
Lin 2016 [42]	USA	Retrospective single-center cohort study	2015/01-2013/01	Surgical	52	Obese (BMI >35 kg/m²): 26 Non-obese (BMI <30 kg/m²): 26	CVVH (35%) Differentiation obese/non-obese Mechanical ventilation (~100%)	Css: 15-25 AUC24: ND	**24 h:** All: 20.32±3.72 Obese: 20.3±3.81 Non-obese: 20.03±3.8 CVVH: Obese: 19.8±3.05 Non-obese: 21.6±3.02 Preserved renal function: Obese: 20.6±4.21 Non-obese: 19.6±4.41 Obese: 488±91.5 Non-obese: 480.9±91 CVVH: Obese: 474±73.2 Non-obese: 517±48.6 Preserved renal function: Obese: 496±101 Non-obese: 471±106	ECF	Mortality (in-hospital)	50% (7/14)		
										ECS	Target attainment	**24 h:** Obese: 92.3% Non-obese: 88.5%	CVVH Obese: 100% Non-obese: 100%	
										SR	Not requiring CVVH: Increase in SCr by 0.5 mg/dL or at least 50 % increase from baseline over two consecutive SCr values Hemodialysis upon discharge from hospital	AKI: 0%; Hemodialysis: 0%		
										SNR	Hearing loss	Hearing loss: 0%		
Mohammedi 2006 [74]	France	Prospective single-center cohort study	12 months	Medical	40	A (LD 500 mg): 20 B (LD 15 mg/kg): 20	Mechanical ventilation (90%) Sepsis (100%)	Css: 20	**24 h:** A: 14.9±5.4 B: 18.5±6.4	ECF	Mortality (ICU)	A (LD 500 mg): 50% (10/20)	B (LD 15 mg/kg): 35% (7/20)	
										ECS	Cure (in patients with proven infection)	A (LD 500 mg): 56% (10/18)	B (LD 15 mg/kg): 93% (14/15)	
										SR	Alterations in renal function	0%		
Ocampos-Martinez 2012 [59]	Belgium	Retrospective single-center cohort study	2009-2008	Medical: 59.8% Surgical: 40.2%	261		Mechanical ventilation (71%) Sepsis (100%)	Css: 20-30	**24 h:** 20.4±8.9 **48 h:** 24.1±9.1 **72 h:** 25.5±10.1 Time to target: 2 d (1-3)	ECF	Mortality (ICU)	29% (77/261)		
										ECS	Target attainment	*Target:* **24 h:** 47% **48 h:** 67% **72 h:** 86%	*Subtherapeutic:* **24 h:** 42% **48 h:** 14% **72 h:** ND	*Supratherapeutic:* **24 h:** 11% **48 h:** 19% **72 h:** ND
Omuro 2021 [61]	Germany	Retrospective single-center cohort study	2019-2012	Medical: 30.3% Surgical: 68.9% Neurolog.: 0.8%	119		CKD (8%) Mechanical ventilation (87%)	Css: 20-40	**Overall therapy:** 20.7±7.9	ECF	Mortality (ICU)	CI: 25.2% (30/119)	(VCM-AKI (CI+II): 48%	Non VCM-AKI (CI+II): 16.8%)
										SR	AKI (AKIN [100])	20,2% (eventually higher rate of AKI in medical patients (CI/II: surgical: 25,7%; medical: 42,6%))		
Perin 2020 [48]	France	Retrospective single-center	2018/12-2016/01	No data on type of ICU provided	179		Augmented renal clearance (4%)	Css: 20-25	**24-48 h:** 20.3±6.8	ECF	Mortality (ICU, in-hospital, 28-day)	**28-day:** All: 26% (46/178)	D2/3 VCM level 20-25 mg/L: 19% (8/42) D2/3 VCM level <20/>25 mg/L: 28% (37/132)	

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome				
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results		
		cohort study			Primary outcome: 176 Finished follow-up: 131 (follow-up = 15 consecutive days after VCM initiation)		Mechanical ventilation (85%) RRT (27%)			ECF	Persistence or progression of baseline signs and symptoms of infection after ≥ 2 d of treatment, consistent with active infection Requirement for additional antibacterial treatment	Failure without identification: 13% (23/179)		
										ECS	Target attainment	**24-48 h**: 24%		
										ECS	Cure (= Resolution of clinical signs and symptoms compared with baseline, no requirement for antibiotic escalation)	65% (116/179) (test of cure could not be assessed in 13% (23/179))		
										EMF	Relapse (= Finding of same pathogen); Reinfection (= Presence of another pathogen)	Relapse: 3% (5/179) Reinfection 7% (12/179)		
										SR	AKI (KDIGO [101] (measured on D1-4; D10; D15))	During VCM administration: 60% (107/179) With RRT: 27% (49/179)	VCM >25 mg/L at d2/3: 77% (34/44) With RRT: 36% (16/44)	VCM <25 mg/L at d2/3: 55% (72/131) With RRT: 25% (33/131)
Saugel 2013 [44]	Germany	Retrospective single-center cohort study	2008/12-2004/01	Medical	164		Mechanical ventilation (54%) RRT (43%)	Css: 20-30	**Overall therapy**: 19.7±14.7	SR	Start of RRT	7.3% (12/164)		
Sin 2018 [41]	USA	Prospective single-center cohort study	2017/01-2014/11	Surgical: 65.4% Medical: 34.6%	52		CVVH (100%)	Css: 15-25	**24 h**: 20.1±4.7 **48 h**: 20.7±3.7 **72 h**: 21.9±3.5	ECF	Mortality (in-hospital)	63.5% (33/52)		
										ECS	Target attainment	*Target*: **24 h**: 82.7% **48 h**: 81.8% **72 h**: 75.0%	*Subtherapeutic*: **24 h**: 3.8% **48 h**: 6.1% **72 h**: 8.3%	*Supratherapeutic* **24 h**: 13.5% 48 h: 12.1% **72 h**: 16.7%
										SNR	Infusion reaction; Ototoxicity	0%		
Spadaro 2015 [43]	Italy	Retrospective single-center cohort study	2013/07-2010/03	Medical: CrCl >50 mL/min: 57% ≤50 mL/min: 50% Surgical: CrCl >50 mL/min: 43% ≤50 mL/min: 50%	348	CrCl >50 mL/min: 210 CrCl ≤50 mL/min: 138	CKD (40% CrCl ≤50 mL/min) Differentiation in CrCl ≤/>50 mL/min	Css: 15-25 AUC24: >400	Not described CrCl >50 mL/min: 468±79 (AUC/MIC) CrCl ≤50 mL/min: 490±84 (AUC/MIC)	ECF	Mortality (ICU)	CrCl >50 mL/min: 21.4% (45/210)	CrCl ≤50 mL/min: 23.9% (33/138)	
										ECS	Target attainment	**24 h**: CrCl >50 mL/min: 44% CrCl ≤50 mL/min: 57%	**48 h**: CrCl >50 mL/min: 41% CrCl ≤50 mL/min: 40%	**72 h**: CrCl >50 mL/min: 41% CrCl ≤50 mL/min: 41%
										SR	AKI (Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) [113])	CrCL >50 mL/min: 2.4% (5/210) CrCL ≤50 mL/min: 9.4% (13/138)	VCM level 25-30 mg/L: 0% VCM level >30 mg/L: <8%	
Spapen 2011 [46]	Belgium	Retrospective two-center cohort study	2009/11-2008/01	No data on type of ICU provided	129	AKI: 38 No AKI: 91	CKD (0%; SCr >1.5 mg/dL))	Css: 15-25	**Overall therapy**: VCM level <25 mg/L: No AKI: 95.6% (65/68) (71.4%, 65/91)	ECF	Mortality (no differentiation between "infection-related" or "AKI-induced")	AKI: 53% (20/38)	No AKI: 20% (18/91)	
										SR	AKI (AKIN [100] 1)	Total: 29.5% (38/129)	VCM level 25-30 mg/L:	

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome			
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results	
									AKI: 4.4% (3/68) (7.9%, 3/38) VCM level 25-30 mg/L: No AKI: 69.0% (20/29) (22.0%, 20/91) AKI: 31.0% (9/29) (23.7%, 9/38) VCM level >30 mg/L: No AKI: 18.8% (6/32) (6.6%, 6/91) AKI: 81.3% (26/32) (68.4%, 26/38)			Distribution according to VCM level: VCM level <25 mg/L: 7.9% (3/38) VCM level 25-30 mg/L: 23.7% (9/38) VCM level >30 mg/L: 68.4% (26/38) VCM level <25 mg/L: No AKI: 95.5% (65/68) (71.4% (65/91)) AKI: 4.5% (3/68) (7.9% (3/38))	No AKI: 69% (20/29) (22% (20/91)) AKI: 31% (9/29) (23.7% (9/38)) VMC level >30 mg/L: No AKI: 18.8% (6/32) (6.6% (6/91)) AKI: 81.3% (26/32) (68.4% (26/38)) Return of SCr to baseline at discharge (surviving): 66% (12/18)
Stepan 2009 [47]	Czeck Republic	Prospective single-center randomized controlled trial	2008/05-2004/05	Medical and Surgical	33		ND	Css: 15-25	**Overall therapy:** 19.0±4.3	ECF	Mortality (infection-related)	18% (6/33)	
										ECF	Persistence of symptoms; Increase of symptoms	Not described	
										ECS	Cure (= Vanishing of all symptoms of an infection); Improvement (= Reduction of symptoms of infection; LOS; LOV; LOT; Reduction of leukocytes; Reduction of CRP)	Cure/improvement: 64% (21/33) LOS: 26 d (12.8-40.3) LOV: 25 d (10.5-39.3)	LOT: 9 (7-10) Leukocytes: d0: 13.4 (9,7-18.9) end: 10.9 (8.6-17.9) (-18.7%) CRP: d0: 192.0±98.1 end: 123±83.1 (-35.9%)
										EMF	Persistency; Superinfection; Relapse	Not described	
										EMS	Cure (=Eradication; Suspected eradication)	76% (25/33)	
										SR	Increase of SCr; Reduction of CrCl	0%	
Tuon 2021 [75]	Brazil	Prospective single-center cohort study	2020/09-2018/01	No data on type of ICU provided	33		CNS infection (100%)	Css: ND AUC24: ND	**Overall therapy:** 33.8±16.0 788±384	SR	AKI (AKIN [100])	Total: 21% (7/33) AKIN 1: 3% (1/33)	AKIN 2: 6% (2/33) AKIN 3: 12% (4/33)
Udy 2013 [57]	Australia	Retrospective single-center cohort study	2010/12-2008/01	No data on type of ICU provided	81	CVVH: 41 CVVHDF: 40	CRRT (100%) Mechanical ventilation (85%) Sepsis (100%)	Css: 20-30	**24 h:** 24.6±9.2	ECF	Mortality (not specified)	58% (47/81)	
Wysocki 2001 [34]	France	Prospective multicenter cohort study	36 months	Medical and Surgical	61		Mechanical ventilation (79%)	Css: 20-25	**Overall therapy:** 24±8 Success: 23±4 Failure: 25±5	ECF	Mortality (infection-related: 10-day; end of treatment; overall: 10-day; end of treatment; ICU)	**Infection-related:** D10: 8% (5/61) End of treatment: 10% (6/61)	**Overall:** D10: 8% (5/61) End of treatment: 18% (11/61) **ICU:** 37% (21/61)
										ECF	Persistency or impairment of clinical, laboratory,	D10: 21% (13/61)	End of treatment: 21% (13/61)

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome			
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results	
									Time to target: 36±31 h		radiological statuses		
										ECS	Cure; Improvement	78.7% (48/61)	
								AUC24: ND	577±120	EMF	Presence of *Staphylococcus spp.* or other species in specimen on day 5	*Staphylococcus*: 39% (24/61)	Other species: 15% (9/61) Bacteremia: 28% (17/61)
									Failure: 685±260 Success: 596±159	EMS	Cure (= Eradication of *Staphylococcus spp.* In specimen on d5)	46% (28/61)	
										SR	50% increase of SCr from D0 until end of treatment	16.4% (10/61) Dialysis: 9.8% (6/61)	
										SNR	Phlebitis/fever	3% (2/61)	

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, AHSP: American Society of Health-System Pharmacists, AUC24: vancomycin area under the serum concentration-time curve for 24 hours, CI: continuous infusion of vancomycin, CrCl: creatinine clearance, Css: steady-state serum concentration, CKD: chronic kidney disease, CNS: central nervous system, CVVH: continuous veno-venous hemofiltration, CVVHDF: continuous veno-venous hemodiafiltration, d: day, D10: day 10 after initation of vancomycin therapy, ECF: failure of clinical effectivity, ECS: success of clinical effectivity, EMF: failure of microbiological effectivity, EMS: success of microbiological effectivity, h: hour, ICU: intensive care unit, IDSA: Infectious Diseases Society of America, II: intermittent infusion of vancomycin, KDIGO: Kidney Disease Improving Global Outcomes, LD: loading dose, LOS: length of stay, LOT: length of therapy, LOV: length of ventilation, MD: maintenance dose, MIC: minimum inhibitory concentration, ND: not described, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, (C)RRT: (continuous) renal replacement therapy, SNR: non-renal safety, SCr, Serum creatinine, SR: renal safety, SIDP: Society of Infectious Diseases Pharmacists, VCM: vancomycin.

***Table 3**: Significant predictors for the outcomes "acute kidney injury", "mortality" and "target attainment" identified by univariate and multivariate regression analysis in the studies.*

8.4 Significant predictors of outcomes

Univariate		Multivariate	
Target attainment (TA)		*Target attainment (TA)*	
• Loading dose (↑ dose → ↑ TA)	[59]		
• Daily vancomycin dosage (↑ dosage → ↑ TA)	[58]	• Daily vancomycin dosage (↑ dosage → ↑ TA)	[58]
• Serum creatinine (↑ SCr → ↑ TA)	[59]		
• Creatinine clearance (↓ CrCl → ↑ TA)	[59]	• Creatinine clearance (↓ CrCl → ↑ TA)	[52, 59]
• CRRT intensity (↓ intensity → ↑ TA)	[55, 58]	• CRRT intensity (↓ intensity → ↑ TA)	[58]
• Age (↓ age → ↑ TA)	[58]	• Age (↓ age → ↑ TA)	[58]
• Body weight (↑ body weight → ↑ TA)	[52, 55]	• Body weight (↑ body weight → ↑ TA)	[52]
		• Body mass index (↑ BMI → ↑ TA)	[52]
• Gender (male → ↓ TA)	[59]	• Gender (male → ↓ TA)	[59]
• Prolonged ICU stay before initiation of vancomycin (↑ stay → ↓ TA)	[48]	• Prolonged ICU stay before initiation of vancomycin (↑ stay → ↓ TA)	[48]
• SOFA score (↑ score → ↑ TA)	[59]		
ICU mortality		*In-hospital mortality*	
• AKI (AKI → ↑ mortality)	[61]	• C24 <15 mg/L (↓ C24 → ↑ mortality)	[43]
		• SAPS II score (↑ score → ↑ mortality)	[43]
Acute kidney injury (AKI)		*Acute kiney injury (AKI)*	
• Diabetes mellitus (diabetes → ↑ AKI)	[46]	• Css of CI (esp. >30 mg/L) (↑ Css → ↑ AKI)	[46, 56, 76]
• Shock (shock → ↑ AKI)	[46]	• Duration of therapy (at time of highest SCr (risk/injury)) (↑ duration → ↑ AKI)	[56, 76]

Univariate	Multivariate	
	• CrCl at ICU admission	[43]
	• Body weight (↑ lean body weight → ↑ AKI)	[46]
	• SAPS 3 score (↑ score → ↑ AKI)	[46]
	Early AKI	
	• Bacteremia (bacteremia → ↑ AKI)	[56]
	• Cmean day 1-3 (↑ Cmean → ↑ AKI)	[56]
	• Daily vancomycin dosage (day 1-3) (↓ dosage → ↑ AKI)	[56]
	Late AKI	[56]
	• Diabetes (diabetes → ↑ AKI)	[56]
	• Duration of therapy (↑ duration → ↑ AKI)	[56]

AKI: acute kidney injury, BMI: body mass index, C24: mean steady-state vancomycin serum concentration about 24 hours after initiation of therapy, Cmean: mean steady-state vancomycin serum concentration during the entire duration of therapy or at least three days of therapy, CI: continuous infusion of vancomycin, CrCl: creatinine clearance, CRRT: continuous renal replacement therapy, Css: steady-state serum concentration, ICU: intensive care unit, SAPS: Simplified Acute Physiology Score, SCr: serum creatinine, SOFA score: Sepsis-related Organ Failure Assessment score, TA: target attainment, ↑: increase, ↓: reduction

8.5 Target attainment

***Figure 2**: Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's rate of target attainment. **a)** Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=9 studies representing 953 patients). **b)** Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=4 studies representing 488*



Filled square: Css target range of 20-30 mg/L, filled circle: Css target range of 15-25 mg/L, filled triangle: Css target range of 20-25 mg/L,

aLD: applied average loading dose, aMD: applied average maintenance dose, Sepsis: proportion of patients with sepsis in the study population

8.6 Mortality



Figure 3*: Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's mortality rate. The dashed lines represent the regression lines (RL) of ICU mortality (▲ filled black triangle) in studies without 100% dialysis patients.* ***a)*** *Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=10). RL: n=4 studies representing 615 patients; R^2=0.7435.* ***b)*** *Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=10). RL: n=6 studies representing 1,420 patients; R^2=0.0057.* ***c)*** *Studies in which mean vancomycin areas under the serum concentration-time curve for 24 h for continuously administered vancomycin (AUC24) were reported (n=6). RL: n=4 studies representing 635 patients;*

Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered cross: in-hospital mortality, X: x-day mortality (e.g. 10-day, 28-day, 30-day), non-filled circle: mode of mortality not reported, non-filled square: infection-related mortality.

CKD: chronic kidney disease, (C)RRT: (continuous) renal replacement therapy, CVVH: continuous veno-venous hemofiltration, ICU: intensive care unit, SCr: serum creatinine.

8.7 Nephrotoxicity

Figure 4**: Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's rate of acute kidney injury (AKI) (= Nephrotoxicity). The dashed lines represent the regression lines calculated from the data of all cohorts of a respective Css class.* ***a) *Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=5 studies representing 582 patients; R^2=0.0242).* ***b)*** *Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=9 studies representing 1,479 patients; R^2=0.1174).* ***c)*** *Studies in which mean vancomycin areas under the serum concentration-time curve for 24 h for continuously administered vancomycin (AUC24) were reported (n=5 studies representing 613 patients; R^2=0.0411).*



Filled black diamond: AKIN, filled black square: KDIGO, squared triangle: other definition of AKI, star: RIFLE, non-filled triangle: RRT, non-filled diamond: Rybak2009 AKIN: Acute Kidney Injury Network, KDIGO: Kidney Disease Improving Global Outcomes, LOT: length of therapy with continuously administered vancomycin, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, RRT: renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-

System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

***Figure 5**: Forest plot comparing the influence of vancomycin steady-state serum concentration below or above 25 mg/L on acute kidney injury (AKI) (n=3 studies representing 515 patients). Overall risk ratio = 0.535 (95% confidence interval 0.432-0.662; z = -5.745; p = <0.0001).*



Risk ratio <1 indicates a lower risk of acute kidney injury at a vancomycin serum concentration of <25 mg/L as opposed to ≥25 mg/L. The dark grey diamond represents the overall risk ratio.

9 Supplementary data

9.1 Study Design

***Table S1**: Overview of study designs, number of patients, inclusion and exclusion criteria and primary purpose of studies. Thirty-eight studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)) or safety (e.g. acute renal failure). Only twenty-one studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified time course or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
Akers [49]	USA	Retrospective single-center cohort study	2009/12-2006/01	171	90	CI: 90; II: 81	≥1 VCM serum level (Css or trough); Burn injury; With/without high-dose CVVH; Contribution of data of patients only once	≤1 VCM level; Pediatric patients; Pregnancy; Admission for other than a primary thermal burn injury	Determination of serum vancomycin levels resulting from CI vs II in critically ill burn patients with or without CRRT
Albanèse [60] ***Excluded due to number of patients <30 and unspecified length of time course***	*France*	*Prospective single-center cohort study*	*Not described*	*13*	*13*	*Bacterial meningitis: 7;* *Other infection: 6*	*Infection with VCM-sensitive bacteria;* *Mechanical ventilation for acute respiratory failure*	*Renal dysfunction;* *Expected hospital stay <72 h;* *Pediatric patients*	*Evaluation of CSF penetration and PK of VCM after CI in mechanically ventilated patients*
Baptista [53]	Portugal	Prospective single-center	A (MD 30 mg/kg/d):	104	104	A (MD 30 mg/kg/d): 79; B (MD nomogram): 25	A: Mechanical ventilation; Adult (≥18 years); Severe sepsis	SCr >1.3 mg/dL; CKD;	Development of a dosing nomogram for administration of VCM by CI for the first 24

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
		cohort study	13 months; B (MD nomogram): Not described				or septic shock; Empirical or directed treatment with VCM; B: Administration of LD + MD per protocol; Evaluation of 8 h CrCl the day of initiation of VCM; Interval between LD and TDM >12 h + <24 h; Stable renal function;	RRT; Pediatric patients (<18 years); Pregnancy; ICU stay <48 h	h of therapy based on the measured urinary CrCl (8 h CrCl)
Beumier [55]	Belgium	Prospective single-center cohort study	2012/05-2011/01	32	32	32	Sepsis; CRRT	VCM therapy in previous 48 h	Evaluation of the adequancy of a new CI VCM regimen in septic patients undergoing CRRT; description of impact of CRRT intensity on drug concentrations; assessment of correlation between AUC/MIC and VCM concentration during CI
Carricajo [62] Excluded due to number of patients <30 and unspecified length of time course	*France*	*Prospective single-center cohort study*	*Not described*	*22*	*22*	*Microbiological identification in 12 patients*	*CrCl >50 mL/min*	*-*	*Evaluation of an administration protocol (LD 30 mg/kg; MD 30 mg/kg/d) for VCM using CI in patients with CrCl > 50 mL/min*
Cianferoni [56]	Belgium	Retrospective single-center cohort study	2009/12-2008/01	207	207	No AKI: 157; AKI: 50; (Early AKI: 28;	VCM therapy ≥48 h; VCM levels (daily); No RRT (CRRT or HD) at time of	VCM therapy within the week prior to present episode;	Evaluation of the occurrence of renal failure during CI of VCM in critically ill patients with sepsis; identification of risk factors and time

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
						Late AKI: 22)	VCM initiation; Sepsis; TBW noted in data file;	RRT; ESRD chronically treated with HD; Missing data on SCr, urine output and/or concomitant nephrotoxins	course (early vs late) of development of AKI; long-term (1 month ±7 d) consequences of CI on renal function
Covajes [58]	Belgium	Retrospective single-center cohort study	2010/12-2008/01	85	85	85	VCM therapy ≥48 h; VCM level (daily); CRRT; Sepsis according to standard criteria	Previous administration of VCM by II (within 48 h of start of CI); Residual urine output >500 mL/d; Pregnancy; Burn; Cystic fibrosis	Determination of the application of VCM by CI in septic patients receiving CRRT
Cristallini [52]	Belgium	Prospective single-center cohort study	2013/05-2012/01	107	107	107	VCM monotherapy or combination with other antibiotics; Adult (≥18 years); Sepsis	VCM application in the previous 48 h; RRT; ECMO	Validation of a dosing regime of VCM given by CI to septic patients
Di Filippo [63] Excluded due to number of patients <30 and time course of only 7 months	*Italy*	*Retrospective single-center cohort study*	*7 months*	*25*	*11*	*CI: 11;* *II: 14*	*VCM therapy ≥5 d;* *Documented MRSA/MRCoNS infection;* *Clinical cure*	*History of hypersensitivity to glycopeptides;* *Severe renal failure (=SCr >5 mg/dL);* *Pediatric patients;* *Pregnancy;* *AIDS*	*Verification of the therapeutic response/efficacy of VCM in MRS (MRSA/MRCNS) administered by CI vs II*
Duszynska [31] Excluded due to	*Poland*	*Prospective single-center cohort study*	*2014/04-2012/05*	*42*	*21*	*CI: 21;* *II: 21*	*Adult (≥18 years);* *Microbiologically confirmed gram-positive*	*History of intolerance to glycopeptides;* *CKD requiring HD;*	*Evaluation of the effectivity and safety of VCM in treatment of gram-positive pathogens other than MRSA + determination of*

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
number of patients <30							*infection;* *Non-MRSA infection*	*AKI already treated by CRRT;* *Pregnancy;* *Burn* *Cystic fibrosis*	*optimal AUC/MIC and VCM concentration for treatment of septic patient with non-MRSA gram-positive infection*
Eldemiry [38] ***Excluded due to number of patients <30***	*Egypt*	*Prospective single-center cohort study*	*2012/09-2009/11*	*40*	*20*	*CI: 20;* *II: 20*	*SCr >1.4 mg/dL;* *Oliguria <0.5 mL/kg/h for 6 h*	*SCr ≥4 mg/dL;* *RRT;* *Critical illness potentially resulting in renal dysfunction (e.g. septic shock, cardiac arrest);* *Systolic blood pressure <90 mmHg*	*Comparison of CI vs II in renally impaired critically ill patients*
Hanrahan [76]	UK	Retrospective single-center cohort study	2009/08-2004/12	1430	653	CI: 653; II: 390; Mixed Infusion: 221; Unknown Mode of Infusion: 166	First episode of VCM treatment	No VCM serum level, dosing amount, SCr; Incomplete SOFA score availability	Evaluation of VCM dose, trough and dosing strategy on evolution of AKI in critically ill patients
Hong [26] ***Excluded due to time course of only 9 months***	*USA*	*Retrospective single-center cohort study*	*2014/06-2013/10*	*130*	*65*	*CI: 65;* *II: 65*	*≥1 VCM serum level (Css or trough);* *CrCl ≥20 mL/min*	*Change between II/CI;* *CrCl (CG/MDRD) <20 mL/min;* *Dialysis: HD, PD; RRT; Postoperative prophylaxis;* *Pregnancy;* *Prisoner*	*Evaluation of target plasma level attainment and safety (nephrotoxicity) in neurosurgical ICU patients receiving CI vs II VCM*
Hutschala [33]	Austria	Retrospective single-center cohort study	2005/12-2001/01	149	119	CI: 119; II: 30	Adult (>19 years); SCr ≤1.5 mg/dL; ICU-admission after elective CS (open heart); Presumed or documented hospital acquired gram-positive infection; Preoperative no period of AKI or	VCM therapy 72 h before elective CS; Verified betalactam allergy; SCr >1.5 mg/dL; Necessity of RRT; Intraoperative: prolonged extracorporeal circulation; Preoperative: clinical signs of	Comparison of the nephrotoxic impact of VCM during CI vs II

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
							CKD; no preoperative RRT	infection, SIRS; Increased body temperature > 37.5 °C; bleeding (>4 red packed cells), hemofiltration on CPB; perioperative and/or postoperative: AKI in accordance with AKIN classification, hemodynamic instability, increased vasopressor support, norepinephrin dosage > 0.5 µg/kg*min, epinephrin dosage >0.2 µg/kg*min, dobutamin dosage >5 µg/kg*min, increased inotropic support, hypotension, urine production <0.5 mL/kg*h, necessity of additional administration of proven nephrotoxic drugs (immunosuppressive drugs), ≥ 2 organ failures (MOD Score ≥9), SAPS II >70 on ICU admission	
Lin [32] ***Excluded due to number of patients <30***	*USA*	*Retrospective single-center cohort study*	*2014/08-2011/01*	*54*	*14*	*CI: 14;* *II: 45*	*VCM 24 h serum level;* *CVVH*	*First dose of VCM received ≥ 6 h prior to initiation of CVVH;* *Residual renal function during CVVH;* *Average urine output >0.5 mL/kg/h for 6 consecutive hours;* *ECMO (concomitantly)*	*Comparison of VCM administration during CVVH by II vs CI*

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
Lin [42]	USA	Retrospective single-center cohort study	2015/01-2013/01	52	52	Obese (BMI >35 kg/m²): 26; Non-obese (BMI <30 kg/m²): 26	VCM level 24 h after initiation of therapy; BMI ≥35 kg/m²	VCM application within 48 h prior to start of CI	Evaluation of difference in the weight-based maintenance dose required to reach a therapeutic VCM concentration at 24 hours when given as a CI in obese versus non-obese critically ill patients
Ma [37] Excluded due to inclusion of ICU and non-ICU patients in analysis	*Canada*	*Retrospective multicenter cohort study*	*2016/12-2010/01*	*292*	*146*	*CI: 146; II: 146*	*VCM therapy ≥48 h; ≥1 VCM serum level (Css or trough); ≥2 SCr levels (1 before VCM initiation + 1 either during or within 2 weeks after VCM therapy)*	*Start of VCM at non-study hospital; Rise in SCr within first 48 h of VCM initiation; RRT at baseline or immediately before initiation of VCM*	*Comparison of the nephrotoxicity with CI vs II when the target concentration ranges were the same*
Mohammedi [74]	France	Prospective single-center cohort study	12 months	40	40	A (LD 500 mg): 20; B (LD 15 mg/kg): 20	Presumed or proven gram-positive sepsis	History of prior allergy to VCM	Determination of the better loading dose of VCM in critically ill patients with suspected gram-positive infection
Ocampos-Martinez [59]	Belgium	Retrospective single-center cohort study	2009-2008	261	261	261	VCM therapy ≥48 h; VCM levels (daily); Diagnosis of sepsis according to standard criteria (2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference); TBW available in the medical file	Pediatric patients; CKD requiring dialysis; CRRT; Pregnancy; Burns; Cystic fibrosis; Previous II VCM administration (within 48 h of the start of CI);	Evaluation of the efficacy of CI in septic patients by evaluation of the VCM concentrations within the first 24-48 h of therapy in patients receiving CI + of the determinant of early insufficient VCM concentration in this population
Omuro [61]	Germany	Retrospective single-center	2019-2012	578	119	CI: 119; II: 147;	VCM therapy ≥48 h; Adult (≥18 years);	VCM therapy within previous 7 days;	Evaluation of the incidence of AKI and identification of predictors of AKI in CI vs II

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
		cohort study				Control: 312	SCr levels (up to 72 h after cessation of VCM); Urinary time volume (up to 72 h after cessation of VCM)	RRT at VCM initiation; ESRD requiring dialysis	VCM
Perin [48]	France	Retrospective single-center cohort study	2018/12-2016/01	179	179	Primary outcome: 176; Finished follow-up: 131 (follow-up = 15 consecutive days after VCM initiation)	Adult (≥18 years); ICU stay; Clinical indication for CI according to physician in charge	Ongoing VCM treatment; II of VCM; No iv infusion of VCM; >14 d treatment with VCM (e.g. endocarditis); Decision over withdrawing care would be decided in the next 48 h; No VCM level; Chronic renal failure with previous RRT; Pediatric patients (<18 years); Pregnancy; Previous participation in the present study; Expression of refusal to participate in study	Assessment of the proportion of ICU patients with VCM serum concentration between 20-25 mg/L after 24-48 h
Ricard [115] ***Excluded due to number of patients <30 and unspecified length of time course***	*France*	*Prospective multicenter cohort study*	*Not described*	*14*	*14*	*14*	*Adult (>18 years);* *Presumed or proven pneumococcal meningitis;* *D2/3: 2nd lumbar puncture*	*Not described*	*Determination of the VCM concentration in serum and CSF of patients with suspected or proven pneumococcal meningitis receiving dexamethasone to assess the penetration of VCM into CSF during steroid therapy*
Saugel [54]	*Germany*	*Prospective single-*	*2013/02-2012/06*	*34*	*34*	*34*	*VCM LD + MD according to study protocol*	*Not described*	*Evaluation of a dosing algorithm for CI administration in ICU*

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
Excluded due to time course of only 9 months		*center cohort study*							*patients*
Saugel [44]	Germany	Retrospective single-center cohort study	2008/12-2004/01	239	164	CI: 164; II: 75	-	*Not described*	Evaluation of CI in ICU patients
Schmelzer [45] Excluded due to number of patients <30 and unspecified length of time course	*USA*	*Prospective single center randomized controlled trial*	*Not described*	*55*	*28*	*CI: 28;* *II: 27*	*VCM therapy ≥48 h;* *VCM levels obtained;* *Adult (>18 years);* *Trauma;* *Suspected VAP after BAL;* *Double inclusion if patient met the inclusion criteria on later occasion again*	*History of prior allergy to VCM;* *Pediatric patients;* *Abnormal renal function (CrCl <60 mL/min);* *Pregnancy;* *Ascites;*	*Comparison of CI vs II in VAP trauma patients*
Sin [41]	USA	Prospective single-center cohort study	2017/01-2014/11	52	52	52	Adult (≥18 years) CVVH due to acute or chronic renal failure with minimal or no urine output; Critical illness; Switch from II possible	No level drawn 24 h after CI initiation; Urine output >0.5 mL/kg/h while undergoing CVVH; ECMO	Evaluation of a CI dosing nomogram that incorporates CVVH intensity
Spadaro [43]	Italy	Retrospective single-center cohort study	2013/07-2010/03	348	348	CrCl >50 mL/min: 210; CrCl ≤50 mL/min: 138	VCM therapy ≥48 h; Empiric or targeted sepsis treatment	CRRT; Pregnancy	Estimation of the efficacy of a VCM dosing protocol in target attainment in critically ill patients with or without kidney dysfunction to analyse which factors are related to subtherapeutic VCM levels
Spapen [46]	Belgium	Retrospective two-center	2009/11-2008/01	129	129	AKI: 38; No AKI: 91	VCM therapy ≥5 d; Adult (≥18 years)	VCM/SCr data missing; Polymicrobial infection;	Determination of the incidence and risk factors of AKI during CI

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
		cohort study					SCr (baseline) <1,5 mg/dL; Microbiologically documented gram-positive pneumonia/bacteremia; Neutrophil count ≥1000/µL	Meningitis Cystic fibrosis; Bronchiectasis; iv contrast (within 7 d of VCM initiation);	
Stepan [47]	Czeck Republic	Prospective single-center randomized controlled trial	2008/05-2004/05	65	33	CI: 33; II: 32	VCM therapy ≥4 d; Gram-positive infection indicated for VCM administration	SCr >2.3 mg/dL; Pregnancy;	Comparison of the clinical and microbiological efficacy and safety of CI vs II in critically ill patients
Tiede [116] ***Excluded due to number of patients <30***	*Germany*	*Retrospective single-center cohort study*	*2017/03-2016/01*	*11*	*11*	*11*	*Ventriculitis secondary to subarachnoid hemorrhage (with insertion of EVD to manage hydrocephalus/monitor intracranial pressure --> source of infection)*	*Infection due to other sources than external ventricular drains*	*Individualized dosing strategy for continuous meropenem + VCM + TDM to optimized antimicrobial exposure in ventriculitis patients*
Tuon [75]	Brazil	Prospective single-center cohort study	2020/09-2018/01	33	33	33	Presumed or documented EVD infection (meningitis/ventriculitis); ICU stay	History of hypersensitivity to VCM; Pediatric patients (<18 years); Inability to obtain informed consent	Evaluation of CI (high-dose) in patients with nosocomial ventriculitis + utility of a commercial kit used to measure serum VCM concentration in cerebrospinal fluid (CSF) sample
Udy [57]	Australia	Retrospective single-center cohort study	2010/12-2008/01	81	81	CVVH: 41; CVVHDF: 40	VCM therapy ≥48 h; ≥ 1 VCM level; Adult (>18 years); Sepsis according to standard criteria;	Previous administration of VCM by II within 48 h of start of CI; Urine output >500 mL/d; Pregnancy;	Conduction of a population PK analysis in septic patients undergoing CRRT + determination of parameters associated with inadequate VCM concentration

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
							CRRT	Burns; Cystic fibrosis	
van de Vijsel [39] ***Excluded due to number of patients <30***	*Canada*	*Retrospective single-center cohort study*	*2008/06-2003/01*	*24*	*24*	*24*	*VCM therapy ≥24 h;* *≥2 VCM serum levels (peak + trough; 2 post-dose Css);* *Adult (≥18 years);* *Concurrent CVVHD*	*Unclear nursing notes as to when VCM had been administered or serum sampling was conducted;* *Burns*	*Development of a practical recommendation for initial dosing of VCM in critically ill patients undergoing CVVHD*
van den Heever [40] ***Excluded due to number of patients <30***	*South Africa*	*Prospective single-center cohort study*	*2011/02-2010/02*	*10*	*10*	*10*	*Severe infection caused by gram-positive organism (MRSA; CoNS; enterococci)*	*Continued empirical use for infection;* *Children <12 y;* *Renal failure with RRT;* *Hypersensitivity to VCM;* *Selective bowel decontamination;* *Eradication of MRSA colonization;* *Primary treatment of Clostridioides difficile colitis;* *Topical application or irrigation of VCM;* *CNS infection;* *Endocarditis;* *Pregnancy;* *Neutropenia;* *Thrombocytopenia;* *Concurrent use of nephrotoxic drugs*	*Testing of a feasible regimen for adjusting the maintenance dose in critically ill patients in order to reach therapeutic levels*
Vazquez [50] ***Excluded due to number of patients <30***	*Uruguay*	*Prospective single-center cohort study*	*12 months*	*25*	*25*	*25*	*Documented gram-positive infection;* *Severe sepsis;* *Septic shock;*	*Not described*	*Test of the usefulness of a multi-compartment model in order to understand the rapid changes that occur in critically ill patients during CI therapy*
Wysocki [34]	France	Prospective multicenter cohort study	36 months	119	61	CI: 61; II: 58; (Therapy success: 95; Therapy failure: 24)	Presumed or documented MRS infection acquired 72 h after admission; Direct microbiologic examination	VCM administration 72 h before current infection; Betalactam allergy; Participating currently in	Comparison of CI vs II in regard to microbiological and clinical outcomes, safety, pharmacokinetics, ease of treatment adjustment, cost

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
							showing gram-positive cocci; Adult (≥18 years); SCr ≤2.3 mg/dL; Neutrophil count >1000/µL; ≤3 Organ failures according to organ system failure score; Only first course of VCM therapy is counted	another protocol;	
Wysocki [117] ***Excluded due to number of patients <30***	*France*	*Prospective single-center cohort study*	*1986/11-1983/05*	*26*	*13*	*CI: 13;* *II: 13*	*Expected VCM therapy ≥5 days;* *Documented MRSA infection;* *SCr ≤3.6 mg/dL on initiation of VCM therapy;* *Neutrophil count ≥1000/µL*	*Not described*	*Evaluation of the efficacy and nephrotoxicity of CI vs II*
Yamada [29] ***Excluded due to number of patients <30***	*Brazil*	*Prospective single-center cohort study*	*2019/07-2018/01*	*23*	*11*	*CI: 11;* *II: 12*	*Presumed or documented gram-positive infection*	*History of hypersensitivity to VCM;* *Pediatric patients;* *SCr ≥2.5 mg/dL or eGFR ≤40 mL/min;* *Life expectancy ≤48 h;* *Inability to obtain informed consent*	*Comparison of the PK characteristics between II vs CI in critically ill patients admitted to ICU*

CG: Cockcroft-Gault formula, CI: continuous infusion of vancomycin, CKD: chronic kidney disease, CNS: central nervous system, CoNS: coagulase-negative staphylococci, CrCl: creatinine clearance, (C)RRT: (continuous) renal replacement therapy, CS: cardiosurgery, Css: concentration at steady state, CVVHD: continous veno-venous hemodialysis, eGFR: estimated glomerular filtration rate, ESRD: end-stage renal disease, EVD: external ventricular drain, HD: hemodialysis, ICU: intensive care unit, II: intermittent infusion of vancomycin, LD: loading dose, MD: maintenance dose, MRCoNS: methicillin-resistant coagulase-negative staphylococci, MRDR: modification of diet in renal disease, MRS: methicillin-resistant staphylococci, MRSA: methicillin-resistant *Staphylococcus aureus*, PD: peritoneal dialysis, Pediatric patients: age <18 years; SCr: serum creatinine, TBW: total body weight, VCM: vancomycin.

9.2 Study population

***Table S2**: Overview of the study population. Thirty-eight studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)) or safety (e.g. acute renal failure). Only twenty-one studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
Akers [49]	90 (out of 171)	40.8±19.8	Male: 91.1 % Female: 8.9 %	Not described	Surgical (burn)	Burn patients (100 %)	Not described	Not described	Gram-negative bacteremia or candidemia (18.9 %, 17/90); Gram-positive bacteremia (27.8 %, 25/90); Pneumonia (22.2 %, 20/90); Sepsis without confirmed gram-positive bacteremia (22.2 %, 20/90);	*MSSA;* *MRSA;* *CoNS;* *E. faecium; E. faecalis; Enterococcus spp.;* *Streptococcus pneumoniae;* *Streptococcus viridans; Streptococcus agalactiae; Nonenterococcal Group D Streptococci; Streptococcus mutans*
Albanèse [60] Excluded due to number of patients <30 and unspecified length of time course	*Total: 11* *Bacterial meningitis: 7;* *Other infections: 6*	*25-58*	*Male: 50 %* *Female: 50 %*	*Primary pathologies: medical coma (27 %); subarachnoid hemorrhage (18 %); stroke (9 %)*	*No data on type of ICU*	*Mechanical ventilation (100 %);* *CNS infection (100 %)*	*Not described*	*Not described*	*Infection due to VCM sensitive bacteria;* *Bacterial meningitis (53.8 %, 7/13* *Other CNS infection (46.2 % ,6/13)*	*Staphylococcus aureus (23 %, 3/13);* *Staphylococcus epidermidis (46 %, 6/13);* *Streptococcus pneumoniae (15 %, 2/13);* *Enterococcus faecalis (8 %, 1/13);* *Corynebacterium (8 %, 1/13)*
Baptista [53]	Total: 104 A (MD 30 mg/kg/d):	A: 57.8±15.5 ;	A: Male: 66 % Female: 34 %; B: Male: 68 %	Not described	Medical: A: 39.2 %; B: 20 %;	Augmented renal clearance (76.7 %); Mechanical	SAPS II: A: 39 (34-50);	A: 19 (9-29); B: 23 (18-30)	Sepsis (100 %, 104/104)	Not described

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
	79; B (MD nomogram): 25	B: 59.9±17.2	Female 32 %		Surgical: A: 60.8 %; B: 80 %	ventilation (100 %); Sepsis (100 %)	B: 43 (37-46)			
Beumier [55]	32	55 (47-64)	Male: 53.1 % Female: 46.9 %	COPD/asthma (9 %); Cardiopathy (41 %); Diabetes (19 %); Chronic haemodialysis (9 %); Liver cirrhosis (19 %); Cancer (13 %); Corticosteroids (1 %); Other immunosuppression (19 %); Organ transplantation (16 %)	Medical: 69 %; Surgical: 31 %	CRRT (100 %); Mechanical ventilation (78 %); Sepsis (100 %);	APACHE II (on admission): 21 (17-25); SOFA (on start of CI): 14 (11-17)	14 (9-29)	Sepsis (100 %, 32/32) Pneumonia (46.9 %, 15/32); Abdomen (18.8 %, 6/32); Catheter-related (12.5 %, 4/32); Urogenitary (3.1 %, 1/32); Other site (18.8 %, 6/32)	Positive cultures*: 16 % (5/32) *MRSA* (40 %, 2/5); *MRSE* (40 %, 2/5); *Enterococcus faecium* (60 %, 3/5)
Carricajo [62] Excluded due to number of patients <30 and unspecified length of time course	*Total: 22 Microbiological identification in 12 patients*	*59.8 (40-76)*	*Not described*	*Not described*	*Medical: 25 %;* *Surgical: 75 %*	*Augmented renal clearance (32 %);* *CKD (0 %;* *CrCl <50 mL/min)*	*SAPS II:* *42.4 (22-64)*	*Not described*	*Bacteremia;* *Pneumonia;* *SSTI*	*Staphylococcus aureus (83 %, 10/12): MIC 0.5-3;* *CoNS (17 %, 2/12);* *CrCl < 120 mL/min: microbiological evaluation 57.1 % (8/14); CrCl ≥120 mL/min: 42.9 % (6/14)*
Cianferoni [56]	Total: 207 No AKI: 157; AKI: 50; (Early AKI: 28;	All: 60±15; No AKI: 60±15; AKI: 61±14;	All: Male: 62.8 % Female: 37.2 %; No AKI: Male: 62.4 % Female: 37.6 %; AKI:	All: Asthma/COPD (25 %); Hypertension (38 %); Cardiopathy (27 %); Diabetes (26 %); Liver cirrhosis (8 %); Cancer (31 %);	Medical: All: 59 %; No AKI: 59 %; AKI: 62 %; (Early AKI: 60 %; Late AKI: 63 %));	Mechanical ventilation (69 %) Sepsis (100 %);	APACHE II (on admission): All: 20 (16-27); (No AKI:19	All: 10 (6-18); No AKI: 10 (5-18); AKI: 12 (8-21); (Early AKI:	Sepsis (100 %, 207/207) Abdomen (21 %, 44/207); Bacteremia (all: 18 %, 37/207; no AKI: 16 %, 26/157; AKI: 22 %, 11/50; early AKI: 32 %, 9/28; late AKI: 9 %, 2/22); Pneumonia (50 %, 103/207) ;	Positive cultures*: 65 % (112/207); *MSSA* (27 %, 30/112); *MRSA* (20 %, 22/112); *CoNS* (27 %, 30/112); *Enterococcus* (19 %, 21/112); Others (8 %, 9/112)

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
	Late AKI: 22)	(Early AKI: 62±13; Late AKI: 59±15)	Male: 64.0 % Female: 36.0 %; (Early AKI: Male: 64.3 % Female: 35.7 %; Late AKI: Male: 59.0 % Female: 41.0 %)	Thromboembolic venous disease (6 %); Smoking (19 %); Alcohol (17 %);	Surgical: All: 41 %; No AKI: 41 %; AKI: 38 %; (Early AKI: 40 %; Late AKI: 37 %)		(15-25); AKI: 24 (18-30); early AKI: 24 (19-29); late AKI: 21 (16-29)); SOFA (on admission): All: 8 (5-11); (No AKI:7 (3-10); AKI: 9 (4-12); early AKI: 10 (6-13); late AKI: 8 (6-11))	11 (8-19); Late AKI: 12 (8-19)	Urogenitary (13 %, 27/207)	
Covajes [58]	85	65±15	Male: 65.9 % Female: 34.1 %	Asthma/COPD (22 %); Hypertension (24 %); Cardiopathy (49 %); Diabetes (27 %); Liver cirrhosis (14 %); Cancer (15 %); Immunosuppresion (26 %); Thromboembolic disease (5 %)	Medical: 69 %; Surgical: 31 %	CRRT (100 %); Mechanical ventilation (84 %) Sepsis (100 %);	APACHE II (on admission): 24 (20-29); SOFA (on start of CI): 11 (7-14)	12 (6-20)	Sepsis (100 %, 85/85) Septic shock (82 %, 70/85); Abdomen (32 %, 27/85); Bacteremia (33 %, 28/85) Pneumonia (46 %, 39/85);	Positive cultures*: 55 % (47/85); *MSSA* (14.9 %, 7/47); *MRSA* (25.5 %, 12/47); *CoNS* (38.3 %, 18/47); *Enterococcus spp.* (21.3 %, 10/47)
Cristallini [52]	107	59 (48-71)	Male: 72 % Female: 38 %	Asthma/COPD (18 %); Cancer (16 %); CKD (29 %); Corticosteroids (32	Medical: 36 %; Surgical: 64 %	Mechanical ventilation (54 %); Sepsis (100 %)	APACHE II (on admission):	Not described	Sepsis (100 %, 107/107) Septic shock (53 %, 57/107); Abdomen (11 %, 12/107);	Positive cultures*: 79 % (84/107) *MRSA* (12 %, 10/84); *MRSE* (12 %, 10/84);

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
				%); Diabetes (21 %); Hearth disease (22 %); Liver cirrhosis (6 %); Organ transplantation (16 %); Other immunosuppression (23 %);			19 (13-25); SOFA (on admission, daily): 6 (4-9)		Bacteremia (17 %, 18/107); Catheter-related (6 %, 7/107); CNS (5 %, 5/107); Pneumonia (44 %, 47/107); SSTI (7 %, 8/107); Urogenitary (7 %, 8/107)	*Enterococcus faecium* (5 %, 4/84) Gram-negative bacteria (71 %, 60/84)
Di Filippo [63] Excluded due to number of patients <30 and time course of only 7 months	*11 (out of 25)*	*70±14*	*Male: 81.8 % Female: 18.2 %*	*Cardiogenic shock (27 %); head trauma (18 %); multitrauma (9 %); new acute COAD (9 %); polyneuropathy (9 %); pulmonary embolism (18 %)*	*No data on type of ICU*	*MRSA/MRCoNS (100 %)*	*SAPS II: 50±9; SOFA: Before start of CI: (6.6±2.2); End of CI: (4.37±3.5) (-33.8 %)*	*13±4*	*Bacteremia (27.3 %, 3/11); Pneumonia (72.7 %, 8/11)*	*Clinical sample: bronchial sputum, BAL, blood culture; Methicillin-resistant staphylococcal: MRSA; MRCoNS; Mixed infection: MRS + Klebsiella pneumoniae (n=2); MRS + Pseudomonas spp. (n=2)*
Duszynska [31] Excluded due to number of patients <30	*21 (out of 42)*	*62±14*	*Male: 76,5 % Female: 33,5 %*	*Not described*	*Surgical*	*Mechanical ventilation (100 %); Non-Staphylococcus aureus (100 %); Sepsis (100 %)*	*APACHE II: 21±6*	*36 (15-65)*	*Abdomen (Peritonitis) (29 %, 6/21); Catheter-related (19 %, 4/21); CNS (19 %, 4/21); Others (5 %, 1/21); Pneumonia (HAP/VAP) (14 %, 3/21); Septic shock (43 %, 9/21); SSTI (14 %, 3/21)*	*CoNS (71 %, 14/21); Enterococcus faecium (24 %, 5/21); Streptococcus pneumoniae (5 %, 2/21)*
Eldemiry [38] Excluded due to number of patients <30	*20 (out of 40)*	*Not described*	*Not described*	*Not described*	*No data on type of ICU*	*Pneumonia (100 %); CDK (100 %; SCr >1.4 mg/dL)*	*APACHE II: 14.2±4.6; SAPS; SOFA*	*-*	*Pneumonia (100 %, 40/40)*	*Positive cultures*: 60 % (12/20) Staphylococcus aureus*
Hanrahan [76]	653 (out of 1430)	59 (44-69)	Male: 63.9 % Female: 36.1 %	Not described	Medical; Surgical	Not described	SOFA (on admission): 7 (5-9)	Not described	Not described	*MRSA* (9.8 %, 64/653)
Hong [26]	*65 (out of 130)*	*56±15.5*	*Male: 53.8 %*	*Reason for admission:*	*Surgical (neurosurgical)*	*CNS patients*	*Not described*	*Not described*	*SIRS criteria;*	*Positive cultures* (with MIC): 23 % (15/65)*

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
Excluded due to time course of only 9 months			*Female: 46.2 %*	*stroke (16 %); ICH (60 %); CNS tumor (6 %); epidural abscess (8 %); seizure (3 %); meningitis (5 %); spinal cord injury (3 %); suicide attempt (3 %)*		*(100 %); CKD (0 %; CrCl <20 mL/min)*			*Bacteremia (0 %, 0/65); CNS (Meningitis) (4.6 %, 3/65); Empiric (41.5 %, 27/65); Epidural abscess (9.2 %, 6/65); Pneumonia (69.2 %, 45/65)*	*MSSA (66.7 %, 10/15); MRSA (7 %, 1/15); MRSE (13 %, 2/15); CoNS (7 %, 1/15); Enterococcus (7 %, 1/15)*
Hutschala [33]	119 (of 149)	59±14 (19-86); >75 years: 22.7 %	Male: 61 % Female: 39 %	COPD (17 %); Acute liver failure (2 %); Extracardiac arteriopathy (12 %); Disseminated intravascular coagulation (4 %)	Surgical (cardiosurgical)	Cardiosurgery (100 %); CKD (0 %; SCr >1.5 mg/dL))	SAPS II: 37±13 (13-70)	15±13 (1-78)	Bacteremia (14 %, 17/119); Catheter-related (15 %, 18/119); Mediastinitis (7 %, 8/119); Pneumonia (HAP) (18 %, 21/119); Septic shock (0.9 %, 1/119) Severe sepsis (5 %; 6/119); SSTI (30 %, 36/119); Sternal infection (16 %, 19/119)	*MRSA* (22 %, 26/119); *CoNS* (11 %, 13/119)
Lin [32] Excluded due to number of patients <30	*14 (out of 54)*	*60.64±17.91*	*Male: 64.2 % Female: 35.8 %*	*Not described*	*Medical: 91.6 %; Surgical: 8.4 %*	*CKD (43 %); CVVH (100 %); Mechanical ventilation (100 %)*	*APACHE II (on admission): 26.42±8.01; SOFA (on start of CI): 14.5±2.28*	*Not described*	*Not described*	*Not described*
Lin [42]	Total: 52 Obese (BMI >35 kg/m²): 26; Non-obese (BMI <30 kg/m²):	Obese: 54.2±16.8; Non-obese: 55.4±16	Obese: Male: 69.2 % Female: 30.8 %; Non-obese: Male: 80.8 % Female: 19.2 %	Not described	Surgical	CVVH (35 %) Differentiation obese/non-obese; Mechanical ventilation (~100 %)	APACHE II (on admission): Obese: 20.3±9.24; Non-obese: 18.7±8.46	Not described	Abdomen (obese: 12 %, 3/26, non-obese: 8 %, 2/26); Bacteremia (obese: 8 %, 2/26, non-obese: 0 %, 0/26); Pneumonia (obese: 62 %, 16/26, non-obese: 73 %, 19/26); SSTI (obese: 8 %, 2/26, non-obese:	*MSSA* (obese: 8 %, 2/26, non-obese: 12 %, 3/26); *MRSA* (obese: 23 %, 6/26, non-obese: 27 %, 7/26); *CoNS* (obese: 15 %, 4/26, non-obese: 12 %, 3/26); *Enterococcus* (obese: 0 %, 0/26, non-

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
	26								12 %, 3/26); Unknown (obese: 12 %, 3/26; non-obese: 8 %, 2/26)	obese: 4 %, 1/26); *Streptococcus spp.* (obese: 8 %, 2/26, non-obese: 12 %, 3/26); Other (obese: 26 %, 12/26, non-obese: 35 %, 9/26)
Ma [37] ***Excluded due to inclusion of ICU and non-ICU patients in analysis***	*146 (out of 292)*	*56.3±18.5*	*Male: 60.2 %* *Female: 39.8 %*	*Asplenia (1 %);* *CHF (4 %);* *COPD (3 %);* *Diabetes (17 %);* *Haematological malignancy (3 %);* *Immunosuppression (11 %);* *Any comorbidity or immunosuppression (32 %)*	*No data on type of ICU + general ward*	*Not described*	*APACHE II (≥20) (ICU);* *Pitt bacteraemica score (≥4) (ward)*	*Not described*	*Abdomen (1 %, 2/146);* *Bacteraemia (2 %, 3/146);* *BJI (65 %, 95/146);* *Cardiovascular (2 %, 3/146);* *Catheter-related (2 %, 3/146);* *CNS (10 %, 14/146); CNS abscess (3 %, 4/146);* *Pneumonia (1 %, 2/146);* *SSTI (13 %, 19/146);* *Urogenitary (0 %, 0/146);* *Unknown (1 %, 1/146)*	*MSSA (6 %, 9/146);* *MRSA (16 %, 24/146);* *CoNS (42 %, 62/146);* *other Staphylococcus spp (1 %, 1/146);* *E. faecium (3 %, 5/146); E. faecalis (10 %, 14/146); other Enterococcus spp (1 %, 1/146);* *Streptococcus spp. (7 %, 10/146);* *Other gram-positive bacteria (29 %, 23/146);* *Gram-negative bacteria (29 %, 43/146);* *Acid-fast bacilli (1 %, 1/146);* *Fungal (1 %, 1/146)*
Mohammedi [74]	Total: 40 A (LD 500 mg): 20; B (LD 15 mg/kg): 20	A: 62.2; B: 61.2	A: Male: 70 % Female: 30 %; B: Male. 75 % Female: 25 %	Not described	Medical	Mechanical ventilation (90 %); Sepsis (100 %)	SAPS II: A: 59±17; B: 57±17	Not described	Bacteremia (A. 25 %, 5/20; B: 30 %, 6/20); Catheter-related (A: 15 %, 3/20; B: 10 %, 2/10); Others (A: 10 %, 2/20; B: 10 %, 2/20); Pneumonia (A: 50 %, 10/20; B: 50 %, 10/20) Sepsis (simple (A: 35 %, 7/20; B: 40 %, 8/20), severe (A: 30 %, 6/20; B: 30 %, 6/20), shock (A: 35 %, 7/20; B: 30 %, 6/20))	Positive cultures*: A: 90 % (18/20); B: 75 % (15/20); *MSSA* (A: 17 %, 3/18; B: 33 %, 5/15); *MRSA* (A: 67 %, 12/18; B: 40 %, 6/15); *MRCoNS* (A: 11 %, 2/18; B: 33 %, 5/15)

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
Ocampos-Martinez [59]	261	60±15	Male: 61.7 % Female: 38.3 %	Asthma/COPD (24 %); Cancer (23 %); CKD (13 %); Diabetes (25 %); Heart disease (30 %); Hypertension (36 %); Immunosuppres-sion (16 %); Liver cirrhosis (10 %); Smoking (18 %); Alcohol (16 %); Thromboembolic disease (5 %);	Medical: 59.8 %; Surgical: 40.2 %	Mechanical ventilation (71 %) Sepsis (100 %)	APACHE II (on admission): 22 (17-28); SOFA: 8 (5-11)	10 (6-18)	Sepsis (100 %, 261/261); Septic shock (42 %, 112/261); Abdomen (23 %, 60/261); Pneumonia (49 %, 128/261)	Positive cultures*: 50 % (131/261); *MSSA* (29 %, 38/131); *MRSA* (18 %, 24/131); *CoNS* (31 %, 40/131); *Enterococcus ssp* (21 %, 27/131); *Corynebacterium spp* (1.5 %, 2/131)
Omuro [61]	119 (out of 578)	59 (48-75)	Male: 60.5 % Female: 39.5 %	Cancer (10 %); Cardiopathy (43 %); CKD (8 %) Diabetes (15 %); Hypertension (50 %); Liver cirrhosis (4 %); Venous thrombosis (6 %);	Medical: 30.3 %; Surgical: 68.9 %; Neurological: 0.8 %	CKD (8 %); Mechanical ventilation (87 %)	SAPS II (on admission): 37 (31-48)	26 (16-39)	Not described	Positive cultures*: 23.5 % (28/119)
Perin [48]	Total: 179 (Primary outcome: 176; Finished follow-up: 131	67 (59-75)	Male: 66 % Female: 34 %	Cancer (6 %); Cardiac insufficiency (7 %); Coronaropathy (10 %); Diabetes (19 %); Hypertension (30 %); Liver cirrhosis (4 %);	No data on type of ICU	Augmented renal clearance d1 or d2 (4 %); Mechanical ventilation (85 %); RRT (27 %)	SAPS II (at ICU admission); SOFA (at d1-4, d10, d15)	ICU: 6 (3-13); Hospital: 23 (14-47)	Sepsis or septic shock (61 %; 110/179); Abdomen (37 %, 53/143); Bacteremia (20 %, 29/143); Bone (6 %, 9/143); Meningitis (2 %, 3/143); Pneumonia (17 %, 25/143);	Positive cultures*: 80 % (143/179); (identification and analysis of isolated pathogens let to cessation of VCM therapy: 53 %, 94/179) *MSSA* (15 %, 21/143); *MRSA* (5 %, 7/143); *CoNS* (15 %, 21/143);

Reference	Study Population with Continuous Infusion									
	Number of Patients	**Age [years]**	**Gender**	**Comorbidities**	**ICU**	**Specialty**	**Severity Score**	**ICU Length of Stay [days]**	**Type of infection**	**Microbiology**
	(follow-up = 15 consecutive days after VCM initiation))			Peripheral arterial disease (16 %); Single kidney (3 %)					Skin (6 %, 9/143); Urogenitary (10 %, 15/143)	*E faecalis* (15%, 22/143); *E. facium* (16 %, 23/143); Other gram-positive bacteria (10 %, 15/143); *Enterobacterales* (50 %, 71/143); *Pseudomonas aeruginosa/Acinetobacter baumannii* (13 %, 18/143); Other gram-negative bacteria (7 %, 10/143); *Anaerobes* (9 %, 13/143); *Yeast* (12 %, 17/143); Others (1 %, 2/143);
Ricard [115] ***Excluded due to number of patients <30 and unspecified length of time course***	*14*	*52±20 (19-83)*	*Male: 57.1 %* *Female: 42.9 %*	*Not described*	*Medical*	*CNS infection (100 %);* *Mechanical ventilation (71 %)*	*SAPS II: 43±20;* *Glasgow coma: 7±3*	*Not described*	*Presumed or proven pneumococcal meningitis (100 %)* *S. pneumonia bacteremia (57.1 %, 8/14)*	*Gram-positive cocci in CSF (1st lumbar puncture: 93 %, 13/14; 2nd lumbar puncture: 7);* *Streptococcus pneumoniae (1st lumbar puncture: 86 %, 12/14; 2nd lumbar puncture: 0 %, 0);* *Neisseria meningitides (7 %, 1/14)*
Saugel [54] ***Excluded due to time course of only 9 months***	*34*	*62 (49-71)*	*Male: 62 %* *Female: 38 %*	*Not described*	*Medical*	*Mechanical ventilation (76 %)*	*APACHE II: 30 (21-36);* *SOFA: 13 (10-16);* *TISS: 18 (18-23);* *MODS: 1 1 (7-12)*	*Not described*	*Presumed or proven infection;* *Sepsis (44 %, 15/34)*	*Gram-positive bacteria*
Saugel [44]	164 (out of	65.1±13.1	Male: 61 %	Diabetes (18 %)	Medical	Mechanical	Not	Not	Not described	Not described

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
	239)		Female: 39 %			ventilation (54 %); RRT (43 %)	described	described		
Schmelzer [45] Excluded due to number of patients <30 and unspecified length of time course	*28 (out of 55)*	*40.3±16.4*	*Male: 89.2 % Female: 11.8 %*	*COPD; ischemic heart disease; diabetes; cancer*	*Surgical (trauma)*	*CKD (0 %; CrCl <60 mL/min) Trauma patients (100 %); VAP (100 %)*	*Injury Severity Score: 26.7±11.5*	*Not described*	*VAP (100 %, 28/28); Presumed VAP after BAL; Documented gram-positive pneumonia*	*Gram-positive bacteria; MRSA (< 10 %)*
Sin [41]	52	60.1±15.5	Male: 73.1 % Female: 27.9 %	Not described	Surgical: 65.4 %; Medical: 34.6 %	CVVH (100 %)	APACHE II (upon ICU admission): 25.3±7.8	32.4±30.9	Not described	Not described
Spadaro [43]	Total: 348 CrCl >50 mL/min: 210; CrCl ≤50 mL/min: 138	CrCl >50 mL/min: 63±11.2; CrCl ≤50 mL/min: 70.6±9.9	CrCl >50 mL/min: Male: 73 % Female: 37 %; CrCl ≤50 mL/min: Male: 69 % Female: 31 %	Not described	Medical: CrCl >50 mL/min: 56.7 %; CrCl ≤50 mL/min: 50%; Surgical: CrCl >50 mL/min: 43.3 %; CrCl <50 mL/min: 50 %	CKD (40 %; CrCl ≤50 mL/min); Differentiation in CrCl ≤/>50 mL/min	SAPS II (first 24 h): CrCl >50 mL/min: 40.3±8.0; CrCl ≤50 mL/min: 46.2±7.7	Not described	Abdomen (>50 mL/min: 20.5 %, 43/210/≤50 mL/min: 31.8 %, 44/138); Bacteremia (>50 mL/min: 14.3 %, 30/210/≤50 mL/min: 4.3 %, 6/138); Pneumonia (>50 mL/min: 48.6 %, 102/210/≤50 mL/min: 36.2 %, 50/138); Sepsis (>50 mL/min: 30 %, 63/210; ≤50 mL/min: 26 %, 36/138); SSTI (>50 mL/min: 10.9 %, 23/210/≤50 mL/min: 27.5 %, 38/138); Others (>50 mL/min: 5.7 %, 12/210/≤50 mL/min: 0 %, 0/138)	*Staphylococci spp.* (CrCl >50 mL/min: 63.3 %/CrCl ≤50 mL/min: 62.3 %); *Enterococci spp.* (CrCl >50 mL/min: 35.2 %/CrCl ≤50 mL/min: 37.7 %); *Streptococci spp.* (CrCl >50 mL/min: 1.4 %/CrCl ≤50 mL/min: 0 %)
Spapen [46]	Total: 129	No AKI:	No AKI:	Diabetes	No data on type	CKD (0 %;	SAPS 3	Not	Gram-positive bacteremia (29.5 %,	Positive cultures*: 100 % (129/129)

Reference	Study Population with Continuous Infusion									
	Number of Patients	**Age [years]**	**Gender**	**Comorbidities**	**ICU**	**Specialty**	**Severity Score**	**ICU Length of Stay [days]**	**Type of infection**	**Microbiology**
	AKI: 38; No AKI: 91	60.8±14.6; AKI: 62.6±15.9	Male: 51.6 % Female: 48.4 %; AKI: Male: 60.5 % Female: 39.5 %	(No AKI: 54 %; AKI: 79 %) Shock (No AKI: 59 %; AKI: 87 %)	of ICU	SCr >1.5 mg/dL))		described	38/129); Pneumonia (60.5 %, 78/129); Bacteremia + Pneumonia (10.1 %, 13/129)	*MRSA* (63.6 %, 82/129); *MRCoNS* (31 %, 40/129); *Enterococcus spp* (5.4 %, 7/129)
Stepan [47]	33 (out of 65)	56±14.6	Male: 69.7 % Female: 30.3 %	Not described	Medical; Surgical	Not described	APACHE II: 23.4±9.1; SOFA: 9.97±4.1	26 (12.8-40.3)	Gram-positive infection: Abdomen (39.3 %, 13/33); Bacteremia (54.4 %, 18/33); BJI+SSTI (0 %, 0/33); Pneumonia (6.3 %, 2/33); Urogenitary (0 %, 0/33);	*Staphylococci* (56.3 %, 18/33); *Staphylococcus aureus* (9.1 %, 3/33); *Staphylococcus epidermidis* (15.6 %, 5/33); *Staphylococcus haemolyticus* (3.1 %, 1/33); *CoNS* (28.1 %, 9/33); *Enterococci* (37.5 %, 12/33); *Enterococcus faecalis* (18.8 %, 6/33); *Enterococcus faecium* (15.6 %, 5/33); *Enterococcus spp.* (3.1 %, 1/33); Polymicrobial infection (staphylococci + streptococci) (9.4 %, 3/33); MIC (Etest): 0.5 (9.1 %), 1.0 (42.4 %), 2.0 (48.5 %); CI: 1 (1-2); II: 2 (1-2)
Tiede [116] ***Excluded due to number of patients <30***	*9*	*53* *(29-84)*	*Male: 78 %* *Female: 22 %*	*Not described*	*No data on type of ICU*	*CNS infection* *(100 %)*	*Not described*	*Not described*	*CNS (Ventriculitis) (100 %, 9/9)*	-
Tuon [75]	33	54	Male: 57 %	Cancer (21 %)	No data on type	CNS infection	Not	Not	CNS (Ventriculitis (nosocomial)) (100	Positive cultures*: 6 % (2/33);

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
		(40-61)	Female: 43 %	CKD + dialysis (6 %); COPD (3 %); Dementia (3 %); Diabetes (18 %); Hypertension (36 %);	of ICU	(100 %)	described	described	%, 33/33)	Repeated sampling after 5.5 d (4-8) *MRSA* (3 %, 1/33); *CoNS* (3 %, 1/33)
Udy [57]	CVVH: 41; CVVHDF: 40	61.0±15.6	Male: 65.4 % Female: 34.6 %	Not described	No data on type of ICU	CRRT (100 %); Mechanical ventilation (85.2 %) Sepsis (100 %)	APACHE II: 24.5±8.4; SOFA: 10.9±4.0	12 (16-19)	Presumed or documented gram-positive infection; Sepsis (100 %; 81/81)	Not described
van de Vijsel [39] Excluded due to number of patients <30	*24*	*64.3±15 (36-88)*	*Male: 79 % Female: 21 %*	*Not described*	*Medical; Surgical (cardiovascular)*	*CVVHD (100 %)*	*APACHE II (upon admission): 24.2±8.8 (12-46)*	*54±51 (7-189)*	*Abdomen (4 %, 1/24); Bacteremia (54 %, 13/24); CNS (4 %, 1/24); Pneumonia (13 %, 3/24); Urine (8 %, 2/24)*	*Positive cultures*: 63 % (15/24) MSSA (28 %, 7/25; blood (12 %, 3/25); sputum (12 %, 3/25); urine (4 %, 1/25)) MRSA (0 %) CoNS (40 %, 10/25; blood (36 %, 9/25); CSF (4 %, 1/25)) E. faecalis (12 %, 3/25); E. faecium (0 %); Streptococcus mitus (4 %, 1/25); Streptococcus anginosus-milleri (4 %, 1/25); Streptococcus oralis (4 %, 1/25)*
van den Heever [40] Excluded due to number of patients <30	*10*	*44.2±17.3 (19-70)*	*Male: 50 % Female: 50 %*	*Not described*	*Medical; Surgical*	*CKD (10 %) Sepsis (100 %)*	*Not described*	*Not described*	*Sepsis (100 %, 10/10)*	*Not described*
Vazquez [50] Excluded due to number of patients <30	*25*	*Not described*	*Not described*	*Not described*	*No data on type of ICU*	*CKD (16 %) Sepsis (100 %)*	*Not described*	*Not described*	*Severe sepsis; Septic shock; MRSA-infection*	*MRSA (documented infection)*
Wysocki [34]	61 (out of 119) (Therapy success: 48;	64±13	Male: 69 % Female: 31 %	Diabetes (12 %)	Medical; Surgical	Mechanical ventilation (79 %)	SAPS: 14±5; (Total CI+II: Therapy	Not described	Presumed or documented MRS infection acquired 72 h after admission; Bacteremia (40 %, 25/61);	*MRSA* (80 %, 49/61); *CoNS* (20 %, 12/61); MIC: 0.5 (14 %, 3/61), 1 (36 %, 8/61), 2 (50 %; 11/61);

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
	Therapy failure: 13)						success: 13±4; Therapy failure: 16±4)		Catheter-related (20 %, 12/61); CNS (20 %, 12/61); Endocarditis (2 %, 1/61); Mediastinitis (6 %, 4/61); Pneumonia (43 %, 26/61); Septicemia (11 %, 7/61); Others (18 %, 11/61)	Disk agar; 40 strains additionally on Mueller-Hinton agar
Wysocki [117] Excluded due to number of patients <30	*13 (of 26)*	*61±17*	*Male: 77 % Female: 23 %*	*Not described*	*No data on type of ICU*	*MRSA (100 %)*	*SAPS: 17±5*	*Not described*	*Severe MRSA infection; Bacteraemia (54 %, 7/13); Pneumonia (46 %, 6/13)*	*MRSA (100 %, 13/13)*
Yamada [29] Excluded due to number of patients <30	*11 (of 23)*	*49 (42.5-64)*	*Male: 63 % Female: 37 %*	*Not described*	*No data on type of ICU*	*CKD (0 %, eGFR ≤40 mL/min)*	*APACHE II*	*Not described*	*Abdomen (18.2 %, 2/11); Catheter-related (9.02, 1/11); CNS (18.2 %, 2/11); Pneumonia (45.5 %, 5/11); SSTI (9.05 %; 1/11); Others (0 %, 0/11)*	*Not described*

APACHE: Acute Physiology And Chronic Health Evaluation score, BAL: bronchoalveolar lavage, BJI: bone and joint infection, CKD: chronic kidney disease, CNS: central nervous system, COAD: chronic obstructive airway disease, CoNS: coagulase-negative staphylococci, CSF: cerebrospinal fluid, ICH: intracranial hemorrhage, ICU: intensive care unit, LD: loading dose, MD: maintenance dose, MRCoNS: methicillin-resistant coagulase-negative staphylococci, MRSA: methicillin-resistant *Staphylococcus aureus*, MRSE: methicillin-resistant *Staphylococcus epidermidis*, SAPS: Simplified Acute Physiology Score, SOFA: Sepsis-related Organ Failure Assessment score, SSTI: skin and soft tissue infection, TISS: Therapeutic Intervention Scoring System, VAP: ventilator associated pneumonia.

* Sum of positive cultures with gram-positive pathogens

9.3 Characteristics of Continuously Administered Vancomycin Therapy

***Table S3**: Overview of the characteristics of the continuous infusion of vancomycin. Thirty-eight studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)) or safety (e.g. acute renal failure). Only twenty-one studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Akers [49]	Not described	3000 mg/d	Not described	29.5±11.8 mg/kg/d; 2500±720 mg/d; CVVH: Initially 31.7±10.4 mg/kg/d	20-25	≥400	**Overall therapy:** 20.0±3.8; Gram-positive bacteremia: 19.3±3.2; Sepsis without proven gram-positive bacteremia: 21.2±4.2; Pneumonia: 22.0±3.9	Lack of postinfusion peak data prevented actual calculation of AUC	Non-CVVH (n=68): 30.7±19.9 %; *Subtherapeutic*: 50.0±26.7 %; *Supratherapeutic*: 19.3±21.7 %; CVVH (n=22): 30.0±20.3 %; *Subtherapeutic*: 45.1±29.6 %; *Supratherapeutic*: 24.9±24.1 %	First: 24 h after initiation of CI Regular: Not described	Gram-positive bacteremia: 12.4±11.8; Sepsis without proven gram-positive bacteremia: 8.7±5.9; Pneumonia: 13.5±11.1
Albanèse [60] Excluded due to number of patients <30 and unspecified length of time course	*15 mg/kg (2 h)*	*50-60 mg/kg/d*	*Not described*	*62±17 mg/kg/d*	*20-30*	*Not described*	***Overall therapy:*** *32±8 (range: Meningitis: 11.6-46.8; Without meningitis: 14.6-36.1)*	*Not described*	*Not described*	*First: 1st day: 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00 pm, midnight; 2nd day: 6:00 am; 12:00 noon, 2:00 pm, midnight; 3rd day: 6:00 am, 2:00*	*13±7*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
										pm; *Regular:* *Daily at 6:00 am*	
Baptista [53]	≤70 kg: 1000 mg; >70 kg: 1500 mg	A: 30 mg/kg/d; B: nomogram	A: 14.3 mg/kg (12.8-17.6); 1000 mg/d (1000-1500); B: 18.8 mg/kg (16.7-21.4); 1500 mg/d (1000-1500)	A: 1920 mg/d (1512-2400); B: 2072 mg/d (1750-2622)	20-30	Not described	**24 h:** A: 20.6 (16.7-26); B: 24.5 (22.2-27.4)	Not described	A: 51 %; B: 84 %	Daily at 7:00 am	Not described
Beumier [55]	35 mg/kg (4 h) (Adapted from Roberts, 2011. [118])	14 mg/kg/d	2750 mg (2250-3150)	1100 mg/d (975-1270)	20-30	>400	**24 h:** 23 (19-31)	652 (596-789)	**12 h:** 69 %; **24 h:** 63 %; *Subtherapeutic*: **12 h:** 3 %; **24 h:** 19 %; *Supratherapeutic*: **12 h:** 28 %; **24 h:** 19 %	First: End of LD (T1); 12 h after initiation of CI (T2); 24 h after initiation of CI (T3); Regular: daily at 8:00 am	3 (2-7)
Carricajo [62] Excluded due to number of patients <30 and unspecified length of time course	*30 mg/kg (1 h)*	*30 mg/kg/d*	*Not described*	*Not described*	*25-30*	*≥350*	***24 h:*** *All:* *21.33±7.64 (14.1-25.4);* *< 120 mL/min:* *25.8±6.37 (21.9-27.3);* *≥120 mL/min:* *13.45±1.98 (12.6-14.7)*	***AUC24/MIC:*** *All:* *548.3±300.3 (325.3-568.9);* *<120 mL/min:* *679.25±357.9 (371.8-667.0);* *≥120 mL/min:* *286.5±93.75 (264.8-345.3)*	***Css:*** *All: 27.3 %;* *<120 mL/min: 42.9 %;* *≥120 mL/min: 0 %;* *Subtherapeutic:* *All: 59.1 %;* *<120 mL/min: 35.7 %;* *≥120 mL/min: 100 %;*	*First:* *24 h after initiation of CI;* *Regular:* *Not described*	*Not described*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
									Supratherapeutic: *All: 13.6 %;* *<120 mL/min: 21.4 %;* *≥120 mL/min: 0 %;* ***AUC/MIC**:* *All: 66,7 %;* *<120 mL/min: 87,5 %;* *≥120 mL/min: 25 %*		
Cianferoni [56]	15 mg/kg (1-1.5 h)	According to renal function 20-30 mg/kg/d (TBW); VCM level <20 mg/L: Bolus (500 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for ≥4 h + reduction of daily dose by 500-1000 mg/d	1000 mg (1000-1500)	All: 2000 mg/d (1697-2500); No AKI: 2000 mg/d (1800-2642); AKI: 1940 mg/d (1431-2212); (Early AKI: 1747 mg/d 1206-2000); Late AKI: 2050 mg/d (1714-2691)) Total dose All: 8.1 g (6-13.5); No AKI: 9.45 g (7-14); AKI: 11.5 g (7.5-16.9)	20-30	Not described	**Overall therapy:** All: 22.3±7.0; No AKI: 21.2±6.8; AKI: 25.8±6.6; (Early AKI: 27.2±5.1; Late AKI: 24.1±7.8) **24 h:** All: 19.7±8.5; No AKI: 18.7±7; AKI: 22.5±9.6; (Early AKI: 24.5±7.8; Late AKI: 20.2±11.1)	Not described	Not described	Daily at 8:00 am	All: 4 (3-6); No AKI: 4 (3-6); AKI: 5 (3-9); (Early AKI: 5 (3-7); Late AKI: 5 (4-9))

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Covajes [58]	15 mg/kg (TBW)	20-30 mg/kg/d; VCM level <20 mg/L: Bolus (500-1000 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for 4-8 h + reduction of daily dose by 500-1000 mg/d	16.4±6.4 mg/kg	**24 h:** 23.5 ± 8.1 mg/kg/d; **48 h:** 23.2 ± 7.4 mg/kg/d; **72 h:** 23.3 ± 11.0 mg/kg/d	20-30	Not described	**24 h:** 24.7±9.0; **48 h:** 26.0±8.1; **72 h:** 27.7±9.3	Not described	**24 h:** 51 %; **48 h:** 56 % ; **72 h:** 67 %; *Subtherapeutic*: **24 h:** 29 %; **48 h**: 22 % ; **72 h:** 8 %; *Supratherapeutic*: **24 h**: 20 %; **48 h**: 21 % ; **72 h**: 26	Daily at 8:00 am	4 (3-7)
Cristallini [52]	35 mg/kg (4 h)	According to renal function >150 mL/min: 45 mg/kg/d; 120-150 mL/min: 40 mg/kg/d; 80-119 mL/min: 30 mg/kg/d; 50-69 mL/min: 25 mg/kg/d; 25-50 mL/min: 14 mg/kg/d; <25 (anuria):	2650 mg	2112 mg/d	20-30	Not described	**12 h:** 25 (21-32); **24 h:** 22 (19-28); **48 h:** 26 (22-30)	771 (664-905)	**12 h:** 56 %; **24 h:** 54 %; **48 h:** 73 %	First: End of LD; 12 h, 24 h, 48 h after initiation of CI Regular: Daily at 8:00 am	Not described

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		7 mg/kg/d; VCM level <20 mg/L: Bolus (500-1000 mg) + increase of daily dose by 25 %/d; VCM level >30 mg/L: Stop for 4 h + reduction of daily dose 25 %/d									
Di Filippo [63] ***Excluded due to number of patients <30 and time course of only 7 months***	*500 mg (10 min)*	*2000 mg/d*	*Not described*	*Not described*	*30-40*	*Not described*	***24 h:*** *13.88±5.7;* ***48 h:*** *17.76±7.6;* ***72 h:*** *24.3±3.9*	*Not described*	*Not described*	*First: 2 h, 48 h, 96 h after initation of CI; Regular: Not described*	*6.14±1.37*
Duszynska [31] ***Excluded due to number of patients <30***	*500 mg*	*30 mg/kg/d (TBW); VCM level <15 mg/L: Bolus (500 mg) + increase of daily dose by 25 %/d; VCM level >20 mg/L: Reduction of daily dose by 25 %/d*	*500 mg*	*29.6±5.5 mg/kg/d; 2219±476 mg/d; Total: 17.7±5.2 g*	*15-20*	*≥400*	*Time to target: 72 h (24-120)*	*316 (123-577); MIC: 2 (1-2); AUC24/MIC: All: 195 (133-343); Clinical cure: 194 (134-389); Microbiological eradication: 162 (116-389) AUC96/MIC: All: 1112 (650-1414)*	*Css: 71.4 % Subtherapeutic: 19 %; Supratherapeutic: 10 % AUC24/MIC: 23.8 %; AUC96/MIC: 24 %*	*First: Immediately + 30 min after LD; 24 h, 48 h, 96 h after initiation of CI; Regular: Not described*	*7 (7-8)*
Eldemiry [38] ***Excluded due to number of patients <30***	*none*	*Rate of infusion (g/d) = [0.0205 CrCl + 3.47] * (Css) * (24/1000)*	*Not described*	*Total: 9.93±2.21 g*	*15-20*	*Not described*	***Overall therapy:*** *18.13±14.15*	*Not described*	*40 %; Subtherapeutic: 30 %; Supratherapeutic: 30 %*	*Not described*	*5.05±0.99*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Hanrahan [76]	Not described	Not described	Not described	1700 mg/d (1200-2100); Total: 9.0 g (6.0-14.4)	Not described	Not described	**Overall therapy:** 18.4 (15.6-21.2)	Not described	Not described	First: ≥18 h after dose change; Regular: Not described	5.3 (3.4-10.3)
Hong [26] ***Excluded due to time course of only 9 months***	*20 mg/kg (1 g/h)*	*According to renal function ≥90 mL/min: 40 mg/kg/d; 50-90 mL/min: 30 mg/kg/d; 20-50 mL/min: 15 mg/kg/d; (Dose adjustment via ratio method (current total daily dose x desired Css = new total daily dose x current Css) or pharmakokinetic equation: Css = (dose/24 h)/clearance)*	*19.9±3 mg/kg*	*Achieving goal: 33±10.6 mg/kg/d; 2572±784 mg/d*	*20-30*	*>400*	***24 h:*** *28±9.2* *Time to target: 1.96 d;* *Time within target: 55 %*	*671.5±219.9*	***24 h:*** *40 %;* *Subtherapeutic: 21.5 %* *Supratherapeutic: 38.5 %* ***AUC24/MIC*** *(S. aureus, 11/15):* *MIC=0.5: 100 % (2/2);* *MIC=1: 88.9 % (8/9);* *MIC=2: 0 % (0/0)* *Population-based:* *MIC=0.5: 100 % (65/65);* *MIC=1: 92.3 % (60/65);* *MIC=2: 27.7 % (18/65)*	*First: 24 h after initiation of CI; CrCl <50 mL/min: 36-48 h after initiation of CI; Regular: not described*	*10.4±7.8*
Hutschala [33]	20 mg/kg (1 h)	36 mg/kg/d (0.025 mg/kg/min)	Not described	1935±688 mg/d (352-3411)	20-25	Not described	**Overall therapy:** 25.0±4.0 (7-30); Time to target: 16±8 h	529±98	Not described	Daily at 7:00 am	9±6 (3-19); Time between surgery and start of therapy: 4.9±1.8
Lin [32] ***Excluded due to number of***	*25 mg/kg*	*1500 mg/d (60 mg/h)*	*26.65±3.06 mg/kg; 2232.14±385.61 mg*	***Overall therapy:*** *15.66±6.26 mg/kg/d;* ***24 h:*** *1329.85±335.61*	*15-25*	*Not described*	***24 h:*** *20.35±2.78;* ***48 h:*** *20.8±2.66;* ***72 h:*** *19.25±2.01;*	*Not described*	***24 h:*** *100 %*	*First: 24 h after initiation of CI;*	*6.57±3.25*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
patients <30				*mg/d;* ***48 h:*** *1339.28±348.17 mg/d;* ***72 h:*** *1428.57±301.09 mg/d;* *Total dose prior to first 24 h level: 3625±497.5 mg*			*Time to target: 24±0.56 h*			*Regular:* *Daily, but no further monitoring, when two consecutive serum concentrations within target range and no change in CVVH flow rate*	
Lin [42]	25-30 mg/kg	According to renal function >60 mL/min: 2000 mg/d; max. 4.25 g/d; Concomitant CVVH: Initial dose 1500 mg/d; VCM level <15 mg/L: Bolus (500-1000 mg) + proportional increase of daily dose; VCM level >25 mg/L: Stop for 4-6 h + proportional reduction of daily dose	Obese: 24.8±2.05 mg/kg; 2894±525 mg; Non-obese: 25.6±1.66 mg/kg; 1923±345 mg; CVVH: Obese: 25.3±0.744 mg/kg; 2722±441 mg; Non-obese: 25.4±1.49 mg/kg; 1833±280 mg Preserved renal function: Obese: 24.6±2.47	Obese: 24.8±12.7 mg/kg/d; 2885±1450 mg/d; Non-obese: 41.9±20 mg/kg/d; 3039±1313 mg/d; CVVH: Obese: 13.3±4.73 mg/kg/d; 1389±39 7 mg/d; Non-obese: 21.7±8.33 mg/kg/d; 1500±375 mg/d; Preserved renal function: Obese: 30.8±11.3 mg/kg/d;	15-25	Not described	**24 h:** All: 20.32±3.72; Obese: 20.3±3.81; Non-obese: 20.03±3.79; CVVH: Obese: 19.8±3.05; Non-obese: 21.6±3.02; Preserved renal function: Obese: 20.6±4.21; Non-obese: 19.6±4.41	Obese: 488±91.5; Non-obese: 480.9±91.04; CVVH: Obese: 474±73.2; Non-obese: 517±48.6; Preserved renal function: Obese: 496±101; Non-obese: 471±106	**24 h:** Obese: 92.3 %; Non-obese: 88.5 % CVVH Obese: 100 %; Non-obese: 100 %	First: 24 h after initiation of CI; Regular: Every 24 h until 2 serum concentrations within target range	Obese: 6.88±3.02; Non-obese: 6.5±3.06

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
			mg/kg; 2985±555 mg; Non-obese: 25.9±1.88 mg/kg; 1941±370 mg	3676±1131 mg/d; Non-obese: 53.4±13.7 mg/kg/d; 3882±674 mg/d							
Ma [37] ***Excluded due to inclusion of ICU and non-ICU patients in analysis***	*Not described*	*Not described*	*Not described*	*Inital: 2047±466 mg/d (1000-3750);* *Final: 2098±766 mg/d (600-4000)*	*15-20[a]; BJI: 12-20*	*Not described*	*Initial:* *13±5 (2-27);* *Final:* *16±3 (7-46)*	*402±118;* *Nephrotoxic risk:* *535±233;* *No nephrotoxic risk:* *360±116*	*78 %*	*At steady state*	*46±31*
Mohammedi [74]	A: 500 mg; B: 15 mg/kg (1 h)	0.227 * CrCl + 5.67 (according to Rodvold 1988 [119])	A: 500 mg; 7.54±1.52 mg/kg; B: 1147±317 mg; 15 mg/kg	Not described	20	Not described	**24 h:** A: 14.9±5.4; B: 18.5±6.4	Not described	Not described	First: 1 h after end of LD; Regular: Not described	Not described
Ocampos-Martinez [59]	15 mg/kg (1-1.5 h)	According to renal function >80 mL/min: 30 mg/kg/d; 50-80 mL/min: 20-30 mg/kg/d; <50 mL/min: 10-20 mg/kg/d; VCM level <20 mg/L: Bolus (500 mg) +	16.2±5.4 mg/kg; 1199±366 mg	**24 h:** 26.8±8.1 mg/kg/d; 1975±507 mg/d; **48 h:** 28.7±10.1 mg/kg/d; 2103±636 mg/d; **72 h:** 29.7±13.9 mg/kg/d; 2232±688 mg/d	20-30	Not described	**24 h:** 20.4±8.9; **48 h:** 24.1±9.1; **72 h:** 25.5±10.1; Time to target: 2 d (1-3)	Not described	**24 h:** 47 %; **48 h:** 67 %; **72 h:** 86 %; *Subtherapeutic*: **24 h:** 42 %; **48 h:** 14 %; **72 h:** - %; *Supratherapeutic*: **24 h:** 11 %; **48 h:** 19 %;	First: ≥16 h after initiation of CI; Regular: daily at 8:00 am	4 (3-7)

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for ≥4 h + reduction of daily dose by 500-1000 mg/d							**72 h**: - %		
Omuro [61]	1000 mg	2000 mg/d; VCM level <20 mg/L: Bolus (500-1000 mg)	Not described	2374 mg/d (2168-2764); Total: 14 g (9.3-18.5)	20-40	Not described	**Overall therapy**: 20.03 (15.67-26.25)	Not described	Not described	Not described	6 (4-7)
Perin [48]	1000-1500 mg according to physician's choice	Not described	15.6 mg/kg (12.5-20.8); 1000 mg (1000-1500)	**24 h**: 27.5 mg/kg/d (21.3-31.9); 2000 mg/d (1600-2000); **48 h**: 28.4 mg/kg/d (23.8-34.8); 2000 mg/d (2000-2500)	20-25	Not described	**24-48 h**: 19.8 (16-25.1)	Not described	**24-48 h**: 24 %	First: 24-48 h after initiation of CI Regular: Daily	4 (2-7) (max. 14 d due to protocol)
Ricard [115] Excluded due to number of patients <30 and	*15 mg/kg*	*60 mg/kg/d*	*Not described*	*Not described*	*Not described*	*Not described*	***Overall therapy**: 25.5±7.1 (20.9-31.0); Died: 31.9±2.82 (30.2-33.65) (3/14); Survived: 23.76±6.88 (19.1-26.7)*	*612.03±169.72 (502.2-744.6); **AUC24/MIC**: 1257.5±699.0*	*Not described*	*Not described*	*Not described*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
unspecified length of time course							*(11/14)*	*(746.4-1448.7) (12/14);* *Died:* *1627.7±1037.5* *(905.6-2100.8) (3/14);* *Survived:* *1134.15±481.5* *(768.0-1363.2) (9/14)*			
Saugel [54] ***Excluded due to time course of only 9 months***	*20 mg/kg* *(TBW) (3 h)* *(max 2 g)*	*According to renal function* *20-30 mg/kg;* *max. 2-3 g;* *VCM level <20 mg/L:* *Bolus (500 mg) + increase of daily dose by 500 mg/d;* *VCM level >30 mg/L:* *Stop for 4 h + reduction of daily dose by 500 mg/d;* *VCM level >40 mg/L:* *Stop for 12 h + reduction of daily dose by 1000 mg/*	*1750 mg* *(1400-2000)*	***24 h:*** *3120 mg/d (2596-3980);* ***48 h:*** *1584 mg/d (1271-1817);* ***72 h:*** *1171 mg/d (832-1392)* ***96 h:*** *645 mg/d (396-1218);* ***120 h:*** *480 mg/d (180-960);* ***144 h:*** *504 mg/d (152-1124);* ***168 h:*** *873 mg/d (408-1500)*	*20-30*	*Not described*	***Overall therapy:*** *29.0 (25.2-33.2)*	*Not described*	***24 h:*** *48 %;* ***48 h:*** *39 %;* ***72 h:*** *33 %;* ***96 h:*** *26 %;* ***120 h:*** *43 %;* ***144 h:*** *57 %;* ***168 h:*** *69 %* *Subtherapeutic:* ***24 h:*** *16 %;* ***48 h:*** *10 %;* ***72 h:*** *6%;* ***96-169 h:*** *11 %, 14 %, 24 %, 15 %;* *Supratherapeutic:* ***24 h:*** *36 %;* ***48 h:*** *52 %;* ***72 h:*** *61;* ***96-169 h:*** *63 %; 39 %; 19 %; 15 %*	*Daily*	*7 (5-9)*
Saugel [54]	1000-1250 mg (depending on BW+renal function)	60 mg/h (=1.440 mg/d); Renal impairment: 40 mg/h (=960 mg/d)	1400 mg	960 mg/d (526-1723)	15-25	Not described	**Overall therapy:** 19.8 (9.8-29.4)	Not described	*Subtherapeutic*: **24 h:** 44 %; **48 h:** 29 %; **72 h:** 23 %	Not routinely and only after discretion of treating ICU physician	6 (2-21)
Schmelzer [45]	*20 mg/kg*	*According to*	*Not described*	*Not described*	*15-25*	*Not described*	***Overall therapy:***	*Not described*	*57.1 %*	*First:*	*Not described*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Excluded due to number of patients <30 and unspecified length of time course		*renal function 0.9-2.4 mg/kg/h (TBW unless BW was ≥30 % than IBW --> ABW)*					*19.8±6.13*		*Subtherapeutic: 21.5 % Supratherapeutic: 21.4 %*	*48 h after LD; Regular: Every 7 d*	
Sin [41]	25 mg/kg	Nomogram based on CVVH intensity: CVVH intensity 10-15 mL/kg/h: 1000 mg/d; 15.1-20 mL/kg/h: 1250 mg/d; 20.1-25 mL/kg/h: 1500 mg/d; 25.1-30 mL/kg/h: 1750 mg/d; >30 mL/kg/h: 2000 mg/d	24±1.9 mg/kg; 2125±294.6 mg	**24 h:** 16.1±6.1 mg/kg/d; 1355.7±272.7 mg/d; **48 h:** 15.3±5.2 mg/kg/d; 1324.3±311 mg/d; **72 h:** 14.4±4.7 mg/kg/d; 1267.8±311.2 mg/d	15-25	Not described	**24 h:** 20.1±4.7; **48 h:** 20.7±3.7; **72 h:** 21.9±3.5	Not described	**24 h**: 82.7 %; **48 h:** 81.8 %; **72 h:** 75 %; *Subtherapeutic*: **24 h:** 3.8 %; **48 h:** 6.1 %; **72 h:** 8.3 %; *Supratherapeutic* **24 h:** 13.5 %; 48 h: 12.1 %; **72 h:** 16.7 %	First: 24 h after LD; Regular: Every 24 h	4.9±3.4
Spadaro [43]	<65 kg: 1000 mg (1 h); >65 kg: 1500 mg (1.5 h)	According to renal function (CrCl) >50 mL/min: 2000 mg/d; 20-50 mL/min: 1500 mg/d; 10-20 mL/min:	CrCl >50 mL/min: 16.7±4.8 mg/kg; CrCl ≤50 mL/min: 18±2 mg/kg	Total (0-48 h): CrCl >50 mL/min: 5.4±0.3 g; CrCl ≤50 mL/min: 3.6±0.8 g	15-25	>400	Not described	CrCl >50 mL/min: AUC/MIC: 468±79; CrCl ≤50 mL/min: AUC/MIC: 490±84	**24 h:** >50 mL/min: 44 %; ≤50 mL/min: 57 %; **48 h:** >50 mL/min: 41 %; ≤50 mL/min: 40 % **72 h:**	Every 48 h at 7:30 am	>50 mL/min: 9±1.1; ≤50 mL/min: 9.1±1.6

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		1000 mg/d; <10 mL/min: 500 mg/d							>50 mL/min: 41 %; ≤50 mL/min: 41 %		
Spapen [46]	15 mg/kg (1 h)	30 mg/kg/d VCM level <15 mg/L: Increase of daily dose by 500 mg/d; VCM level >25 mg/L: Reduction of daily dose by 500 mg/d; VCM level >30 mg/L: Stop for 6 h	Not described	Not described	15-25	Not described	**Overall therapy:** VCM level <25 mg/L: No AKI: 95.6 % (65/68) (71.4 %,65/91); AKI: 4.4 % (3/68) (7.9 %, 3/38); VCM level 25-30 mg/L: No AKI: 69.0 % (20/29) (22.0 %, 20/91); AKI: 31.0 % (9/29) (23.7 %, 9/38); VCM level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91); AKI: 81.3 % (26/32) (68.4 %, 26/38)	Not described	Not described	Daily at 8:00 am	AKI: 14.9±9.8; No AKI: 9.2±4.9
Stepan [47]	≤65 kg: 1000 mg (1 h); >65 kg: 1500 mg	According to renal function SCr <1.4 mg/dL: 1.5 g/d; SCr >1.4 mg/dL:	Not described	1500±620 g/d; Total 12.9±6.9 g	15-25	Not described	**Overall therapy:** 19.0±4.3	Not described	Not described	Daily at 5:00 am	9 (7-10)

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
	(1.5 h)	1 g/d; VCM level <15 mg/L: Increase of daily dose by 500 mg/d; VCM level >25 mg/L: Reduction of daily dose by 500 mg/d; VCM level >30 mg/L: Stop for 6 h + reduction of daily dose by 500 mg/d									
Tiede [116] ***Excluded due to number of patients <30***	*1000 mg (1 h)*	*Nomogram based on kidney function (According to Pea. 2012 [120] and Minichmayr, 2018 [121])*	*1000 mg/d*	*57.2 mg/kg KG/d (41.2-68.6);* *4250 mg/d (3500-7000)*	*20-30*	*>400*	***24 h***: *24.5±4.04 (22.5-25.7)*	*Not described*	*Not described*	*First:* *24 h, 72 h after initiation of CI* *Regular:* *Not described*	*13 (8-18)*
Tuon [75]	30 mg/kg	60 mg/kg/d	Not described	Not described	Not des-cribed	Not described	**Overall therapy**: 34.9 (21.47-42.1)	838 (515-1010)	Not described	First: ≤48 h after initiation of CI; Regular: Not described	10-14
Udy [57]	15 mg/kg (TBW)	15 mg/kg/d; VCM level <20 mg/L: Bolus (500-1000 mg) + increase of	16.4±5.5 mg/kg	**24 h:** 23.7±8.1 mg/kg/d	20-30	Not described	**24 h:** 24.6±9.2	Not described	**24 h:** 69.1 %; *Subtherapeutic*: 8.6 %;	Not described	Not described

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for 4-8 h + reduction of daily dose by 500-1000 mg/d							*Supratherapeutic*: 22.2 %		
van de Vijsel [39] ***Excluded due to number of patients <30***	*1500 mg*	*1000-1500 mg/d (42-62 mg/h)*	*Not described*	*Not described*	*15-20*	*≥400*	*Not described*	*403 (89-792)*	*71 %*	*Not described*	*15.2±14.6 (2-52)*
van den Heever [40] ***Excluded due to number of patients <30***	*15 mg/kg*	*30 mg/kg/d (without renal impairment)*	*1100±214 mg (750-1500)*	*3282 mg/d*	*15-20*	*≥360*	***24 h:*** *15* *Time to target: 21 h*	*Not described*	*50 % after 21 h;* *100 % within 33 h*	*First:* *1 h after LD;* *Regular:* *Every 6 h*	*Not described*
Vazquez [50] ***Excluded due to number of patients <30***	*Not described*	*3000 mg/d*	*Not described*	*2400±640 g/d (2000-3000)*	*20-25*	*Not described*	***Overall therapy:*** *19.5 (14.9-24.8)* ***24 h:*** *15.1 (12.4-19.2);* ***48 h:*** *19.5 (15.5-25.7)* ***72 h:*** *22.8 (16.8-29.0)* *Clinical condition:* *Serious:* *11.3 (10.4-13.8) (7/25);* *Worse:* *12.1 (10.8-13.5) (2/25);* *Improvement:* *23.5 (22.0-27.3) (16/25=;*	*Not described*	***Mean:*** *20.7 %* ***24 h:*** *16.0 %* ***48 h:*** *20.0 %* ***72 h:*** *22.2 %*	*Routinely*	*Not described*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
							Apyretic: *43.2 (41.7-44.8) (2/25)*				
Wysocki [34]	15 mg/kg (adjustment according to nomogram (Moellering, 1984 [10]))	30 mg/kg/d; VCM level <20 mg/L: Increase daily dose by 500 mg; VCM level >25 mg/L: Decrease daily dose by 500 mg	Not described	Not described	20-25	Not described	**Overall therapy**: 24±8; Success: 23±4; Failure: 25±5 Time to target: 36±31 h	577±120 Failure: 685±260; Success: 596±159	Not described	Daily at 7:00 am until two consecutive VCM levels in target range, afterwards sampling only if 10 % change in BW or SCr	13±5
Wysocki [117] Excluded due to number of patients <30	*15 mg/kg*	*30 mg/kg/d*	*Not described*	*24±14 mg/kg/d*	*20-30*	*Not described*	***Overall therapy**: 24±6* *Time to target: 2.3±1.5 d*	*Not described*	*Not described*	*Daily at 7:00 am*	*16±10*
Yamada [29] Excluded due to number of patients <30	*30 mg/kg*	*30 mg/kg/d*	*Not described*	*Not described*	*15-25*	*Not described*	***12 h:*** *19.6 (14.4-23.7)* ***24 h:*** *23.59 (14.52-28.97);* ***36 h:*** *21.5 (12.2-30.0);* ***48 h:*** *18.28 (10.6-27.125)*	*530.2 (108-958.4)*	*Not described*	*First:* *1 h after LD;* *Regular:* *12 h, 24 h, 36 h, 48 h after initiation of CI*	*Not described*

a: pneumonia, meningitis, endocarditis, ABW: adjusted body weight, AUC: area under the curve, AUC24/MIC: area under the curve of drug concentration during the first 24 hours of therapy divided by the minimal inhibitory concentration, AUC24: area under the curve of drug concentration during the first 24 hours of therapy, AUC96/MIC: area under the curve of drug concentration during the first 96 hours of therapy divided by the minimal inhibitory concentration, AUC96: area under the curve of drug concentration during the first 96 hours of therapy, BJI: bone and joint infection, (T)BW: (total) body weight, CI: continuous infusion of vancomycin, Css: concentration at steady state (12 h: Css about 12 hours after initiation of CI or on the 1st day of CI, sometimes called “day 0” or “day 1” in publications; 24 h: Css about 24 hours after initiation of CI or on the 2nd day of CI, sometimes called “day 1” or “day 2” in publications;

48 h: Css about 48 hours after initiation of CI or on the 3rd day of CI, sometimes called “day 2” or “day 3” in publications; 72 h: Css about 72 hours after initiation of CI or on the 4th day of CI, sometimes called “day 3” or “day 4” in publications), IBW: ideal body weight, LD: loading dose, MD: maintenance dose (24 h: MD on the 1st day of CI (= D1) or within the 1st 24 hours of CI, 48 h: MD on the 2nd day of CI (= D2) or within 24-48 hours after initiation of CI, 72 h: MD on the 3rd day of CI (= D3) or within 48-72 hours after initiation of CI), MIC: minimum inhibitory concentration, TDM: therapeutic drug monitoring, VCM: vancomycin.

9.4 Main findings Clinical and Microbiological Efficacy

***Table S4**: Overview of the clinical and microbiological efficacy of continuously applied vancomycin. Thirty-five studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)). Only eighteen studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	**Results**	**Definition**	**Results**	**Univariate**	**Multivariate**
Akers [49]	Clinical failure + success	Mortality (in-hospital, 14-day, 28-day)	**In-hospital mortality**: All: 32.2 % (29/90); Non-CVVH: 19.1 % (13/68); Gram-positive bacteremia: 16 %, 4/25 / 4.4 %, 4/90; Sepsis without gram-positive bacteremia: 70 %, 14/20 / 15.6 %, 14/90; Pneumonia: 35 %, 7/20 / 7.8 %, 7/90; **14-d mortality**: All: 10 % (9/90); **28-d mortality**: All: 18.9 % (17/90)	Not defined	Not defined	Not defined	Not defined
	Microbiological failure	Recurrence of gram-positive bacteremia after beginning of CI	MSSA: (2 of an unknown quantity); MRSA: (2 of an unknown quantity);	Not defined	Not defined	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
			Enterococci: (3 of an unknown quantity) CI+II: 17.5 % (10/57)				
Albanèse [60] Excluded due to number of patients <30 and unspecified length of time course	*Clinical success*	*Not defined*	*Not defined*	*Cure;* *Recovery*	*100 %*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Bacteriological cure*	*100 %*	*Not defined*	*Not defined*
Beumier [55]	Clinical failure + success	Mortality (ICU)	57 % (18/32)	Target attainment	**12 h:** 69 %; **24 h:** 63 %; *Subtherapeutic*: **12 h:** 3 %; **24 h:** 19 %; *Supratherapeutic*: **12 h:** 28 %; **24 h:** 19 %	Target attainment: Body weight; CRRT intensity	Not defined
Carricajo [62] Excluded due to number of patients <30 and unspecified length of time course	*Clinical success*	*Not defined*	*Not defined*	*Target attainment*	***Css****:* *All: 27.3 %;* *≥120 mL/min: 0 %;* *<120 mL/min: 42.9 %;* *Subtherapeutic:* *All: 59.1 %;* *≥120 mL/min: 100 %;* *<120 mL/min: 35.7 %;* *Supratherapeutic:* *All: 13.6 %;* *≥120 mL/min: 0 %;* *<120 mL/min: 21.4 %;* ***AUC/MIC****:*	*Not defined*	*Not defined*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
					All: 66.7 %; *≥120 mL/min: 25 %;* *<120 mL/min: 87.5 %*		
Cianferoni [56]	Clinical failure	Mortality (ICU)	All: 23 % (48/207); No AKI: 18 % (28/157); AKI: 40 % (20/50); (Early AKI: 46 % (13/28); Late AKI: 32 % (7/22))	Not defined	Not defined	Not defined	Not defined
Covajes [58]	Clinical failure + success	Mortality (ICU)	59 % (50/85)	Target attainment	**24 h:** 51 %; **48 h:** 56 % ; **72 h:** 67 %; *Subtherapeutic*: **24 h:** 29 %; **48 h**: 22 % ; **72 h:** 8 %; *Supratherapeutic*: **24 h**: 20 %; **48 h**: 21 % ; **72 h**: 26 %	**24 h** target attainment: Age; Daily VCM dose (mg/kg); CRRT intensity	**24 h** target attainment: Age; Daily VCM dose (mg/kg); CRRT intensity
Cristallini [52]	Clinical failure + success	Mortality (ICU)	22 % (24/107)	Target attainment	**12 h:** 56 %; **24 h:** 54 %; **48 h:** 73 %	Not defined	**24 h**: BMI; Body weight; uCrCl
Di Filippo [63] Excluded due to number of patients <30 and time course of	*Clinical success*	*Not defined*	*Not defined*	*Improvement* *(= Reduction in SOFA score; leukocytes; body temperature (T); tachycardia; tachypnea)*	*SOFA: -33.8 % (before initiation of CI: 6.62±2.2; end of therapy: 4.37±3.5);* *Leukocytes: -37.6 % (before initiation of CI: 17.24±12.84; end of therapy: 10.76±3.61);*	*Not defined*	*Not defined*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
only 7 months					*T: 100 % (11/11);* *Tachycardia: 100 % (11/11);* *Tachypnea: 100 % (11/11);* *(CI+II: Resolution of fever, tachycardia, tachypnea)*		
	Microbiological success	*Not defined*	*Not defined*	*Cure* *(= Negative culture of the same type of biological sample)*	*100 % (25/25)*	*Not defined*	*Not defined*
Duszynska [31] ***Excluded due to number of patients <30***	*Clinical failure + success (evaluation 24 h after end of CI)*	*Persistence or progression of clinical symptoms of infection;* *Initial recovery followed by deterioration;* *Change to broader spectrum antibiotic therapy (escalation);* *Increased radiological infiltrates/computer tomography (CT)-scan pathology;* *Worsening of laboratory data;* *Need for surgery source control;* *Catecholamines*	***Css:*** *All: 19 % (4/21);* *Reaching target at least once: 17.6 % (3/17);* *No reaching of target: 25 % (1/4);* ***AUC24/MIC:*** *>400: 20 % (1/5);* *≤400: 18.7 % (3/16)*	*Cure* *(= Hemodynamic stabilization: resolution of clinical infection signs (body temperature < 37.5 °C);* *laboratory abnormalities (reduction of leukocytes, CRP, PCT concentration by more than 80 % compared to baseline); no further need for VCM)*	***Css:*** *All: 81 % (17/21);* *Reaching target at least once: 82.4 % (14/17);* *No reaching of target: 75 % (3/4)* ***AUC24/MIC:*** *>400: 80 % (4/5);* *≤400: 81.3 % (13/16);* *Clinical cure: 194 (134-389)*	*Not defined*	*Not defined*
	Microbiological failure + success (evaluation 24 h after end of CI)	*Persistence colonization of new gram-positives or the same pathogen(s) in laboratory samples*	***Css:*** *All: 19 % (4/21);* *Reaching target at least once: 23.5 % (4/17);* *No reaching of target: 0 % (0/4)* ***AUC24/MIC:*** *>400: 20 % (1/5);* *≤400: 18.7 % (3/16)*	*Microbiological eradication* *(= Negative culture from blood, intra-abdominal fluids, CSF, etc.)*	***Css:*** *All: 81 % (17/21);* *Reaching target at least once: 76.5 % (13/17);* *No reaching of target: 100 % (4/4)* ***AUC24/MIC:*** *>400: 80 % (4/5);* *≤400: 81.3 % (13/16);* *Microbiological eradication: 162 (116-389)*	*Not defined*	*Not defined*
Eldemiry [38] ***Excluded due to number of patients <30***	*Clinical failure + success*	*Mortality (15-day)*	*Not described*	*Improvement* *(= Reduction in BUN; leukocytes; pCO2; body temperature (T); APACHE II; increase in pO2; spO2)*	*BUN: (-23.1 %; 46.8±20.27/36±18.71);* *Leukocytes: -40.6 % (16.82±13.23/9.99±3.78);* *pCO2: -15.2 % (42.55±11.7/36.07±8.34);* *T: -3.1 % (reduction in 90 % of patients; 38.335±1.16/37.15±0.42);* *APACHE II: -30.3 % (14.2±4.6/9.9±5.54);*	*Not defined*	*Not defined*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
					pO2: +36.3 % (69.3±46.79/94.45±30.1); spO2: +22.2 % (76.94±17.8/94.01±11.03)		
	Microbiological success	*-*	*-*	*Cure*	*83.3 % (2/12)*	*-*	*-*
Hanrahan [76]	Clinical failure	Mortality (ICU all-cause; within 72 h of last recorded VCM dose)	ICU: 26.3 % (172/653); Within 72 h of last VCM: 19.9 % (130/653); Mortality or nephrotoxicity within 72 h of cessation: 38.7 % (253/653)	Not defined	Not defined	Not defined	Not defined
Hong [26] Excluded due to time course of only 9 months	*Clinical failure + success*	*Mortality (ICU)*	*15.4 % (10/65)*	*Target attainment*	***24 h**: 40 %; Subtherapeutic: 21.5 % Supratherapeutic: 38.5 % **AUC24/MIC** (S. aureus, 11/15): MIC=0.5: 100 % (2/2); MIC=1: 88.9 % (8/9); MIC=2: 0 % (0/0) Population-based: MIC=0.5: 100 % (65/65); MIC=1: 92.3 % (60/65); MIC=2: 27.7 % (18/65)) Time to target: 1.96 d; Time within target: 55 %*	*Not defined*	*Not defined*
	Microbiological success	*-*	*-*	*Eradication*	*55.5 % (11/20)*	*Not defined*	*Not defined*
Hutschala [33]	Clinical failure + success	Mortality (ICU, in-hospital)	ICU: 21 % (25/119); In-hospital: 30.3 % (36/119); Timing of death in course of VCM administration:	Improvement (= Reduction of CRP; leukocytes)	CRP: -66.4±41.6 % (before CS: 3.7±5.1 (0.5-25.1); at start of VCM: 22.64±10.1	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
			9±3.3 d (1-20)		(7.3-55); on 10th day of VCM: 7.6±5.69 (0.7-32.1))		
Lin [32] ***Excluded due to number of patients <30***	*Clinical failure + success*	*Mortality (in-hospital)*	*50 % (7/14)*	*Target attainment;* *Time to target*	***24 h**: 100 %* *Time to target: 24±0.56 h*	-	-
Lin [42]	Clinical failure + success	Mortality (in-hospital)	Obese: 19.2 % (5/26); Non-obese: 15.4 % (4/26)	Target attainment	**24 h:** Obese: 92.3 %; Non-obese: 88.5 % CVVH Obese: 100 %; Non-obese: 100 %	Not defined	Not defined
Ma [37] ***Excluded due to inclusion of ICU and non-ICU patients in analysis***	*Clinical failure + success*	*Mortality (infection-related, in-hospital)*	*Infection-related: 1 % (2/141);* *All: 2 % (3/141)*	*Target attainment*	*78 %*	*Not defined*	*Not defined*
				Cure *(= Resolution of infection signs and symptoms)*	*93 % (62/67)*	*Not defined*	*Not defined*
	Microbiological success	*Readmission within 14 d of discharge for infection recurrence;* *Initiation of a new antibiotic with a similar spectrum due to lack of response*	*7 % (3/40)*	*Cure* *(= Negative culture during/up to 14 d after discontinuing CI after initial positive culture)*	*93 % (37/40)*	*Not defined*	*Not defined*
Mohammedi [74]	Clinical failure + success	Mortality (ICU)	A (LD 500 mg): 50 % (10/20); B (LD 15 mg/kg): 35 % (7/20)	Cure (in patients with proven infection)	A (LD 500 mg): 56 % (10/18); B (LD 15 mg/kg): 93 % (14/15)	Not defined	Not defined
Ocampos-Martinez [59]	Clinical failure + success	Mortality (ICU)	29 % (77/261)	Target attainment	**24 h:** 47 %; **48 h:** 67 %; **72 h:** 86 %; *Subtherapeutic*: **24 h:** 42 %;	Target attainment: **24 h:** CrCl; Loading dose; SCr;	Target attainment: **24-48 h**: CrCl; Gender (male)

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
					48 h: 14 %; **72 h:** ND *Supratherapeutic*: **24 h:** 11 %; **48 h:** 19 %; **72 h:** ND	**48 h**: CrCl; Gender (male); SCr; SOFA	
Omuro [61]	Clinical failure	Mortality (ICU)	CI: 25.2 % (30/119); (VCM-AKI (CI+II): 48 %; Non VCM-AKI (CI+II): 16.8 %)	Not defined	Not defined	ICU Mortality: AKI	Not defined
Perin [48]	Clinical failure + success	Mortality (ICU, in-hospital, 28-day)	**28-day**: All: 26 % (46/178); D2/3 VCM level 20-25 mg/L: 19 % (8/42); D2/3 VCM level <>20-25 mg/L: 28 % (37/132)	Target attainment	**24-48 h:** 24 %	Target attainment: Prolonged ICU stay before initiation of CI; *Subtherapeutic*: AKI on d1/2; Prolonged ICU stay before initiation of CI	Target attainment: Prolonged ICU stay before initiation of CI; *Subtherapeutic*: AKI on d1/2
		Persistence or progression of baseline signs and symptoms of infection after ≥ 2 d of treatment, consistent with active infection Requirement for additional antibacterial treatment	Failure without identification: 13 % (23/179)	Cure (= Resolution of clinical signs and symptoms compared with baseline) (= No requirement for additional antibacterial treatment)	65 % (116/179) (test of cure could not be assessed in 13 % (23/179))		
	Microbiological failure + success	Relapse (= Finding of same pathogen); Reinfection	Relapse: 3 % (5/179); Reinfection 7 % (12/179);	Not defined	Not defined	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
		(= Presence of another pathogen)					
Ricard [115] ***Excluded due to number of patients <30 and unspecified length of time course***	*clinical failure + success*	*Mortality (ICU)*	*21.4 % (3/14)*	*Cure;* *Improvement* *(= Reduction of CSF leukocytes; CSF protein; CSF glucose);*	*Cure: 64.3 % (9/14);* *Improvement: 14.3 % (2/14);* *(Leukocyte: 1st lumbar puncture: 8±24; 2nd lumbar puncture: 0.7±0.11;* *Protein: 1st: 8.6±7.22; 2nd: 5.4±4.35;* *Glucose: 1st: 0.5±0.77; 2nd: 2.6±1.43)*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Cure* *(= Eradication of pathogens in CSF)*	*Gram-positive cocci:* *46 % (1st: 13; 2nd: 7/13);* *S pneumoniae:* *100 % (1st: 12; 2nd: 0/12)*	*Not defined*	*Not defined*
Saugel [54] ***Excluded due to time course of only 9 months***	*Clinical failure*	*Mortality (in-hospital; ICU)*	*ICU: 44 % (15/34);* *Hospital: 59 % (20/34)*	*Not defined*	*Not defined*	*Not defined*	*Not defined*
Schmelzer [45] ***Excluded due to number of patients <30 and unspecified length of time course***	*Clinical success*	*Not defined*	*Not defined*	*Target attainment*	*57.1 %* *Subtherapeutic:* *21.5 %* *Supratherapeutic:* *21.4 %*	*Not defined*	*Not defined*
Sin [41]	Clinical failure + success	Mortality (in-hospital)	63.5 % (33/52)	Target attainment	**24 h**: 82.7 %; **48 h:** 81.8 %; **72 h:** 75 %; *Subtherapeutic*: **24 h:** 3.8 %; **48 h:** 6.1 %; **72 h:** 8.3 %; *Supratherapeutic*	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
					24 h: 13.5 %; 48 h: 12.1 %; **72 h:** 16.7 %		
Spadaro [43]	Clinical failure + success	Mortality (ICU)	CrCl >50 mL/min: 21.4 % (45/210); CrCl ≤50 mL/min: 23.9 % (33/138)	Target attainment	**24 h:** CrCl >50 mL/min: 44 %; CrCl ≤50 mL/min: 57 %; **48 h:** CrCl >50 mL/min: 41 %; CrCl ≤50 mL/min: 40 % **72 h:** CrCl >50 mL/min: 41 %; CrCl ≤50 mL/min: 41 %	Not defined	Mortality: Subtherapeutic level at first VCM measurement (→ AUC/MIC was in therapeutic range); SAPS II score
Spapen [46]	Clinical failure	Mortality (no differentiation between "infection-related" or "AKI-induced")	AKI: 53 % (20/38); No AKI: 20 % (18/91)	Not defined	Not defined	Not defined	Not defined
Stepan [47]	Clinical failure + success	Mortality (infection-related)	18 % (6/33)	Cure (= Vanishing of all symptoms of an infection); Improvement (= Reduction of symptoms of infection; LOS; LOV; LOT; Reduction of leukocytes; Reduction of CRP)	Cure/improvement: 64 % (21/33); LOS:: 26 d (12.8-40.3); LOV: 25 d (10.5-39.3) LOT: 9 (7-10) Leukocytes: d0: 13.4 (9.7-18.9); end: 10.9 (8.6-17.9) (-18.7 %); CRP: d0: 192.0±98.1; end: 123±83.1 (-35.9 %)	Not defined	Not defined
		Persistence of symptoms; Increase of symptoms	Not described				

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
	Microbiological failure + success	Persistency; Superinfection; Relapse	Not described	Cure (=Eradication; Suspected eradication)	76 % (25/33)	Not defined	Not defined
Tiede [116] Excluded due to number of patients <30	*Clinical success (study not designed for efficacy evaluation)*	*Not defined*	*Not defined*	*Cure; Improvement (= Reduction of infection parameter within 7 d after initation of CI: CRP (serum), leukocyte (serum, CSF))*	*Cure: 100 % (9/9); CRP: 100 % (9/9); Leukocyte serum: overall decrease, but not in every patient; Leukocyte CSF: 100 % (9/9)*	*Not defined*	*Not defined*
Udy [57]	Clinical failure	Mortality (not specified)	58 % (47/81)	Not defined	Not defined	Not defined	Not defined
van de Vijsel [39] Excluded due to number of patients <30	*Clinical failure + success*	*Mortality (ICU, infection-related)*	*ICU: 92 % (20/22); Infection-related: 59 % (13/22)*	*Target attainment*	*71 %*	*Not defined*	*Not defined*
van den Heever [40] Excluded due to number of patients <30	*clinical failure + success*	*Mortality (ICU)*	*10 % (1/10)*	*Target attainment*	*50 % after 21 h; 100 % within 33 h*	*Not defined*	*Not defined*
Vazquez [50] Excluded due to number of patients <30	*Clinical failure + success*	*Worsening of clinical condition; Serious condition*	*Worsening: 8 % (2/25) Serious: 28 % (7/25)*	*Improvement of clinical condition; Afebrile*	*Improvement: 64 % (16/25); Apyretic: 8 % (2/25)*	*Not defined*	*Not defined*
Wysocki [34]	Clinical failure + success	Mortality (infection-related: 10-day; end of treatment; overall: 10-day; end of treatment; ICU)	**Infection-related**: D10: 8 % (5/61); End of treatment: 10 % (6/61); **Overall**: D10: 8 % (5/61); End of treatment: 18 % (11/61); ICU: 37 % (21/61)	Cure; Improvement	78.7 % (48/61)	Not defined	Not defined
		Persistency or impairment of	D10: 21 % (13/61);				

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
		clinical, laboratory, radiological statuses	End of treatment: 21 % (13/61)				
	Microbiological failure + success	Presence of *Staphylococcus spp.* or other species in specimen on day 5	*Staphylococcus*: 39 % (24/61); Other species: 15 % (9/61); Bacteremia: 28 % (17/61)	Cure (= Eradication of *Staphylococcus spp*. in specimen on day 5)	46 % (28/61)	Not defined	Not defined
Wysocki [117] Excluded due to number of patients <30	*Clinical failure + success*	*Mortality (infection-related, overall)*	*Infection-related: 15 % (0-33) (2/13) ICU: 38 % (11-65) (5/13)*	*Duration of fever (<38.5 °C)*	*3 d (1-8)*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Duration of bacteremia*	*2 d (1-7)*	*Not defined*	*Not defined*
Yamada [29] Excluded due to number of patients <30	*Clinical failure*	*Mortality (not specified)*	*36 % (4/11)*	*Not defined*	*Not defined*	*Not defined*	*Not defined*

AKI: acute kidney injury, APACHE: Acute Physiology and Chronic Health Evaluation, BUN: blood urea nitrogen, BW: body weight, CI: continuous infusion of vancomycin, (u)CrCl: creatinine clearance (measured on daily urine excretion), CRP: C-reactive protein, CRRT: continuous renal replacement therapy, CSF: cerebrospinal spinal fluid, LOS: length of stay, LOT: length of therapy with vancomycin, LOV: length of ventilation, PCO2: partial pressure of carbon dioxide, PCT: procalcitonin, PO2: partial pressure of oxygen, SOFA: sepsis-related organ failure, VCM: vancomycin.

9.5 Main findings Safety

***Table S5**: Overview of the safety of continuously applied vancomycin. Twenty-seven studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and safety (e.g. nephrotoxicity in the form of acute renal failure). Only sixteen studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
Akers [49]	Non-CVVH: Increase in SCr by ≥0.5 mg/dL or at least 50 % increase from start to end of vancomycin therapy CVVH: Urine output <0.3 mL/kg/d	**All (CVVH + Non-CVVH):** ≥ 50 % SCr increase: 7.8 % (7/90); ≥0.5 mg/dL SCr increase at end of therapy: 6.7 % (6/90); ≥0.5 mg/dL SCr increase at any time during therapy: 20 % (18/90); **Non-CVVH**: ≥ 50 % SCr increase: 10.4 % (7/68); ≥0.5 mg/dL SCr increase at end of therapy: 8.8 % (6/68); ≥0.5 mg/dL SCr increase at any time during therapy: 22.1 % (15/68)	Mean: 0.99±0.39	**CrCl**: 90.8±39.2	Not described	Not described	Not described	Not described
	Bone marrow toxicity: Difference in leukocytes, neutrophils and platelets at the beginning and end of CI	Leukocytes: Start of CI: 10.6 (8.4-17.5); End of CI: 12.2 (8.4-18.8) (not significant) Neutrophils: Start of CI: 9.1 (6.7-14.8); End of CI: 9.9 (6.4-16.5) (not significant) Platelets: Start of CI: 176 (101-271); End						

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
		of CI VCM: 236 (108-417) (significant)						
Albanèse [60] Excluded due to number of patients <30 and unspecified length of time course	*No specific definition for nephrotoxicity mentioned ("no adverse effect")*	*0 % (no renal impairment detected despite high level of VCM in serum)*	*D1: 0.76±0.27; Last day of treatment: 0.63±0.21*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Baptista [53]	Increase in SCr by >0.3 mg/dL on ≥2 consecutive days; Red-man syndrome	A (MD 30 mg/kg/d): 6.3 %; B (MD nomogram): 4 %	A: 0.68±0.3; B: 0.68±0.3	**CrCl**: A: 125.1±66.5; B: 120.5±54.2; ARC on d1: A: 36.7 %; B: 40 %	Not described	Not described	Not described	Not described
Carricajo [62] Excluded due to number of patients <30 and unspecified length of time course	*No specific definition for nephrotoxicity mentioned*	*0 %*	*Not described*	*CrCl: 105.5±34.6 (50-178)*	*Not described*	*Not described*	*Not described*	*Not described*
Cianferoni [56]	Daily urine output <0.5 ml/kg/h and/or increase of SCr ≥0.3 mg/dl or 50-100 % increase from baseline (=VCM on first day of therapy)	Total: 24 % (50/207); VCM level <15 mg/L: 6 % (2/34) 15-20 mg/L: 11 % (5/47) 20-25 mg/L: 30 % (18/60)	Not described	**CrCl** (1.73 m²): All: 68 (31-108); No AKI:	At least 1 nephrotoxin (All: 74 %; no AKI: 69 %; AKI: 92 %; early AKI: 93 %; late AKI: 91 %); Number of nephrotoxins	Not described	AKI: Mean serum VCM (over d1-3); Duration of therapy; Early AKI: Bacteremia; Mean serum VCM (over d1-3);	AKI: Severity of illness (APACHE II, SOFA); SCr/CrCl at baseline

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
	on at least two consecutive days during and within 72 h after VCM discontinuation Early AKI: Occurrence within first 2 days of therapy; Late AKI: Occurrence after 2 days of therapy; Severe AKI: Need for CRRT or HD within VCM therapy or 3 days after drug discontinuation	25-30 mg/L: 38 % (15/39) >30 mg/L: 37 % (10/27) Early AKI: 56 % (28/50) Late AKI: 44 % (22/50) CRRT: No AKI: 2 % (3/157 patients needing CRRT 9/11/13 d after VCM discontinuation); AKI: 18 % (9/50) during VCM therapy		72 (35-117); AKI: 44 (26-88); (Early AKI: 36 (20-49); Late AKI: 85 (38-101))	(1/patient (1-2)); ACEi/ARB (All: 15 %); Aminoglycosides (All: 8 %); Contrast, iv (All: 22 %) Diuretics (All: 37 %); Vasopressors (All: 33 %); Inotropes (All: 17 %); Others (All: 8 %, e.g. amphotericin B; calcineurin inhibitors; colistin; NSAIDs)		Mean dose/d (over d1-3); Late AKI: Diabetes; Duration of therapy	
Duszynska [31] ***Excluded due to number of patients <30***	*AKIN [100] during VCM therapy until 72 h after drug discontinuation*	*23.8 % (5/21)*	*1±0.6*	***CrCl**:* *94±47*	*Aminoglycosides (0 %);* *Colistin (24 %);* *Contrast, iv (14 %)* *Diuretics (29 %);* *NSAIDs (19 %)*	*Not described*	*Not described*	*Not described*
Eldemiry [38] ***Excluded due to number of patients <30***	*Allergy;* *Ototoxicity*	*0 %*	*2.01±0.63*	-	*Loop diuretics (10 %); Meropenem (15 %)*	*Not described*	*Not described*	*Not described*
Hanrahan [76]	AKI (RIFLE [114])	24.7 % (161/653) Nephrotoxicity or mortality within 72 h of cessation: 38.7 % (253/653)	Not described	Not described	(Inotropes)	Not described	Not described	Not described
Hong [26] ***Excluded due to time course of only 9 months***	*Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009)*	*15.4 % (10/65)*	*0.92±0.31*	***CrCl**:* *88.8±37.6*	*ACEi/ARB; aminoglycosides; amphotericin B; iv contrast dye; loop diuretics*	*Not described*	*Not described*	*Not described*

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
	[113]							
Hutschala [33]	AKI (AKIN [100] and RIFLE [114])	Total: **RIFLE**: 37 % (44/119); RIFLE: R: 30.3 %; I: 4.2 %; F: 2.5 %; **AKIN**: 49.6 % (59/119); AKIN: 1: 29.4 %; 2: 11.8 %; 3: 8.4 %; RRT: 23.5 % (28/119) Necessity to administer diuretics (furosemide): 12.6 % (15/119)	Before surgery: 0.9±0.5 (0.5-1.5); Before VCM: 1.2±0.6 (0.6-4.3); Maximum during VCM: 1.5±0.7 (0.6-5.0)	**CrCl**: Before surgery: 119±21 (81-172); Before VCM: 54±40 (1-254); Minimum during VCM: 36±29 (1-146)	Aminoglycosides (12 %); Constrast, iv; Diuretics (13 %); Vasopressors	Not described	Not described	Not described
Lin [42]	Not requiring CVVH: Increase in SCr by 0.5 mg/dL or at least 50 % increase from baseline over two consecutive SCr values; Hemodialysis upon discharge from hospital; Hearing loss	AKI: 0 %; Hemodialysis: 0 %; Hearing loss: 0 %	Not described	**Urine CrCl**: Obese: 166±62.7; Non-obese: 168.1±59.1	Not described	Not described	Not described	Not described
Ma [37] ***Excluded due to inclusion of ICU and non-ICU patients in***	*AKI (RIFLE [114])*	*Nephrotoxic risk: 12 % (16/129)* *Renal injury: 3 % (4/129)* *Need for RRT: 0 % (0/129)*	*Initial: 0.76±0.25;* *Final: 0.8±0.37;* *Highest up to 2*	***CrCl***: *130±65.6*	*ACEi/ARB (23 %);* *Aminoglycosides (0 %);* *Contrast, iv (19 %);* *Diuretics (20 %);* *NSAIDs (50 %);*	*Not described*	*Bivariate:* ***Risk***: *Dose modality at time of highest SCr;* *VCM duration at time of highest SCr;* *Concomitant piperacillin/tazobactam;*	*Not described*

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
analysis			*weeks after completing VCM: 0.89±0.42*		*Piperacillin/Tazobactam (11 %) PPI (27 %); Cisplatin; drugs of abuse (cocaine, heroin, ketamine, methadone, methamphetamine); gold therapy; methotrexate; pamidronate; pentamidine; quinine; iv voriconazole; zoledronate*		*Concomitant gram-negative bacteria infection; Concomitant diuretics; Concomitant nephrotoxin; **Injury**: Dose modality at time of highest SCr; VCM duration at time of highest SCr Concomitant piperacillin/tazobactam; Concomitant gram-negative bacteria infection*	
Mohammedi [74]	Alterations in renal function	0 %	Not described	Not described	Not described	Not described	Not described	Not described
Omuro [61]	AKI (AKIN [100])	20.2 % (eventually higher rate of AKI in medical patients (CI/II: surgical: 25.7 %; medical: 42.6 %))	Initiation of VCM (mean): 0.9 (0.73-1.5)	-	Number of nephrotoxins (3/patient); ACEi/ARB (35 %); Aminoglycosides (13 %); Contrast, iv (60 %); Diuretics (94 %); Piperacillin/tazobactam (65 %); Vasopressors (94 %) (Inotropes (19 %)	ICU mortality	Not described	Inotropics; Medical ICU; Vasopressors; VCM therapy
Perin [48]	AKI (KDIGO [101] (measured on D1-4; D10; D15)	During VCM administration: 60 % (107/179), With RRT: 27 % (49/179); VCM ≥25 mg/L at d2/3: 77 % (34/44), With RRT: 36 % (16/44);	Baseline: 0.77 (0.67-0.97); Advanced: 1.18 (0.81-1.83)	**CKD-EPI**: 62 (34-88); augmented renal clearance at d1/2: 4 %	ACEi (20 %); Aminoglycosides (79 %); ARB (10 %); Chemotherapy (4 %); Contrast; Diuretics (20 %);	Not described	Not described	Not described

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
		VCM <25 mg/L at d2/3: 55 % (72/131), With RRT: 25 % (33/131)			NSAIDs (9 %); Others (12 %)			
Ricard [115] Excluded due to number of patients <30 and unspecified length of time course	*Alteration of renal function (that could be specifically related to treatment)*	*0 %*	*Mean: 0.95*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Saugel [44]	Start of RRT	7.3 %	Not described	Not described	Not described	Not described	Not described	Not described
Schmelzer [45] Excluded due to number of patients <30 and unspecified length of time course	*50 % increase of SCr from baseline*	*3.6 %*	*0.72±0.2*	*-*	*ACEi; ARB; aminoglycosides; amphotericin B; calcineurin inhibitors; NSAIDs; iv contrast*	*Not described*	*Not described*	*Not described*
Sin [41]	Infusion reaction; Ototoxicity	0 %	Not described	Not described	Not described	Not described	Not described	Not described
Spadaro [43]	AKI (Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) [113])	CrCl >50 mL/min: 2.4 %; CrCl ≤50 mL/min: 9.4 %; VCM level 25-30 mg/L: 0 %; VCM level >30 mg/L: <8 %	Baseline: CrCl >50 mL/min: 1.0±0.4; CrCl ≤50 mL/min: 2.3±1.4	**CrCl**: Baseline: >50 mL/min: 106.4±40.7; ≤50 mL/min: 37±16.2	ACEi (>50 mL/min: 19.5 %; ≤50 mL/min: 15.2 %); Aminoglycosides (>50 mL/min: 5.7 %; ≤50 mL/min: 6.5 %); Vasopressors	Not described	CrCl at ICU admission	No correlation between nephrotoxicity and VCM within or over target range; No association with concomitant vasopressor therapy, aminoglycosides, ACEi

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
					(>50 mL/min: 15.2 %; ≤50 mL/min: 18.1 %)			
Spapen [46]	AKI (AKIN [100] 1)	Total: 29.5 % (38/129); Distribution according to VCM level: VCM level <25 mg/L: 7.9 % (3/38); VCM level 25-30 mg/L: 23.7 % (9/38); VCM level >30 mg/L: 68.4 % (26/38); VCM level <25 mg/L: No AKI: 95.5 % (65/68) (71.4 %, 65/91); AKI: 4.5 % (3/68) (7.9 %, 3/38); VCM level 25-30 mg/L: No AKI: 69 % (20/29) (22 %, 20/91); AKI: 31 % (9/29) (23.7 %, 9/38); VMC level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91); AKI: 81.3 % (26/32) (68.4 %, 26/38); Return of SCr to baseline at discharge (surviving): 66 % (12/18)	AKI: 0.9±0.19; No AKI: 0.8±0.35	Not described	ACEi/ARB (no AKI: 19 %; AKI: 18 %); Aminoglycosides (no AKI: 43 %; AKI: 32 %); Immunosuppressants (no AKI: 2 %; AKI: 0 %); NSAIDs (no AKI: 4 %; AKI: 3 %), Vasopressors (Nephrotoxins considered only relevant when present during VCM infusion and before increase in SCr)	Diabetes mellitus; Shock	VCM level (especially >30 mg/L); (Lean) Body weight; SAPS 3 score	Duration of therapy; No relationship between type of infection and incidence of AKI; No relationship between nephrotoxic medication and incidence of AKI
Stepan [47]	Increase of SCr; Reduction of CrCl	0 %	D0: 1.1 (0.83-1.5); End of therapy: 0.93 (0.73-1.55)	**MDRD**: D0: 60 (39.6-60.0); End of therapy: 60 (42-60.0)	Not described	Not described	Not described	Not described

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
Tiede [116] ***Excluded due to number of patients <30***	*No specific definition for nephrotoxicity mentioned ("renal impairment")*	*0 % (no renal impairment detected despite high-dose of VCM therapy)*	*Not described*	*> 100*	*Not described*	*Not described*	*Not described*	*Not described*
Tuon [75]	AKI (AKIN [100])	21 % (7/33); AKIN 1: 3 % (1/33); AKIN 2: 6 % (2/33); AKIN 3: 12 % (4/33)	0.66 (0.5-0.92)	Not described	Not described	Not described	Not described	Not described
Wysocki [34]	50 % increase of SCr from D0 until end of treatment; Initiation of Dialysis	Increase of SCr: 16.4 % (10/61); Dialysis: 9.8 % (6/61); Phlebitis/fever: 3 % (2/61); Risk factor for nephrotoxicity: Diabetes: 12 % (7/61); Diuretics: 35 % (18/61); iv contrast: 3 % (2/61); Aminoglycosides: 26 % (6/61)	Baseline (mean): 1.11±0.46; D10: 1.21±0.8; End of treatment: 1.36±0.89	**CrCl**: Baseline (mean): 77±41; D10: 73±34; End of treatment: 68±36	Aminoglycosides (26 %); Contrast, iv (3 %); Diuretics (35 %); Immunosuppression	Not described	Not described	Not described
Wysocki [117] ***Excluded due to number of patients <30***	*Baseline SCr <3 mg/dL: Increase of SCr ≥ 0.5 mg/dL over baseline (= highest level or within 48 h of therapy); Baseline SCr ≥3 mg/dL: Increase of SCr ≥ 1 mg/dL over baseline (= highest level or within 48 h of therapy) (according to Smith, 1980 [122])*	*15.4 %*	*Baseline: 1.28±0.93; Later: 1.28±0.66*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Yamada [29] ***Excluded due to number of patients <30***	*AKI (AKIN [100])*	*AKIN 1: 9 %; AKIN 2: 0 %; AKIN 3: 0 %*	*Not described*	***CrCl***: *118.45 (111.2-119.7)*	*Aminoglycosides (9 %)*	*Not described*	*Not described*	*Not described*

ACEi: angiotensin-converting enzyme inhibitor, AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ARB: angiotensin II receptor blocker, CrCl: creatinine clearance, CRRT: continuous renal replacement therapy, D0: Start of vancomycin therapy, D1: Day 1 of vancomycin therapy, DM2: diabetes mellitus type 2, HD: hemodialysis, NSAID: nonsteroidal anti-inflammatory drugs, RIFLE: Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease, SAPS II: Simplified Acute Physiology Score II, SCr: serum creatinine, VCM: Vancomycin.

***Table S6**: Characteristics of studies included in the forest plot analysis comparing the influence of vancomycin steady-state serum concentration below or above 25 mg/L on nephrotoxicity (= acute kidney injury) (n=3).*

Reference	Patients (n)		Age (years) (mean)		Male sex (n)		ICU Type (n)		Target Css	LD (median)		MD (median)		Css (mean)		Duration of Therapy (days) (median)		ICU Mortality (n)		Nephrotoxicity (n)					
	AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI		AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI			<25 mg/L		≥25 mg/L	
Cianferoni 2013 [56]	50	157	61	60	32	98	Medical: 31 Surgical: 18	Medical: 92 Surgical: 65	20-30 mg/L	1000 mg 13 mg/kg	1000 mg 13 mg/kg	2000 mg/d 25 mg/kg/d	1940 mg/d 25 mg/kg/d	C24: 22.5 mg/L Cmean: 25.8 mg/L	C24: 18.7 mg/L Cmean: 21.2 mg/L	5	4	20	28	Other	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase frome baseline, whichever was greater (on at least two consecutive days); daily urine output <0.5 ml/kg/h	25/141	18%	25/66	38%
Perin 2020 [48]	107	72	67		119		ND	ND	20-25 mg/L	1000 mg 15.6 mg/kg		2000 mg/d 27.5 mg/kg/d		C24: 20.3 mg/L		4		46		KDIGO	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase from baseline, whichever was greater (on at least two consecutive days); daily urine output <0.5 mg/kg/h for 6-12 h	72/131	55%	34/44	77%
Spapen 2011 [46]	38	91	63	61	23	36	ND	ND	15-25 mg/L	ND	ND	ND	ND	Cmean: ND	Cmean: ND	15	9	20	18	AKIN	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase from baseline, whichever was greater (on at least two consecutive days); no measurement of urine output due to concerns about dependency on uncontrolled "extrarenal" events (e.g. volume status, loop diuretics, vasoactive agents)	3/68	4%	35/61	57%

AKI: acute kidney injury, C24: mean vancomycin steady-state serum concentration 24 h after initiation of therapy, Cmean: mean vancomycin steady-state serum concentration during the entire duration of therapy or at least three days of therapy, Css: vancomycin steady-state serum concentration, ICU: intensive care unit, LD: loading dose, MD: maintenance dose, ND: not described, SCr: serum creatinine.

***Table S7**: Comparison of the influence of vancomy*
concentration below or above 25 mg/L on the rate of acute

Reference	RR	Lower limit	Upper limit	Z-value	P-value
Cianferoni 2013 [56]	0.468	0.292	0.750	-3.159	0.0016
Perin 2020 [48]	0.711	0.569	0.889	-2.995	0.0027
Spapen 2011 [46]	0.077	0.025	0.237	-4.460	<0.0001
Summary	**0.535**	**0.432**	**0.662**	**-5.745**	**<0.0001**

RR: relative risk, RR <1 indicates a lower rate of acute kidney injury at a vancomycin serum concentration of <25 mg/L in contrast to >25 mg/L. P-value <0.05 was considered significant. Calculations according to Altmann 2011 [73]

9.6 Quality Assessment

***Table S8**: Quality assessment of the non-randomized studies using the Newcastle-Ottawa Scale (NOS). A star system described the suitability of the selection of the study groups (S1-S4) (max. four stars), the comparability of the groups (C1) (max. two stars) and the ascertainment of the exposure or outcome of interest (E1-E3) (max. three stars). The total number of stars was interpreted as "good quality" at 8-9 stars, "fair quality" at 6-7 stars, "questionable quality" at 4-5 stars, "poor quality" at 2-3 stars and "serious risk of bias" at 0-1 stars.*

Reference	S1	S2	S3	S4	C1	E1	E2	E3	Total	Evaluation
Akers 2012 [49]	SG	*	*	ND	**	*	ND	ND	5	Questionable quality
Baptista 2014[53]	SG	*	*	*	-	*	ND	ND	4	Questionable quality
Beumier 2013 [55]	SG	NA	ND	*	NA	ND	*	ND	2	Poor quality
Cianferoni 2013 [56]	SG	*	*	*	*	*	*	*	7	Fair quality
Covajes 2013 [58]	SG	NA	*	*	NA	*	*	-	4	Questionable quality
Cristallini 2016 [52]	SG	NA	ND	*	NA	ND	*	*	3	Poor quality
Hanrahan 2014 [76]	*	*	*	*	**	*	ND	*	8	Good quality
Hutschala 2009 [33]	SG	*	*	ND	**	*	*	*	7	Fair quality
Lin 2016 [42]	SG	*	*	ND	**	*	-	*	6	Fair quality
Mohammedi 2006 [74]	SG	*	ND	ND	**	ND	-	*	4	Questionable quality
Ocampos-Martinez 2012 [59]	SG	NA	*	*	NA	*	*	ND	4	Questionable quality
Omuro 2021 [61]	*	*	*	ND	**	*	ND	ND	6	Fair quality
Perin 2020 [48]	*	NA	*	*	NA	*	*	ND	5	Questionable quality
Saugel 2013 [44]	*	*	*	*	*	*	-	ND	6	Fair quality
Sin 2018 [41]	SG	NA	ND	ND	NA	ND	*	*	2	Poor quality
Spadaro 2015 [43]	SG	*	*	ND	**	*	ND	*	6	Fair quality
Spapen 2011 [46]	*	*	*	*	*	*	ND	*	7	Fair quality
Tuon 2021 [75]	SG	NA	ND	ND	NA	ND	ND	ND	0	Serous risk of bias
Udy 2013 [57]	SG	NA	*	*	NA	*	*	*	5	Questionable quality

*: award of one star within the selection (S1-4) and exposure (E1-3) categories and maximum of two stars in the comparability (C1) category when an item was positively rated, -: no star could be awarded when an item was negatively rated, C1: comparability of cohorts on the basis of design or analysis, E1: assessment of outcome, E2: was follow-up long enough for outcome to occur?, E3: adequacy of follow up of cohorts, NA: not applicable, ND: not described, S1: representativeness of the exposed cohort, S2: selection of the non-exposed cohort, S3: ascertainment of exposure, S4: demonstration that outcome of interest was not present at start of study, SG: selected group, Total: sum of stars in the row.

***Table S9**: Quality assessment of the randomized trials using the revised Cochrane risk of bias tool (RoB 2). The overall bias "some concerns" was interpreted as "questionable quality" in the summary of the quality assessment results.*

Reference	Randomization Process	Effect of assignment to interventions	Effect of adhering to interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Bias	Evaluation
Stepan 2009	Some concerns	Some concerns	Some concerns	Low risk	Some concerns	Some concerns	Some concerns	Questionable

[47]								quality
Wysocki 2001 [34]	Low risk	Some concerns	Some concerns	Low risk	Some concerns	Some concerns	Some concerns	Questionable quality

9.7 Efficacy

***Table S10**: Overview of the clinical failure rates other than mortality, the clinical success rates and the microbiological failure and success rates in comparison to the vancomycin steady-state serum concentrations presented in the eighteen studies included in the efficacy analysis of continuously administered vancomycin.*

Clinical failure				**Clinical success**							
Persistence/Progression				**Cure**				**Improvement**			
Study	**C24**	**Cmean**	**AUC24**	**Study**	**C24**	**Cmean**	**AUC24**	**Study**	**C24**	**Cmean**	**AUC24**
				Mohammedi 2006 (LD 500 mg)	14.9 mg/L 56 %						
				Mohammedi 2006 (LD 15 mg/kg)	18.5 mg/L 93 %						
Perin 2020	20.3 mg/L 13 %			Perin 2020	20.3 mg/L 65 %						
				Stepan 2009		19.0 mg/L 64 %		Stepan 2009		19.0 mg/L 64 %	
Wysocki 2001		24.0 mg/L 21 %	577 mg*h/L 21 %	Wysocki 2001		24.0 mg/L 79 %	577 mg*h/L 79 %	Wysocki 2001		24.0 mg/L 79 %	577 mg*h/L 79 %

Microbiological failure								**Microbiological success**			
Persistence				**Relapse (Reinfection)**				**Cure**			
Study	**C24**	**Cmean**	**AUC24**	**Study**	**C24**	**Cmean**	**AUC24**	**Study**	**C24**	**Cmean**	**AUC24**
				Akers 2012		20.0 mg/L 18 %					
				Perin 2020	20.3 mg/L 3 % (7 %)						
								Stepan 2009		19.0 mg/L 76 %	
Wysocki 2001		24.0 mg/L 54 %	577 mg*h/L 54 %					Wysocki 2001		24.0 mg/L 46 %	577 mg*h/L 46 %

AUC24: area under the curve of serum concentration versus time for 24 h, C24: steady-state concentration 24 h after initiation of therapy, Cmean: mean vancomycin steady-state serum concentration during the entire duration of therapy or at least three days of therapy, (clinical) cure: resolution of clinical infection signs (e.g. body temperature <37.5 °C) and symptoms, (microbiological) cure: negative cultures of the same type of biological sample (e.g. blood, intra-abdominal fluids, cerebrospinal fluid (CSF), etc.), full eradication (e.g. on day 5), negative cultures during or up to 14 days after discontinuing the continuous vancomycin infusion after an initial positive culture, no requirement for antibiotic escalation or additional antibacterial treatment and shorter duration of bacteremia, improvement: reduction of symptoms of infection, decrease of leukocytes, length of stay, length of ventilation, duration of therapy, (clinical) persistence/progression: persistence or progression of baseline signs and symptoms of infection after two or more days of treatment that were consistent with the active infection, impairment of laboratory and radiological statuses, (microbiological) persistence: expansion of colonization of new gram-positives or the same pathogens in laboratory samples, the elongation of *Staphylococcus spp.* or other species in the specimen on day five, relapse: recurrence of gram-positive bacteremia after initiation of continuous vancomycin use, readmission within 14 days

of discharge because of recurrence of infection, detection of the same pathogen or presence of another pathogen.

***Table S11**: Overview of the clinical and microbiological failure and success parameters and frequency ranges presented in the eighteen studies included in the efficacy analysis of continuously administered vancomycin.*

Parameter		Definition	Range	Reference
Clinical failure	**Mortality**	Intensive care unit (ICU)	21-59 %	[33, 46, 47, 58, 63, 70, 71, 73, 75, 98, 100]
		In-hospital	17-63 %	[46, 47, 56, 57, 63, 64]
		X-Day (10-day, 14-day, 28-day, within 72 h of last recorded vancomycin dose)	8-26 %	[47, 63, 64, 100]
		Infection-related	8-18 %	[47, 62]
	Persistence or progress	Persistence or progression of baseline signs and symptoms of infection after two or more days of treatment that were consistent with the active infection, impairment of laboratory and radiological statuses	13-21 %	[47, 62, 63]
Clinical success	**Cure**	Resolution of clinical infection signs (e.g. body temperature <37.5 °C) and symptoms	64-93 %	[46, 47, 62, 63, 98]
	Improvement	Reduction of symptoms of infection, decrease of leukocytes, length of stay (LOS), length of ventilation (LOV), duration of therapy (LOT)		
Microbiological failure	**Persistence**	Expansion of colonization of new gram-positives or the same pathogens in laboratory samples and the elongation of *Staphylococcus spp.* or other species in the specimen on day five	3-54 %	[34, 48, 49]
	Escalation	Initiation of a new antibiotic with a similar spectrum to vancomycin due to lack of response and superinfection		
	Relapse	Recurrence of gram-positive bacteremia after initiation of continuous vancomycin use, readmission within 14 days of discharge because of recurrence of infection, detection of the same pathogen or presence of another pathogen		
Microbiological success	**Cure**	Negative cultures of the same type of biological sample (e.g. blood, intra-abdominal fluids, cerebrospinal fluid (CSF), etc.) or during or up to 14 days after discontinuing CI after an initial positive culture, full eradication (e.g. on day 5), no requirement for antibiotic escalation or additional	46-91 %	[47, 62, 63]

		antibacterial treatment and shorter duration of bacteremia		

9.8 Additional Plots

Figure S1*: Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity) for studies in which mean vancomycin serum levels measured approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=4 studies representing 478 patients).* ***a)*** *Differentiation according to the type of mortality.* ***b)*** *Differentiation according to the AKI definition.*



Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, X: 28-day mortality, filled black diamond: AKIN, filled black square: KDIGO, squared triangle: other definition of AKI, non-filled triangle: RRT

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, RRT: renal replacement therapy, X-Day: 28-day.

***Figure S2**: Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity) for studies in which mean vancomycin serum levels calculated from the average of the levels obtained during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=7 studies representing 1,282 patients). **a)** Differentiation according to the type of mortality. **b)** Differentiation according to the AKI definition.*



Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered cross: in-hospital mortality, non-filled square: infection-related mortality, X: 28-day mortality, filled black diamond: AKIN, squared triangle: other definition of AKI, star: RIFLE, non-filled triangle: RRT, non-filled diamond: Rybak2009

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, RRT: renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

***Figure S3**: Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity) for studies in which the mean vancomycin areas under the serum concentration vs. time curve for 24 h during therapy with continuous infusion of vancomycin (AUC24) were reported (n=4 studies representing 580 patients). **a)** Differentiation according to the type of mortality. **b)** Differentiation according to the AKI definition.*



Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered cross: in-hospital mortality, non-filled square: infection-related mortality, X: x-day mortality (e.g. 10-day, 28-day, 30-day), filled black diamond: AKIN, squared triangle: other definition of AKI, star: RIFLE, non-filled triangle: RRT, non-filled diamond: Rybak2009
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, RRT: renal replacement therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, RRT: renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

***Figure S4**: **a)** Scatterplot of studies in which a mean vancomycin level measured approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24), a target attainment rate and a mortality rate were reported (n=8 studies representing 768 patients). **b)** Scatterplot of studies in which a C24, a target attainment rate and a rate of acute kidney injury (= nephrotoxicity) were reported (n=3 studies representing 335 patients).*



Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, non-filled circle: type of mortality was not reported, X: x-day mortality (e.g. 10-day, 28-day, 30-day), filled black diamond: AKIN, filled black square: KDIGO, squared triangle: other definition of AKI, non-filled triangle: RRT, * target range, ** C24

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, aLD: applied average loading dose, aMD: applied average maintenance dose, APACHE II: Acute Physiology And Chronic Health Evaluation II score, C24: mean vancomycin level measured approximately 24 h after initiation of therapy with continuous infusion of vancomycin, CVVH: continuous veno-venous hemofiltration, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, LOT: length of therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, (C)RRT: (continuous) renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists), SAPS II: Simplified Acute Physiology Score II, SOFA: Sepsis-related Organ Failure Assessment score.

***Figure S5**: **a)** Scatterplot of studies in which a mean vancomycin steady-state serum level during the entire duration of continuously administered vancomycin or at least three days of therapy (Cmean), a target attainment rate and a mortality rate were reported (n=4 studies representing 488 patients). **b)** Scatterplot of studies in which a Cmean, a target attainment rate and a rate of acute kidney (= nephrotoxicity) injury were reported (n=1 study representing 90 patients).*



Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, X: x-day mortality (e.g. 14-day, 28-day), non-filled diamond: Rybak2009, * target range, ** Cmean

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, aLD: applied average loading dose, aMD: applied average maintenance dose, APACHE II: Acute Physiology And Chronic Health Evaluation II score, Cmean: mean vancomycin steady-state serum level during the entire duration of continuously administered vancomycin or at least three days of therapy, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, LOT: length of therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, (C)RRT: (continuous) renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

***Figure S6**: **a)** Distribution of studies for the mean vancomycin serum levels measured approximately 24 hours after initiation of therapy with continuously administered vancomycin (C24) (n=11 studies representing 1,200 patients). **b)** Distribution of studies for the mean vancomycin steady-state serum levels during the entire duration or at least three days of therapy with continuously administered vancomycin (Cmean) (n=12 studies representing 1,877 patients). **c)** Distribution of studies for the mean vancomycin area under the serum concentration-time curve for a period of 24 hours (AUC24) (n=7 studies representing 752 patients).*